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Abstract 
 
Pancreatic cancer is categorized fourth in all cancer-related mortalities worldwide. Much of 
the dismal properties of this malignancy are attributable to the high heterogeneity of its 
microenvironment and the intense desmoplasia formation. A prominent feature of pancreatic 
desmoplasia is the infiltration of tumor mass with high numbers of activated pancreatic 
stellate cells (PSCs). 
In the first part of the study, a prominent observation is the elucidation of tumor necrosis 
factor alpha (TNF-α) as a key element in PSC activation, proliferation and stimulation of 
fibronectin synthesis. In addition, TNF-α, along with chemokine (C-C motif) ligand 4 (CCL-
4), contributes to changing the PSC proteome towards monitoring the endothelial system and 
angiogenesis. On the other hand, fibroblast growth factor 2 (FGF-2) and interleukin 6 (IL-6) 
induction led to better cellular survival and decreased apoptotic activity of the stellate cells by 
the former and a decreasing apoptotic activity through modulation of ionized calcium. Both 
functional and network analysis have indicated a possible role the transcription factor proto-
oncogene c-Fos in PSC activation. 
In the second part, I followed up the functional and network analysis from Part I about the 
potential role of c-Fos as transcriptional regulator of PSCs activation via TNF-α. The results 
showed that the treatment with exogenous TNF-α in stably transfected PSCs with c-Fos small 
interfering RNA (siRNA) failed to propagate the cells to express fibrogenic factors, while un-
transfected cells sustained such activity. Interestingly, activated PSCs constitutively expressed 
intra- and extra-cellular TNF-α when grown in normal conditions. The knockdown of c-Fos 
diminished such capacity suggesting that there is a synergistic feedback loop between TNF-α 
and c-Fos used by PSCs to maintain proliferation and fibrotic activity independently to 
exogenous TNF-α from the pancreatic tumor microenvironment. 
In the third part, the study aimed at investigating the potential involvement of activated PSC 
paracrine in the crosstalk between PSC and PDAC cells. The results of PSC secretome 
analysis provided a list of candidate proteins linked to PDAC development. Among them, 
several matricellular proteins previously reported as involved in cancer aggressiveness were 
identified (i.e., IL-1ß, FGF-1). In addition, proteomic analysis and qRT-PCR results revealed 
that supernatants from the activated PSCs could promote pancreatic cancer apoptosis, cell 
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proliferation and migration. Furthermore, the expression of eIF4E in pancreatic cancer cells 
were increased by active PSCs. Inhibition of eIF4E activation by siRNA blocked the effect of 
activated PSCs on pancreatic cancer cells and inhibited tumor growth in vitro. Taken together, 
our findings suggest that activated PSCs acquire pro-inflammatory phenotype and prompt 
pancreatic cancer growth in an eIF4E-dependent manner, which provides new evidence for 
the modulation of PSCs by tumor microenvironment and further insight to the role of stromal 
cells in pancreatic carcinogenesis and cancer progression. 
The fourth part of the study aimed at evaluating the effect of anti-fibrotic drug candidates on 
activated PSCs in order to suppress desmoplasia in pancreatic cancer, then to test the most 
promising drugs in a co-culture model of tumor cells and PSCs, also in animal models for 
pancreatic fibrosis. Our findings indicate that inhibition PSC activation in combination with 
ribavirin can significantly inhibit the proliferation and migration, induce apoptosis, arrest the 
cell cycle, and decrease expression of translation initiation genes as modifying several other 
cancer-related processes in PDAC cells. Therefore, targeting PSC with ribavirin may offer a 
promising treatment strategy for pancreatic cancer. 
Control of the activation of PSCs and their cell functions are potential targets for the 
development of new treatments for pancreatic fibrosis. Therefore, I tried to investigate the 
effect of some natural products on PSC activation. Our finding indicated that inhibition of 
proliferation by extractions of date palm was correlated with the inhibition of TNF-α 
activation, which is clearly noted by decreased expression of α-SMA. Although these 
observations suggest that extractions of date palm may prove useful as a therapeutic agent for 
the attenuation of pancreatic cancer, we still need to conduct further investigation of the 
precise mechanism by which this extraction directly suppresses PSC cells. 
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Zusammenfassung 
 
Pankreaskrebs ist die vierthäufigste Krebstodesursache weltweit. Viele der malignen 
Eigenschaften dieser Tumorerkrankung sind auf die hohe Heterogenität der Mikroumgebung 
und die ausgeprägte Desmoplasie zurückzuführen. Ein wesentliches Merkmal der 
Desmoplasie ist die Infiltration der Tumormasse mit einer hohen Anzahl von aktivierten 
Sternzellen der Bauchspeicheldrüse (PSCs). 
Im ersten Teil der Arbeit kamen wir zu der entscheidenden Erkenntnis, dass 
Tumornekrosefaktor alpha (TNF-α) eine Schlüsselrolle bei der Aktivierung, der Proliferation 
und der Stimulierung der Fibronektin-Synthese von PSCs spielt. Außerdem trägt TNF-α, 
zusammen mit Chemokin (C-C Motiv) Ligand 4 (CCL-4), zu einer Veränderung des PSC-
Proteoms bei, welches das endotheliale System und die Angiogenese beeinflusst. Des 
weiteren konnte gezeigt werden, dass Fibroblasten-Wachstumsfaktor 2 (FGF-2) und 
Interleukin-6 (IL-6) ein vermehrtes zelluläres Überleben sowie, durch Modulation des 
Kalzium-Ionen-Spiegels, eine verringerte apoptotische Aktivität der Sternzellen bewirken. 
Sowohl funktionelle, als auch Netzwerk-Analysen haben auf eine mögliche Rolle des 
Transkriptionsfaktor-Protoonkogens c-Fos (c-Fos) in der PSC-Aktivierung hingewiesen. 
Im zweiten Teil untersuchten wir, basierend auf den funktionellen und Netzwerk-Analysen 
des ersten Teils, die potenzielle Rolle von c-Fos als Transkriptionsregulator in der TNF-α-
induzierten PSC-Aktivierung. Die Ergebnisse zeigten, dass die Behandlung mit exogenem 
TNF-α in PSCs, welche zuvor mit c-Fos small interfering RNA (siRNA) stabil transfiziert 
wurden, nicht zur Expression fibrogener Faktoren führte, während nicht-transfizierte PSCs 
diese nach der Behandlung exprimierten. Interessanterweise exprimieren aktivierte PSCs 
konstitutiv intra- und extrazelluläres TNF-α, wenn sie unter normalen Bedingungen wachsen. 
Der Knockdown von c-Fos verringert jedoch diese Kapazität, was darauf hindeutet, dass eine 
synergistische Rückkopplungsschleife zwischen TNF-α und c-Fos existiert, welche von PSCs 
genutzt wird, um ihre Proliferation und ihre fibrotische Aktivität unabhängig von exogenem 
TNF-α aus der Pankreastumorumgebung aufrechtzuerhalten. 
Im dritten Teil sollte die potentielle Beteiligung von parakrin sezernierten Faktoren der 
aktivierten PSCs in der gegenseitigen Beeinflussung von PSCs und PDAC-Zellen untersucht 
werden. Die PSC-Sekretom-Analyse ergab eine Liste von Kandidatenproteinen, die mit einer 
PDAC-Entstehung assoziiert sind. Unter ihnen wurden einige matrizelluläre Proteine 
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identifiziert, von denen bereits bekannt ist, dass sie mit Tumor-Aggressivität im 
Zusammenhang stehen (z.B. IL-1ß, FGF-1). Daneben haben die Ergebnisse aus 
Proteomanalyse und qRT-PCR gezeigt, dass die Zellüberstände von aktivierten PSCs die 
Apoptose von Pankreaskarzinom-Zellen reduzieren, sowie deren Proliferation und Migration 
fördern können. Außerdem wurde die Expression von elF4E in Pankreaskarzinom-Zellen 
durch aktivierte PSC erhöht. Unterdrückung der eIF4E-Aktivierung mit siRNA hat den 
Einfluss von aktivierten PSC auf Pankreaskarzinom-Zellen blockiert und das in-vitro 
Tumorwachstum inhibiert. Insgesamt weisen unsere Ergebnisse darauf hin, dass aktivierte 
PSCs einen proinflammatorischen Phänotyp annehmen und das Tumorwachstum eIF4E-
abhängig anregen. Dies liefert neue Erkenntnisse über die Modulation von PSCs durch die 
Tumor-Mikroumgebung sowie weitere Einblicke in die Rolle von Stromazellen in der 
Pankreaskarzinogenese und -tumorprogression. 
Im vierten Teil der Arbeit sollte die Wirkung von anti-fibrotischen Wirkstoffkandidaten auf 
aktivierte PSCs untersucht werden, mit dem Ziel, die Desmoplasie bei Pankreaskrebs zu 
unterdrücken. Anschließend wurden die vielversprechendsten Wirkstoffe in einem Co-Kultur-
Modell von Tumorzellen und PSCs sowie in einem Tier-Modell für Pankreasfibrose getestet. 
Unsere Ergebnisse zeigten, dass eine Hemmung der PSC-Aktivierung mit Ribavirin 
signifikant die Proliferation und Migration inhibiert, Apoptose induziert, den Zellzyklus 
anhält, die Expression von Translations-Initiations-Genen reduziert sowie viele weitere 
Tumor-assoziierte Prozessen in PDAC-Zellen beeinflusst. Demzufolge könnte die 
Behandlung von PSC mit Ribavirin eine vielversprechende Therapie-Strategie bei 
Pankreaskrebs bieten. 
Die Kontrolle der PSC-Aktivierung und deren Zellfunktionen sind potentielle Ziele bei der 
Entwicklung neuer Medikamente zur Therapie von Pankreasfibrose. Deshalb haben wir die 
Wirkung einiger Naturstoffe auf die PSC-Aktivierung untersucht. Wir konnten zeigen, dass 
eine Hemmung der Proliferation durch Extrakte aus der Dattelpalme mit einer Hemmung der 
TNF-α-Aktivierung korreliert, was in einer Verringerung der α-SMA-Expression deutlich 
wurde. Diese Ergebnisse legen nahe, dass Extrakte der Dattelpalme als therapeutisches Mittel 
für die Behandlung von Pankreaskrebs möglicherweise geeignet wären, jedoch müssen wir 
die genauen Mechanismen, wie diese Extrakte die PSC-Zellen unterdrücken, noch weiter 
untersuchen.  
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1 Introduction 
1.1 The pancreas and its exocrine and endocrine function 
The pancreas is a unique exocrine and endocrine organ, which lies behind the peritoneum of 
the posterior abdominal wall and is oblique in its orientation. The head of the pancreas is on 
the right side and lies within the “C” curve of the duodenum to the hilum of the spleen [1].  
 
 
 
Figure ‎1.1  Schematic illustration of the anatomy of the pancreas. 
The Pancreas is composed of a head, body and tail. A main duct begins in the tail and deviates in the head, where an 
accessory‎duct‎emerges.‎An‎islet‎of‎Langerhans‎(endocrine‎pancreas)‎contains‎α,‎β,‎δ‎and‎PP‎cells.‎The‎exocrine‎cells‎
comprise acinar and ductal cells arranged into distinct lobules. Stellate cells are located in the interlobular regions 
around the pancreatic ducts. Source: http://www.britannica.com/EBchecked/topic/440971/pancreas (accessed on June 
2010). 
 
The pancreas is both an endocrine and an exocrine gland. Most of the pancreas consists of 
exocrine tissue and the pancreatic acinar cells (PACs) are the main cells in this part. The main 
function of these cells is to secrete pancreatic juice, which is a fluid containing digestive 
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enzyme. In addition the exocrine pancreas also consists of ductal cells, which help to transport 
the digestive enzymes produced by the acinar cells into the duodenum [2, 3]. The exocrine 
part has embedded islands of endocrine cells (islets of Langerhans). The hormones produced 
by the islets are essential for the regulation of blood glucose. There are five main types of the 
islets. The beta cells are the most common cell in this part, which is responsible for insulin 
production, while the other types include alpha, delta and F cells, which secrets glucagon, 
somatostatin and pancreatic polypeptides, respectively [2]. 
1.2 Acute and chronic pancreatitis 
Pancreatitis is an inflammatory disease that can be classified as acute or chronic. Acute 
pancreatitis is characterized by necrosis and inflammation that resolves with returning to 
normal function and structure, whereas chronic pancreatitis is distinguished by irreversible 
changes of the pancreas [4]. Chronic pancreatitis has several etiologies, including the major 
cause alcohol as well as hereditary, autoimmune or idiopathic [5]. Characteristics that apply to 
all of these forms are acinar atrophy, necrosis, pancreatic fibrosis, chronic inflammation and 
impairment in exocrine and endocrine function [6]. For alcoholic chronic pancreatitis, it is 
believed that it arises from recurring acute episodes of acute pancreatitis [5] and that alcoholic 
acute and chronic pancreatitis are the same disease at different stages [7]. Although alcohol is 
the most common cause for chronic pancreatitis, only about 10 % of heavy drinkers develop 
this disease, which indicates that other factors are involved in the process [8]. It has been 
shown that an early event in experimental pancreatitis is premature enzyme activation [7], 
which directly links acinar cell injury to the development of pancreatitis. Another important 
cell type associated with fibrosis is pancreatic stellate cells (PSCs), which also play a role in 
pancreatic cancer and are discussed in more detail in the next section. 
1.3 Pancreatic cancer 
Although pancreatic cancer is a relatively rare tumor (2% of all cancer cases), it is the 4th 
leading cause of cancer death in Europe and United States with a 5-year survival of less than 
6% and an average survival of 4-6 months depending on the staging of the disease upon 
diagnosis [9, 10]. To date, surgery is the only really effective cure of pancreatic cancer, which 
can be applied to 15-20% of patients, but nevertheless less than two years survival [11]. The 
cause of pancreatic cancer remains unknown, although several risk factors have been 
implicated, including advanced age, cigarette smoking, alcohol consumption, diabetes, male 
gender, chronic pancreatitis, obesity, a diet high in meats and low in vegetables as well as a 
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family history of the disease (although the overwhelming majority of PDAC cases are 
sporadic, that is, occurring without a history of the disease in first degree relatives) [12-15]. 
Because many patients succumb to advanced diseases as the primary tumor metastasizes to 
other organs, early detection and prevention of this disease is urgently needed. 
1.3.1 Pancreatic ductal adenocarcinoma (PDAC) 
Exocrine tumors, which occur in the exocrine cells of the pancreas, are the most common 
form of pancreatic cancer and account for well over 95% of all pancreatic cancers. PDAC, an 
exocrine tumor, represents over 90% of all exocrine tumors [16]. Around 75% of ductal 
adenocarcinomas occur in the head of the pancreas, 15-20% occur in the body, and around 5-
10% occur in the tail [17]. PDAC is a lethal disease due to late diagnosis, early metastasis, 
resistance to all forms of treatment and the lack of effective therapies [18, 19]. 
Unlike many other malignant diseases, PDAC cases are most often diagnosed at late stages, 
which make treatment more difficult and even impossible [20]. Currently, surgery is the only 
successful treatment option for PDAC, although 15-20% of patients are potentially suitable 
for this procedure with only one in five survive up to 5 years, while the majority of patients 
present with locally advanced or metastatic cancer [21, 22]. However, after surgery, most of 
the patients who undergo a successful resection eventually relapse and die from the disease 
[23, 24]. Adjuvant therapy options have been used in pancreatic cancer in the form of 
chemotherapy and/or radiotherapy, which provided in an attempt to improve survival and 
reduce disease recurrence [24]. During the past few years, many trials of adjuvant treatment 
following pancreatic cancer resection have taken place. However, the median survival of 
using an antineoplastic agent (gemcitabine, currently considered as the standard for the 
treatment of patients with advanced PDAC) also has limited success rate, with less than 20% 
[25]. In 2011, Conroy et al. found that combining 5-fluorouracil (5FU), leucovorin, irinotecan 
and oxaliplatin (FOLFIRINOX) demonstrated significant improvement in survival compared 
to gemcitabine alone [26]. To date, three drug combinations have shown some improvement 
in clinical outcome, such as time to progression or overall survival. These combinations 
include gemcitabine plus erlotinib [27], cisplatin [28], and capecitabine [29]. The results of 
several clinical trials have not shown any clinical benefit [30, 31], however. Consequently, 
there is an urgent need of new treatment options for this disease and a continued emphasis on 
clinical trials about all aspects. In addition, it has become increasingly evident that we must 
find opportunities to explore a new therapeutic target in PDAC. 
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1.4 The tumor microenvironment in PDAC 
Although the last years shown that most research has focused on better understanding of the 
pancreatic cancer biology, the main question is still awaiting an answer: what is making 
pancreatic cancer such a lethal disease. In recent years, recurrent evidence has focused on the 
role of reactive stroma as the main contributor to pancreatic cancer lethality. The PDAC 
stroma consists of extracellular matrix (ECM) and cellular components. The ECM includes 
secreted proteoglycans playing both a structural and cell-signaling role. The cellular 
components include fibroblasts, endothelial cells and pericytes of capillary walls, smooth 
muscle, and immune and inflammatory cells. This stroma has played a main role in the 
growth, invasion and metastasis of a cancer [32]. It was found that most of the biological 
functions of PDAC, like proliferation, local invasion, metastasis and drug-resistant, are 
attributed in part to the presence of PDAC stroma [33]. Indeed, in PDAC, which is the 
commonest type of pancreatic cancer, tumor cell form only 10% of a tumor tissue, while the 
vast majority of cells in pancreatic ductal neoplasm are non-malignant stroma cells, which 
form up to 90% of the tumor mass [34, 35]. However, specific interactions between cells as 
well as the molecular mechanisms underlying them are only partially known so far. In vitro, 
chemosensitivity of human cancer cells show a similar response to chemotherapeutic agents 
as cell lines derived from other solid tumor like breast or prostate tumor, while in vivo most of 
patients with pancreatic cancer have a limited response rate to drugs compared to breast and 
prostate cancer. This may be due to the unique microenvironment in pancreatic cancer, which 
plays a role in of cancer progression, prognosis, and therapeutic resistance [35]. Activated 
stroma in pancreatic cancer is associated with overexpression of several growth factors and 
producing extracellular matrix (ECM) proteins [36], highlighting the role of stroma in poorly 
differentiated pancreatic cancer cells, which is attributed to interact with ECM proteins more 
strongly than well or moderately differentiated cells. In addition, stroma also protects tumor 
cells from chemotherapy by diminishing the drug delivery to tumor cells. In pancreatic cancer, 
heavy stroma works as a barrier preventing drugs from penetrating the tissue interstitium [37]. 
In pancreatic tumors, fibroblasts and fibrotic stroma inhibit the formation and the function of 
blood vasculature, which diminishes the drug delivery via the per-fusing blood, resulting in a 
reduction of the effectiveness of systemic chemotherapy that relies on the functional 
vasculature for delivery to tumor cells. Until now, no specific therapies are available to inhibit 
pancreatic fibrosis, a constant pathological feature of chronic pancreatitis and pancreatic 
cancer. Thus, investigation of the molecular crosstalk between PDAC and tumor stroma may 
be essential to unfold the pancreatic cancer ability to progress in such a rapid manner, as well 
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as understand its resistance to therapy. A therapy targeting the non-cancer stroma cells may 
have the additional benefit of pursuing genetically stable cells rather than the inherently 
unstable tumor cells. In addition, the molecular mechanisms of PSC-stroma interaction in 
pancreatic cancer are very complex and only partially understood. Given the importance of 
crosstalk between cells, the work presented here focuses on the finding the molecular events 
at the level of proteome that are associated with PSC-stroma interaction, which are the main 
constituent of the PDAC stroma (Figure  1.2) [38]. 
 
 
Figure ‎1.2 Mechanisms of PSC activation.  
Exposure of the pancreas to ethanol, to its metabolites, and to insults that generate ROS all result in PSC activation by 
autocrine and paracrine products. The paracrine factors are derived from neighboring cells, such as acinar cells, 
ductal cells, endothelial cells, and leukocytes. Activated PSCs can migrate to sites of tissue damage, undergo regulated 
contraction, proliferate, phagocytose, and generate products that modulate the ECM by facilitating repair or 
promoting fibrosis. Persistent activation of PSCs promotes fibrosis, while re-differentiation to a quiescent state or 
stimulation to undergo apoptosis facilitates tissue repair.  
 
1.4.1 Which cells are responsible to create the desmoplastic reaction 
In vitro and in vivo studies have shown that pancreatic cancer stroma have the capability to 
produce ECM components. There is evidence shown that pancreatic stroma is the principle 
effector cells in pancreatic cancer by its ability to produce ECM proteins [39]. From a 
histological point of view, pancreatic cancers stroma has the most prominent stromal reaction 
of all of the epithelial tumors; there is a remarkable increase in the collagen I, alpha Smooth 
Muscle Actin (SMA) and Glial Fibrillary Acidic Protein (GFAP). Yen and co-workers [40] 
studied if these cells are responsible for the scirrhous reaction surrounding pancreatic 
adenocarcinomas. They found that desmoplastic reaction surrounding pancreatic 
adenocarcinoma displayed intense interstitial staining for α-SMA and collagen IV. This study 
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suggested that a massive increase in myofibroblast activity, compatible with the activation of 
stellate cells, is associated with the deposition of collagen types I and IV in the desmoplastic 
reaction around pancreatic adenocarcinomas.  
Data from Apte and colleagues [41] confirmed these findings. Immunohistochemical analyses 
showed that stromal areas of pancreatic cancer tissue sections stain intensely positive for α-
SMA, GFAP and collagen I, a molecular profile highly suggestive for activated pancreatic 
stellate cells (PSCs). Using in situ hybridization, they demonstrated that procollagen 
messenger RNA (mRNA) expression localized to activate PSCs, implicating these cells as the 
predominant source of collagen in PDAC. 
A similar study has revealed that α-SMA positive cells correlate with collagen type I and 
fibronectin surrounded pan-cytokeratin positive carcinoma tissue. This suggested that there is 
no association between the ECM proteins and pan-cytokeratin staining. In addition, they also 
discovered pan-cytokeratin staining to correlate with expression of extracellular matrix 
metalloproteinase inducer (EMMPRIN). This implies that carcinoma cells have the ability to 
induce the formation of matrix metalloproteinase (MMPs) in neighboring stromal cells [42]. 
These results indicate that activated PSCs are present in the stromal reaction in pancreatic 
cancers and are responsible for the production of stromal collagen. 
1.4.2 Pancreatic stellate cells 
Most of early studies of PSCs depended on the study of their counterparts in liver, the hepatic 
stellate cells (HSCs), which were first described more than 130 years ago by Karl von Kupffer 
in 1876. Other studies showed that this type of cells is also present in several other organs, 
including the kidney [43] and lung [44]. However, similar cells in the pancreas were only first 
observed in 1982 by Watari [45]. Watari et al. described the presence of cells exhibiting a 
rapidly fading blue-green fluorescence characteristic of vitamin A in the peri-acinar areas of 
the pancreas [45]. Data from Ikejiri reiterate these findings [46]. However, after Ikejiri’s 
publication, little progress was made in this area for the better part of a decade. This is 
presumably due to either a loss of research interest or more likely due to the lack of a method 
to successfully isolate and culture PSCs. A few years later, in 1998, Apte et al. and Bachem et 
al. isolated and cultured PSCs. These studies demonstrated that PSCs in stromal areas of 
pancreatic cancer tissue sections stain intensely positive for collagen I, α-SMA and GFAP. 
These studies indicated that PSCs are the predominant source of collagen in PDAC [47, 48].  
In the healthy exocrine pancreas, PSCs are located in the periacinar, intralobular space and 
have also been identified around blood vessels. PSCs also comprise only 4-7% of all 
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parenchymal cells in the normal pancreas. PSCs are characterized by the expression of the 
intermediate filament proteins desmin and GFAP which, together with the presence of 
intracellular fat droplets, serve to distinguish PSCs from normal fibroblasts in pancreatic 
stroma [5, 46-48]. Little is known about the mechanisms mediating the accumulation lipid 
droplets in the cytoplasm. Some studies suggested that their accumulation may be due to the 
albumin protein (a protein that is endogenously expressed in PSCs and is co-localized with 
vitamin A in the lipid droplets), which plays a role in lipid droplets formation [49, 50]. In the 
inactivated state, PSC cells have a low rate of proliferation and a low capacity to produce 
ECM. However, other studies have showed that a quiescent PSC may play role in healthy 
pancreas by produced cholecystokinin (CCK), which then induces acinar cells to secrete 
amylase [51]. There is another role for quiescent PSCs in acute pancreatitis by participating in 
temporary tissue repair processes following acute inflammation in both humans and rodents. 
After the inflammation resolves, the PSCs progressively disappear and may re-enter their 
quiescent state again. However, it is the repeated pancreatic damage that can lead to chronic 
inflammation and the persistent activation of PSCs [38].  
When PSCs are activated, their phenotype transforms, and they become myofibroblast-like 
cells with functional alterations including high synthesis of ECM proteins like collagen and 
fibronectin, increased expression of the cytoskeletal protein α-SMA, increased proliferation 
and migration, high motility and secretion of growth factors and cytokines [52]. In addition, 
PSCs also produce matrix degrading enzymes (matrix metalloproteinases, MMPs) and their 
inhibitors (TIMPs, tissue inhibitor of metalloproteinases) [53], indicating that in normal 
pancreas, PSCs may have a role in the maintenance of normal ECM turnover in the pancreas. 
However, this changes during PSC activation and the balance between production and 
degradation of ECM is severely disturbed, which leads to excessive ECM synthesis and 
eventually the development of pathological fibrosis (Table1 summarizes the different 
characteristics of quiescent and activated PSCs) [54].  
PSC activation can be induced by effector molecules. These include inflammatory cytokines 
such as IL-1 and IL-6, growth factors like TGFβ1 and TNF-α, ethanol and its metabolites, and 
reactive oxygen species (ROS), released by damaged neighboring cells, and leukocytes that 
are recruited in response to pancreatic injury [5], as well as platelet derived growth factor 
(PDGF) [55]. There are many different potential sources of cytokines stimulating PSC 
activation, for example, activated macrophages ( secreting TGF-β1and PDGF) [56], acinar 
cells (secreting TNF-α [57], IL-1 and IL-6 [58]). It is important to note that in addition to 
responding to cytokines via paracrine pathways, PSCs themselves are capable of synthesizing 
12 
 
autocrine factors, such as PDGF, TGF-β1, cytokines (IL-1, IL-6, and TRAIL), and 
proinflammatory molecules (COX-2), all of which are capable of activating the cells via 
autocrine pathways [59-62]. These observations suggest that there is an autocrine loop that 
may contribute to the maintenance of PSC activation after an initial external signal, thereby 
promoting the development of fibrosis.  
Table ‎1.4.1 Characteristics of quiescent and activated PSC phenotypes [54]. 
 Quiescent PSCs  Activated PSCs 
Vitamin A lipid droplets Present Absent 
α Smooth muscle actin Absent Present 
Proliferation Limited Increased 
Migration Limited Increased 
ECM production Limited Increased 
Matrix metalloproteinases (MMPs) 
and tissue inhibitors of matrix 
proteinases (TIMPs) 
Complement of MMPs and TIMPs to 
maintain normal ECM turnover 
Change in types of MMPs and 
TIMPs to facilitate ECM 
deposition 
Production of cytokines Limited Increased(PDGF, TGFβ, 
CTGF,IL1,IL6, IL15) 
Proteomic analyses Basal protein expression Differential expression of 
proteins related to the cell 
cytoskeleton, cell metabolism, 
motility, growth and invasion 
 
Although several inflammatory mediators released and are able to regulate PSCs, evidence 
supports major roles for PDGF, TGF-β1 and angiotensin II as modulators of the persistently 
activated and profibrotic phenotype of these cells [63-65] (Figure  1.2).  
It was found that exposure of PSCs to a pro-oxidant complex such as iron sulphate/ascorbic 
acid or hydrogen peroxide can lead to PSC activation [66]. Cultured PSCs respond to ethanol 
application by increased α-SMA expression and collagen synthesis, where this activation is 
blocked by the antioxidant α-tocopherol [66]. PSCs have also been shown to generate ROS 
within the cell and express NADPH oxidase, which, in turn, mediate activation of PSCs [66, 
67]. Apte et al. found that ethanol which metabolized in acinar cells is responsible for 
mediating PSC activation [68]. Other study proposed that activation of PSC by ethanol, 
resulting to release cytokines induced pancreatic damage [69]. Furthermore, in vitro data 
suggest that ethanol and its metabolite acetaldehyde promote the activation of rat PSCs and 
cause lipid peroxidation in these cells [68]. Moreover, the histological analysis from patients 
with chronic pancreatitis revealed that 4-hydroxy-nonenal staining localized to activated PSCs 
within fibrotic areas and to acinar cells adjacent to areas of fibrosis [70]. All these results 
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support that both direct and indirect (cytokine-mediated) effects of ethanol on PSCs are 
involved in the development of pancreatic fibrosis. 
1.4.3 Signaling pathways in PSCs 
After establishing the functional responses of PSCs to exogenous and endogenous factors, the 
next step for researchers in the field was to analyze signal transduction pathways regulating 
PSC functions. Although the cell signaling pathways that regulate PSC activation have not yet 
been fully elucidated, study the signaling molecules participated in PSC activation is a 
promising approach for the development of therapeutic strategies to inhibit pancreatic fibrosis. 
Several studies have identified several major signaling pathways involved in the regulation of 
PSC function. Mitogen-activated protein kinases (MAPK families) are signaling components 
that are important in converting extracellular stimuli into a wide range of cellular responses. 
In PSC, effects of ethanol, acetaldehyde and oxidants are mediated by activation of the 
MAPKs pathway. It was noted on PSC in vitro studies that MAPKs (ERK 1/2, JNK and p38 
kinase) activated after PSC exposure to the ethanol and acetaldehyde [71-73]. Indeed, ERK 
1/2 activation represents an early event that precedes exhibition of a myofibroblastic 
phenotype [74-76]. 
PDGF also induced PSC proliferation via activation of ERK 1/2, while migration was 
regulated by the PI3K pathway [72]. Masamune et al. noted that PDGF also activated PSC 
culture via the p38 signaling pathway [77]. Another study found that proliferation of PSC 
decreased by added JNK inhibitor SP600125 to PSC cultured cells [78]. Modulation of 
MAPKs family pathway in PSCs is often associated with a change in the function of the other 
[79]. Together, these data support the hypothesis that MAPKs are key mediators of activation 
signals in PSCs. 
Another signaling molecule, which influences PSC activation, is TGF-β1. Studies by Ohnishi 
and his collage revealed that TGF-β1 stimulated PSC activation in a Smad-2-dependent 
manner, while Smad3 was required for TGF-β1-induced growth inhibition. It was shown that 
there is a feedback loop between exogenous TGF-β1 and increased TGF-β1 expression in 
PSCs through an ERK-dependent but Smad-2/3-independent pathway [80]. 
Recent studies have implicated Indian hedgehog (IHH) as another signaling molecule which 
influences PSC migration [81]. Indian hedgehog (IHH) is a member of hedgehog peptides 
family that exerts diverse effects on multiple cellular functions. It was found that IHH has no 
influence on the expression of collagen-1 or alpha-smooth muscle actin, neither has it changed 
PSC proliferation. In contrast, IHH increased the amount of membrane-type 1 matrix 
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metalloproteinase (MT1-MMP) and altered its localization on the plasma membrane, which 
plays a stimulatory role in cellular migration, which attenuated by added tissue inhibitor of 
metalloproteinase-2 (TIMP-2). 
Other intracellular signal transduction pathway that has recently been studied regarding its 
role in PSC activation is the Rho-Rho kinase (ROCK) pathway. An in vitro study showed that 
Rho kinase regulates the actin cytoskeleton, stress fiber formation and alteration of cell shape 
during the PSC activation process [82, 83]. In the same study, Masamune and Shimosegawa 
found that growth factors and cytokines activated PSCs throw intracellular calcium signaling 
[83]. 
Hennigs and colleagues have carried out a thorough investigation of PSCs activation. They 
found that PSCs respond to the extracellular nucleotides purines and pyrimidines (known to 
be involved in cell-cell communication of inflammatory signals after cell injury) pathway via 
P2X and P2Y receptors. [84]. It is well known that activation of P2 receptors elicits robust 
intracellular Ca signaling, mediate the fibrogenic function of activated PSCs [84]. 
1.4.4 Role of activated PSCs in pancreatic fibrosis 
In vitro and in vivo studies have shown that PSCs play a critical role in the pathogenesis of 
pancreatic fibrosis. It was documented that after acute necrotizing pancreatitis, activated PSCs 
participate in tissue repair processes in both humans and experimental animals of acute 
pancreatitis [85-88]. During pancreatic injury, PSCs proliferate, migrate, assembly to new 
parenchymal cells and transform into their activated phenotype. This process is associated 
with formation of a provisional matrix at the site of injury leading to the development of 
pancreatic fibrosis [86, 87, 89]. Based upon knowledge of in vivo study, specific molecules, 
factors and cellular pathways that mediate PSC activation were initially identified mostly by 
using cultured PSCs in vitro. These election of putative activating factors for examination 
were include the production of oxidant stress and the release of growth factors and cytokines 
including TGF-ß, PDGF, tumor necrosis factor α (TNF-α) and the interleukins 1, 6 and 8 (IL-
1, IL-6 and IL-8). In addition, factors that may have direct toxic effects on PSCs have also 
been examined. These include ethanol and its metabolites acetaldehyde and fatty acid ethyl 
esters. Findings of these studies were summarized as follows: 
(1) alcohol and its metabolites acetaldehyde and fatty acid ethyl esters [90];  
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(2) endotoxin (given the known association of alcohol abuse and endotoxinaemia [91] as 
well as the correlation of circulating endotoxin levels with severity of pancreatitis [92, 
93]; 
(3) growth factors and cytokines and these are include: 
a. TGF-β1 is a potent fibrogenic cytokine inducing the synthesis and secretion of 
collagen, fibronectin and laminin by PSCs [55, 94]. In addition, TGF-β1 also 
increases the production of MMP-2 by PSCs [53]. 
b. The proinflammatory cytokines TNF-α , IL-1 and IL-6 induce PSC activation as 
assessed by one or more of the following indicators proliferation, migration, α-
SMA expression and fibronectin or collagen synthesis [65, 95]. 
c. PDGF is a potent mitogenic and chemotactic factor for PSCs [53, 65, 94]. 
(4) oxidant stress (known to occur during both acute and chronic pancreatitis), leads to their 
activation as indicated by increased α-SMA expression and collagen synthesis [66] and  
(5) autocrine pathways by PSCs themselves. PSCs are capable of synthesize and secrete 
cytokines such as TGF-β1 and IL-11 [59]. This phenomenon may represent one of the 
mechanisms responsible for progression of chronic pancreatitis and pancreatic fibrosis. 
PSC activated in response to exposure to the above factors has been assessed using at least 
one or more than one of parameters such as cell proliferation, migration, expression of α-
SMA, synthesis of ECM protein, matrix degradation via the production of MMPs, loss of 
vitamin A stores and cytokine release.  
Different animal models, principally mice or rats, have been used to support the role of PSCs 
in human pancreatic fibrosis. Also, we could summarize the findings of these studies as 
follows: 
(1) Collagen is the main extracellular matrix protein in areas of fibrosis [96].  
(2) Increased numbers of PSCs in areas of fibrosis have been reported using the 
trinitrobenzene sulfonic acid (TNBS) model of pancreatic fibrosis and indicated by 
express α-SMA and co-localize with mRNA encoding procollagen α1 [41, 96].  
(3) PSCs in fibrotic areas are the only cells that exhibit positive staining for messenger RNA 
for collagen suggesting that activated PSCs may be the principal source of the collagen 
deposited in the fibrotic pancreas [97].  
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(4) PSCs have the ability to produce ECM degrading proteases and their inhibitors, such as 
tissue inhibitor of metalloproteinase 1 (TIMP-1) [59, 60].  
(5) Growth factors and cytokines such as: 
a. TGF-β1: Haber et al. and Casini et al., found that pancreatic acinar cells 
presence in the fibrotic areas exhibit strongly positive staining for TGF-β1, 
while such staining is absent in acinar cells remote from bands of fibrosis [96, 
97]. Shields and his colleagues found by using transgenic mice expressing 
KrasG12D/SNAIL that Snail cooperates with KrasG12D to promote pancreatic 
fibrosis through TGF-β1 signaling [98]. In another study, it was shown that 
TGF-β1 signaling mediated collagenase MT1-MMP paradoxically contributes 
to pancreatic fibrosis [99]. 
b. Increased connective tissue growth factor (CTGF) expression in fibrotic areas 
[100]. CTGF has been involved in the pancreatic fibrotic diseases, and its 
expression is predominant in PSCs and is regulated by TGF-β1.  
c. Increased expression of the receptor for PDGF (at both mRNA and protein 
levels) in areas of fibrosis in chronic pancreatitis [96, 97]. 
1.5 Bidirectional interaction between PSCs and PDAC  
As mentioned above, there is now significant evidence showing that a bidirectional interaction 
exists between PSCs and pancreatic cancer cells resulting tumor progression [41, 101-104]. 
Cancer cells influence PSCs via mitogenic and fibrogenic factors which promote PSC 
activation, proliferation, migration and ECM remodeling capability. On the other hand, PSC 
recruitment is consequential for cancer cell behavior, as stellate or cancer cell-derived growth 
factors, cytokines and ECM components are sequestered in a fortified niche. 
For instance, Bachem and co-workers [101] demonstrated that conditioned medium derived 
from human pancreatic cancer cell lines increased PSC proliferation and matrix synthesis at a 
significantly greater rate than that of PSCs cultured in regular media. Subsequently, 
neutralizing antibodies against the growth factors PDGF, FGF-2, and TGF-β1 were added to 
the supernatant which then inhibited these effects, confirming the influence of mediators 
released by pancreatic cancer cells on PSC activity.  
The same researchers created a subcutaneous mouse model injected with pancreatic tumor 
cells and PSCs in order to investigate the interaction between the two in vivo. They found that 
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the increased deposition of connective tissue in pancreatic carcinoma is the result of a 
paracrine stimulation of pancreatic stellate cells by carcinoma cells.  
In another study by the same group, co-injection of PSCs and tumor cells into nude mice 
enhanced the expressing of serine protease inhibitor SERPINE2 and resulted in increased 
tumor growth. In addition, histological evaluation demonstrated the presence of large amounts 
of ECM deposits co-localizing with cells staining positive for the PSC marker α-SMA. They 
suggested that PSCs actively proliferate in pancreatic cancer xenograft tumors and 
significantly contribute to the local invasive potential of the tumors [105]. 
Although these studies provided important evidence of stromal-tumor interactions, 
subcutaneous models are not an ideal choice for studying pancreatic cancer. One of the 
defects of this kind of pancreatic model is the absence of the natural tumor microenvironment. 
Therefore, orthotopic models which involve injection/implantation of cancer cells directly into 
the organ of interest are a preferred option. 
Lohr and colleges [106] reported that of the orthotopic injection of pancreatic cancer cells 
(PANC-1cellline) transfected with TGF-β1 cDNA resulted in the stimulation of an extensive 
stromal reaction all over the pancreatic tumor injected. Although not specifically studied at 
the time, this stromal reaction was most likely via the TGF-β1 induced activation of stromal 
cells/fibroblasts in the host (mouse) pancreas. 
In an investigation by Xu and co-workers [104], which created an orthotopic mouse model of 
pancreatic cancer, they co-injected a PSC line with a cancer cell line. Primary tumor 
incidence, size and metastasis were all increased with co-injection compared to cancer cells 
alone, and they noted that human PSCs accompany cancer cells to metastatic sites, and 
significantly enhance tumor angiogenesis as indicated by up-regulation of the endothelial cell 
marker CD31 in orthotopic tumors produced by cancer cell and PSCs as compared to tumors 
produced by injection of cancer cells alone. Similarly, these in vivo findings were also 
observed in vitro. PSCs were found to be able to directly stimulate angiogenesis, and this 
effect mediated by vascular endothelial growth factor (VEGF) secreted by PSCs themselves. 
In addition, In the presence of cancer cells, PSCs have ability to migrate through an 
endothelial layer in vitro, suggesting that PSCs have the capacity to intravasate/extravasate to 
and from blood vessels in vivo [104]. 
In a different study, Vonlaufen et al. [103] found that mice injected with PSCs alone did not 
develop a pancreatic tumor. However, mice injected with cancer cells developed tumors, and 
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mice injected with both cancer cells and PSCs developed even bigger tumors. Hence, PSCs 
alone do not have the potential to form a tumor, but instead play an important role in 
promoting the growth of cancer cells which are already present. On further investigation, 
tumor sections from the mice that were co-injected with PSCs and cancer cells were also 
studied to elucidate the origins of the activated PSCs in the tumor site. They conducted 
immunohistochemical staining for α-SMA and human nuclear antigen, the latter being a 
human cell-specific marker. The results revealed that some of the α-SMA positive cells within 
the tumor resulting from co-injection also did not express human nuclear antigen. This implies 
that cancer cells managed to recruit and activate the PSCs belonging to the host species in 
order to enhance tumor growth. 
In vitro studies by the Kikuta and colleagues [107], which created an indirect co-culture 
model of pancreatic cancer revealed that PSCs stimulate cancer cell proliferation but inhibit 
cancer cell apoptosis thereby effectively enhancing the survival of cancer cells and induce 
cancer cell migration. The PSC-induced cancer cell migration is associated with epithelial-
mesenchymal transition in cancer cells as indicated by decreased expression of epithelial 
markers, such as E-cadherin, and increased expression of mesenchymal markers, such as 
vimentin and Snail in cancer cells. However, these may have been indirect effects PSCs 
through their secretion of laminin and fibronectin, proteins which have previously been 
reported to have antiapoptotic effects [103] 
Farrow and colleagues [108] have carried out a thorough investigation into the involvement of 
PSCs in tumor invasion in pancreatic cancer. Interestingly, they discovered that in co-culture 
the pancreatic cancer cell line Panc-1 migrates toward PSC cells, creating nests of cancer cells 
within the stromal cells. PSC cells promote the invasion of Panc-1 cells and release 
thrombospondin 2 (TSP-2). When TSP-2 expression is reduced in PSC cells using selective 
siRNAs, pancreatic cancer cell invasion was inhibited. This implies that targeting pro invasive 
elements such as TSP2 within the tumor microenvironment may inhibit local invasion. 
Overall, the above studies suggest that pancreatic cancer cells recruit host PSCs to their 
immediate vicinity and that PSCs reciprocate by facilitating cancer cell growth as well as 
local invasion (Figure  1.3). 
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Figure ‎1.3 Effect of PSCs on tumor cell invasion and desmoplasia. 
There is accumulating evidence for PSCs crosstalk with tumor cells, which in turn contributes to the profound tumor 
desmoplasia that is noted in pancreatic cancer. Such direct or indirect cell-cell dialogue can also promote tumor 
invasion and possibly angiogenesis, although a role in angiogenesis has been more studied in liver. Other cells in 
pancreas (for example, acinar cells, ductal cells, endothelial cells and leukocytes) are likely to be involved. 
 
1.6 Role of PSCs in ECM remodeling  
The extracellular matrix is a proteinaceous network of macromolecules that provide a tensile 
scaffold necessary to its surrounding cells. The ECM can be divided into to the basement 
membrane and the interstitial matrix. Collagen IV, represent the major component of 
basement membranes but also collage I, II, and III, can be mostly found in interstitial 
matrices. Along with collagen, laminins, heparan sulfate proteoglycans (HSPGs), and 
fibronectins, can be found and form a mesh-like network [109]. There are also matricellular 
proteins, such as tenascins, entactin, thrombospondins, and SPARC (secreted protein, acidic 
and rich in cysteine), which lack a structural role, but instead act as modulators for the 
interactions between the cell components and the surrounding matrix [109, 110].  
During tumor development, the ECM can modulate carcinogenesis by providing a supporting 
structure for tumor through integrin signaling, affecting processes such as proliferation, 
differentiation, migration, and survival [111]. The ECM also serves as a rich reservoir for pro-
angiogenic and antiangiogenic factors [112], which represent another way to support tumor 
angiogenesis. 
Although PDAC cells can produce several components of the ECM, activated PSCs represent 
the main source of excessive ECM [101, 113, 114]. Experimental and clinical studies have 
shown that activated PSCs reflect a balance between matrix production and degradation. This 
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alteration in the balance between ECM protein synthesis and degradation can result in 
pathological increases in ECM deposition leading to the development of fibrosis [85-88]. 
Pancreatic cancer tissues are characterized by a remarkable increase of interstitial connective 
tissue, which accompanied by increased steady state levels of the mRNA’s for collagens type 
I, III and IV, fibronectin and laminin [115] and of collagen protein. In addition, the collagen 
itself has been shown to increase the proliferation, migration and resistance to apoptosis of 
pancreatic cancer cells, mediated by signaling via its integrin receptors [116]. 
In fact, ECM breaking is key step in the progression of PDAC. During this process, PSCs 
respond to the injury by proliferating and by chemotaxis to the sites of tissue injury to rebuild 
the ECM as a scaffold for tissue regeneration. Secondly, PSCs enable the contraction of the 
matrix to seal an open wound in the event of the loss of tissue through the production of ECM 
degrading proteases and their inhibitors, such as tissue inhibitor of metalloproteinase 1 
(TIMP-1) [53, 59]. The importance of PSCs is further highlighted in a study demonstrating 
that recruited myofibroblast act as a first source of fibronectin and collagen type I, which 
represent 25-40 fold more than collagen type III esters in pancreatic cancer [48]. Also, PSC 
synthesis of MMP-2, a protein crucial for basement membrane degradation, is increased by 
ECM metalloproteinase inducer (EMMPRIN), which is secreted by cancer cells [117]. By 
using indirect co-culture between immortalized PSCs and pancreatic cell lines, Erkan et al. 
[118] studied the role of PSCs in hypoxia and angiogenesis and they noted that PSCs 
contribute to the fibrotic/hypoxic milieu by abnormal ECM deposition and amplifying 
endostatin production in PC cells. 
The activated stellate participate in produce and remodeling of ECM through a multipronged 
approach. First, they provide a repertoire of secreted growth factors, including bFGF, TGF-
β1, PDGFs, IL-ß1 [59]. Combined with other sources of pro-inflammatory factors in the 
tumor, myofibroblast-derived pro-inflammatory factors can tip the ECM balance in favor of 
tumor fibrosis [94, 119]. For instance, TGF-β1 has been shown to be of particular importance 
in biosynthesis and turnover of extracellular matrix [120, 121].  
Böttinger and collaborators [122] used transgenic mice to identify TGF-β1 as one of the 
central regulators of ECM-formation in the pancreas. The dominant-negative mutant type II 
TGF-β1 receptor blocked signaling by all three TGF-β1 isoforms in primary hepatocyte and 
pancreatic acinar cell cultures generated from the transgenic mice. Also they noted that acinar 
cells in the pancreas of these transgenic mice showed increased proliferation and severely 
perturbed acinar differentiation. Additional abnormalities in the pancreas included fibrosis, 
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neoangiogenesis and mild macrophage infiltration. Moreover it is clear that TGF-β1, which is 
released from various cell types including activated macrophages and platelets, induces 
pancreatic fibrogenesis mainly through its effects on pancreatic stellate cells. However, TGF-
β1 not only has the capacity to activate transcription of extracellular matrix forming proteins, 
such as collagen I, collagen III and fibronectin, but also induces the expression of matrix 
degrading proteinases, such as MMP-2, MMP-9, and MMP-13 [53]. A critical element in 
matrix remodeling is a family of matrix-metalloproteinases. These are a family of about 20 
zinc-dependent enzymes that are secreted in the inactive form. MMPs are classified according 
to their substrate specificity and structural features into five major groups: gelatinases (MMP-
2, MMP-9), stromelysins (MMP-3, MMP-10, MMP-11), elastases (MMP-12, MMP-7), 
collagenases (MMP-1, MMP-8, MMP-13, MMP-18), and membrane-type matrix 
metalloproteinases (MT1-MMP, MT2-MMP, MT3-MMP, MT4-MMP) [123]. The activation 
of MMPs occurs via the actions of proteases such as plasmin and trypsin. In return, the 
activity of MMPs can be inhibited by tissue inhibitors of metalloproteinases (TIMPs), which 
divided into four subtypes (TIMP-1-TIMP-4) [124-127]. TIMP-1 inhibits the activity of 
several MMPs (MMP-1, 3, 8, 9, 10, 11, 13, and 18) while TIMP-2 is particularly important in 
the inhibition of MMP2. One of the most important functions of MMPs is their ability to 
degrade type IV collagen, a component of the basement membrane. MMPs have been seen to 
play an important role in pancreatic cancer progression. Bramhall and coworkers [128] 
evaluated the over expression of MMP-2, MMP-3, MMP-7 and MMP-11 and suggested that 
while overexpression of MMP-7 and MMP-11 may be countered by TIMP-1, the aggressive 
phenotype of pancreatic carcinoma may occur because of overexpression of MMP-2, which is 
activated by MTMMP and associated with a reduced expression of TIMP-2. Another study by 
Volker and colleagues [129] has shown that MT1-MMP is involved in the progression of 
pancreatic cancer via activation of MMP-2. MMP-2 itself plays an important role in tumor 
cell invasion and appears to be associated with the development of the characteristic 
desmoplastic reaction in pancreatic cancer. 
As it was mention before, the most important functions of MMPs is their ability to degrade 
type IV collagen, a component of the basement membrane and digestion of this membrane 
allows cancer cells to invade local lymphatic channels and blood vessels, thus representing a 
critical step in tumor progression [130]. Moreover, MMPs also regulate the bioavailability of 
growth factors and cytokines contained within the ECM. These molecules have the ability to 
release after MMPs digest the ECM, which in turn affects tumor proliferation, angiogenesis 
and metastasis. For example, TGF-β1 has been shown to up-regulate collagens, MMP-2 and 
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TIMP-1, whilst down-regulating TIMP-2, MMP-3, and interstitial collagenases such as MMP-
1 and MMP-13 secretion by fibroblasts [53]. Also, insulin like growth factor binding proteins 
and stromal cell derived factor are both cleaved and inactivated through MMP activity. 
Therefore, we must decipher which proteases are contributing to tumor progression, and 
which are acting as part of the host defence. This is a necessary step in determining which 
MMPs are potential drug targets [131]. 
The finding that PSCs can synthesize and secrete MMPs is important because it suggests that 
in addition to their well-documented role in ECM synthesis PSCs may also play a role in 
ECM degradation. Phillips and colleagues revealed that PSCs are able to synthesis a number 
of matrix metalloproteinase, including MMP-2, MMP-9, and MMP-13 and their inhibitors 
TIMP-1 and TIMP-2. MMP-2 secretion by PSCs is significantly increased on exposure to the 
proinflammatory cytokines TGF-ß1 and IL-6. Both ethanol and its metabolite acetaldehyde 
increase MMP-2 as well as TIMP-2 secretion by PSCs [53].  
This is in accordance with studies by Knittel and colleagues, demonstrating that hepatic 
stellate cells (HSCs) are a major source of MMP-2 in the liver and that the MMP-2 secreted is 
largely in the latent form. In the present study, zymography results suggested that PSCs also 
secrete MMP-9 [132]. 
Hence, PSCs may enhance fibrogenesis by inhibiting ECM degradation via autocrine 
signaling which inhibits their own production of MMP-3 and -9 [59]. 
1.7  Role of pancreatic stellate cells in chemo resistance 
PDAC is highly refractory to chemotherapeutics [133]. Five major resistance principles have 
been distinguished explained the cause of chemo resistance: reduced drug uptake; increased 
energy-dependent drug efflux; matrix components increase drug resistance; alterations in 
cellular capabilities affecting drug cytotoxicity, such as reduced apoptosis and deregulated 
drug metabolism; cancer cells or cancer stem cells (CSCs) promote resistance mechanisms 
[134]. However, increasing evidence indicate that chemoresistance of PDAC is closely 
associated with extensive fibrosis produced by PSCs [135, 136]. 
Although many chemotherapy studies showed an increased median survival in pancreatic 
cancer, response rate and effect on overall survival are exceedingly limited. This is mainly 
due to the inevitable generation of drug resistance in the course of chemotherapy treatment of 
the preclinical findings [137]. PDAC therapeutic strategies have been assessed predominantly 
in experimental models of pancreatic fibrosis (although not all studies have examined PSC 
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function). Chemotherapeutic regimes during the past few decades have been restricted to 
neoadjuvant, adjuvant or palliative settings, mostly using gemcitabine-based chemotherapy 
protocols and these have established the current standard of care. Recently, a combination 
chemotherapy treatments have shown promise to act as adjuvant or palliative treatments. For 
example, treatment using oxaliplatin, 5-FU, irinotecan and folinic acid (FOLFIRINOX) led to 
a median survival of 11 months, compared to only 6.8 months for gemcitabine alone [26]. 
Targeted therapies have mostly shown disappointing results in pancreatic cancer until Burris 
and co-workers [25] noted that erlotinib, an epidermal growth factor receptor (EGFR) tyrosine 
kinase inhibitor, in combination with gemcitabine shows a very moderate but significant 
survival advantage. Feldmann et al. [138], Olive and coworkers [139] examined the inhibition 
of smoothened by cyclopamine or IPI-926 in transgenic PDAC models, which showed an 
increased median survival in the former and increased delivery of the chemotherapeutic agent 
to cancer cells in the latter in combination with gemcitabine. However, there was only a 
transient effect on improved blood vessel density and extension of median survival.  
Recently, many studies have been targeting components of the desmoplastic stroma of the 
tumors in animals [139-141]. This is mainly a result of the accumulating evidence that points 
to the primary role of activated PSCs in chemoresistance in pancreatic cancer. For example, 
Hwang and colleagues have found that the supernatants of cultured PSCs can inhibit the 
sensitivity of PDAC cells to chemotherapy and radiotherapy [102]. They suggested that there 
is some soluble component in PSCs secretome that may play a role in the resistance of 
pancreatic cancer to such treatments. Other studies also found that the stroma was 
dramatically depleted leading to increased intra-tumoral vascular density and normalization of 
interstitial fluid pressure (IFP). Following stromal depletion, administering chemotherapeutics 
such as gemcitabine or doxorubicin resulted in enhanced intra-tumoral drug perfusion, 
rendering tumors vulnerable to cytotoxicity, and hence inhibiting tumor growth and 
prolonging overall survival in animals [139-141]. Hwang and colleagues [142] used another 
inhibitor AZD8542 in an orthotopic model of pancreatic cancer produced by implantation of a 
mixture of PSCs and cancer cells in the pancreas. AZD8542 was reported to reduce tumor 
volume, metastasis and Hedgehog downstream signaling activity. The same researcher has 
found that the stroma also impairs tumor cell response to chemotherapy and radiation. 
Moreover, in an orthotopic model of pancreatic cancer, stromal fibroblasts enhanced tumor 
growth, metastasis, and initiation [142]. 
In a different study, Von Hoff et al. [143] investigated the pancreatic cancer stromal depletion 
by using subcutaneous xenograft model (xenografted mice with cells derived from patients), 
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and they were able to produce pancreatic stromal depletion after administering nanoparticle 
albumin-bound paclitaxel (nab-paclitaxel). In this study, an in vitro model of pancreatic 
cancer cell lines with different grades (MiaPaca2, grade 3; Panc1, grade 2; and Capan1, grade 
1) of differentiation were cultured in the presence of collagen (I or IV), fibronectin or laminin. 
The study has shown that fibronectin promoted MiaPaca2 cells to proliferate, whereas 
collagens I and IV and laminin were suppressive. In contrast, Panc1 and Capan1 cells were 
proliferative in the presence of collagens I and IV and fibronectin but not in laminin. When 
these cells were grown on any of the above ECM proteins in the absence or presence of 
chemotherapy agents (cisplatin, doxorubicin, gemcitabine, and 5-fluorouracil) for up to 72 h, 
MiaPaca2 cells showed increased chemoresistance to all of the chemotherapy agents except 
gemcitabine. Capan1 cells were also chemosensitive to gemcitabine, but this effect was not 
observed with Panc1 cells. These results suggest that grade of differentiation of the tumor 
may determine matrix-driven sensitivity to chemotherapy. In addition to stromal depletion, 
they have found an increased vascularization in the tumor milieu and up-regulation of 
mNestin (endothelial marker), which facilitated a 2.8-fold increase in the intratumoral 
concentration of gemcitabine. In two gemcitabine-resistant xenografts, a profuse desmoplastic 
stroma remained after treatment with gemcitabine alone, however with administration of nab-
paclitaxel there was a significant reduction in tumor stroma. In addition, this stromal depletion 
may accords through active transport across endothelial cells (gp60/caveolin-1receptor 
pathway) and active binding of albumin-paclitaxel complexes by osteonectin (also known as 
SPARC), which is highly expressed and secreted by peri-tumoral pancreatic stellate cells 
[144]. The findings from this study supported the theory that the tumor stroma inhibited 
efficient drug delivery to tumor cells because of the compression of the blood vessels 
surrounded by the cancer cells [145]. 
In addition, Müerköster et al. [145] revealed that the resistance of cancer cells to 
chemotherapy may be attributed to the IL-1ß and Nuclear factor NF-kappa-B p105 subunit 
(NFkB-1) dependent autocrine pathway mode, while it was documented that activated PSCs 
are cable of increasing IL-1ß expression in PDAC cells by increasing the secretion and 
paracrine effects of nitric oxide (NO), ultimately leading to the formation of chemotherapy 
resistance. Another mechanism for PDAC chemo-resistance may arise as a result of the ability 
of PSCs to inhibit apoptosis of PDAC cells [95, 101]. It was shown that this desmoplasia 
causes hypo-vascularization of PDAC tissues and inhibits the delivery of chemotherapy drugs 
[118], while hypoxia leads to genomic instability and a more malignant behavior of PDAC 
cells as well as resistance to chemotherapy [146-148]. Others factors secreted by PSCs like 
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Periostin and Decorin, may also increase chemoradiation resistance of cancer cells [113, 149]. 
Another contributing factor to the resistance of PDAC chemotherapy is the ability of PSCs to 
promote EMT, which has been shown to cause chemotherapy resistance in PDAC [150]. 
1.8 Targeting PSCs as an important strategy for comprehensive PDAC 
treatment 
Understanding how stromal proteins influence drug resistance, drug delivery and patient 
survival has the potential to help clinicians make better use of available treatments to improve 
the outcome of patients with pancreatic cancer. Here we will explain a few studies of the 
promising stromal targeting therapies currently being under investigation. 
Yamada et al. [151] studied the role of angiotensin II type I receptor inhibitors in the activity 
of PSC and they demonstrated that oral administration of candesartan (a widely used 
angiotensin II type-I receptor inhibitor) decreased ECM production and α-SMA expression 
(activated PSC marker) in a rat model of chronic pancreatitis. Furthermore, it was found that 
combination of angiotensin II type I receptor inhibitors with gemcitabine may have improved 
clinical outcome [152]. Same group try to examine whether patients treated with candesartan 
in combination with gemcitabine would have improved survival. Unfortunately, they failed to 
demonstrate any significant clinical activity with 35 patients with advanced pancreatic cancer 
[153]. 
By using orthotopic pancreatic tumors model, Chauhan and co-workers [154] found that 
angiotensin II Type 1 receptor inhibitor also decrease stromal collagen and hyaluronan 
production, as well as reduce the number of α-SMA positive PSC. They demonstrated also 
reduced hypoxia and increased sensitivity to chemotherapy agents. This promising pre-clinical 
study has now moved forward to a clinical trial in pancreatic cancer (NCT01821729). 
Recently, Kozono and colleges [155] has generated great interest as a novel therapeutic for 
pancreatic cancer. They demonstrated that an anti-fibrotic agent pirfenidone decreased tumor 
increased drug sensitivity and deceased growth / metastases in a mouse orthotopic model of 
pancreatic cancer (co-injection of PSCs and tumor cells into the pancreas). 
More recently, Sherman et al. [156] reveal that the vitamin D receptor (VDR) is expressed in 
stroma from human pancreatic tumors and that treatment with the VDR ligand calcipotriol 
markedly reduced markers of inflammation and fibrosis in pancreatitis and human tumor 
stroma. They show that VDR acts as a master transcriptional regulator of PSCs to reprise the 
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quiescent state, resulting in induced stromal remodeling, increased intratumoral gemcitabine, 
reduced tumor volume, and a 57% increase in survival compared to chemotherapy alone. 
Finally, Berchtold and colleges [157] conclude that paracrine loops between cancer and 
stromal are mediated by collagen type V which promote the malignant phenotype of 
pancreatic ductal adenocarcinoma and underline the relevance of epithelial-stromal 
interactions in the progression of this aggressive neoplasm. In addition, using 
pharmacological and antibody-mediated inhibition of β1-integrin signaling abolishes collagen 
type V-induced effects on pancreatic cancer cells. Ablation of collagen type V secretion of 
pancreatic stellate cells by siRNA reduces invasion and proliferation of pancreatic cancer cells 
and tube formation of endothelial cells. Moreover, stable knock-down of collagen type V in 
pancreatic stellate cells reduces metastasis formation and angiogenesis in an orthotopic mouse 
model of ductal adenocarcinoma. 
 
 
 
 
Figure ‎1.4 The potential therapeutic implication of targeting both pancreatic cancer cells and pancreatic stellate cells 
in pancreatic cancer. 
 
1.9 Future potential treatments for PSC disorders 
Despite major improvements, many current PDAC therapies have potential harmful side 
effects and are marked by a low overall survival rate. Therefore, PDAC development is 
regarded as the result of different environmental risk factors. Stromal tumor 
microenvironment is the main factor responsible for PDAC progression and development, 
indicating that in the future pancreatic cancer research should switch its focusing either on 
extracellular ligand-receptor interactions, down-stream pathways in tumor cells, or 
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downstream pathways in tumor stroma, as well as targeting ECM components themselves. 
Identifying these altered mechanisms regulating the bidirectional cross-talk between PDAC 
and PDAC microenvironment components may improve our knowledge and is crucial for the 
design of the most promising strategy for future therapies [158]. Several issues should be 
taken into consideration such as (i) resistance to treatment which remains the major challenge 
for targeted therapy, (ii) developing a new strategy to combine chemotherapy regimens with 
different agents aimed at specifically targeting not only tumor cells but also profibrotic 
stromal cells.  
As mentioned earlier, the inhibition PSCs activation represents a potential therapeutic strategy 
for the treatment of PDAC [159]. Future therapeutic strategy may focus on (i) inhibiting or 
control the activation of PSCs; (ii) controlling cell functions of PSCs; (iii) blocking the effect 
of cytokines, proinflammatory factors and chemotactic factors involved in the pathways 
signaling by which PSCs and PDAC cells interact (e.g. inhibition of the Hedgehog cellular 
signaling pathway has been provided a therapeutic strategy for PDAC [160, 161]); (iv) 
inducing the apoptosis of activated PSCs represent one of the treatment strategy; (v) 
regulating the interactions with other pancreatic cells (e.g., endocrine cells, immune cells and 
nerve cells) [118]; and (vi) control PSC activation by removing any factors that promote 
activation of PSCs like inflammation, alcohol, hypoxia and ROS [161]. Identifying new 
targets and their agents will lead to a more personalized therapy. 
1.10  Cancer proteomics 
The proteome is the entire set of proteins expressed by a genome, cell, tissue or organism at a 
certain time, under certain conditions [162, 163]. The term proteomics refers to the large-scale 
study of the proteome; including protein modifications, protein structure, expression, function 
and interactions, produced by an organism or a cellular system [164]. Proteins are expressed 
at distinct times, in distinct cell types and only under certain conditions, as well as undergo 
differential splicing and post-translational modifications. This means that even the basic set of 
proteins that are produced in a cell needs to be determined [165]. In the past few years, the 
development of quantitative proteomics technologies has stimulated considerable interest in 
applying the technology for clinical applications.  
Several novel technologies have recently been implemented in cancer research for proteomic 
analysis (Table 1.10.1) such as western blot, immunohistochemical and 2D-PAGE. For 
example western blot and immunohistochemical analyses are robust but they represent a low 
throughput methods for investigation of protein expression [166]. For a number of years, the 
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main analytical techniques aiming at studying the proteome have traditionally been two-
dimensional gel electrophoresis (2DE) together with mass spectrometry (MS). In 2DE, 
proteins are separated in two dimensions based on isoelectric point (pI) and size (Mw) [167]. 
The gel is stained and protein spots of interest can be cut out and identified using MS. 
Although this technique is uniquely suited for direct comparisons of protein expression and 
has been used to identify proteins that are differentially expressed between normal and tumor 
tissue [166], it has also limitations such as limited throughput, low dynamic range and low 
resolution; a typical 2DE experiment detects approximately 2000-3000 protein spots out of 
which only a subset will be identified [168, 169]. 
Table ‎1.10.1 Comparison of proteomics technologies and their contributions to biomarker discovery and early 
detection [170] 
 ELISA 2D-PAGE Multimensional 
protein 
identification 
technology 
(MudPIT) 
Proteomic 
pattern 
diagnostic 
Protein 
microarray 
Sensitivity Highest Overall low, 
particularly for less 
abundant proteins. 
Sensitivity limited; 
LCM can improve 
specificity via 
enrichment of selected 
cell populations.  
High Medium 
sensitivity  
Medium/ high 
Direct 
identification 
of markers 
N/A Yes Yes No, newer MS 
technologies 
might make this 
possible 
Possible when 
coupled with MS 
technology 
Use Detection of single, 
specific well 
characterized 
analytic in body 
fluid or tissue gold 
standard of clinical 
assays. 
Means for discovery 
and identification of 
biomarkers, not a 
direct means of early 
detection itself 
Detection and 
identification of 
potential 
biomarkers  
Diagnostic 
pattern analysis 
in body fluids 
and tissue; 
potential 
biomarkers 
identification 
Multiparametric 
analysis of many 
analysis 
simultaneously 
Throughput Moderate Low Very low Highest High 
Advantages Very robust; well-
established use in 
clinical assays; 
characterized 
antibody for 
detection and 
extensive 
validation; not 
amenable to direct 
discovery. 
All Ids require 
validation and testing 
before clinical use; 
tried and true 
methodology; 
reproducible and more 
quantitative combined 
with fluorescent. 
Significantly 
higher, 
sensitivity than 
2D-PAGE( 
much larger 
coverage of the 
proteome for 
biomarkers 
discovery. 
Proteins Ids not 
necessary for 
diagnostic 
pattern 
analysis; 
reproducibility 
issue need to be 
addresses; 
coupling to 
adaptive 
informatics the 
field of clinical 
chemistry. 
Format is flexible; 
can be used to assay 
for multiple analysis 
in a single specimen 
or a single analytic 
in a large number of 
specimens; requires 
prior knowledge of 
analytic being 
measured; limited 
by antibody 
sensitivity and 
specificity requires 
use of an amplified 
tag detection 
system. 
2D-PAGE, two-dimensional polyacrylamide gel electrophoresis; ID, identification; LCM, laser capture microdissection; MS, 
mass spectrometry. 
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Antibody microarrays have evolved over the last several years from a promising tool and 
represent a developing tool for global proteomic profiling [171]. Protein microarrays 
technology has become a frequently used to study protein-protein/ protein-DNA interactions 
(functional arrays); the probe on such an array can be either a protein or capturing agent, 
known as aptameric (e.g. oligonucleotides) [172]. The most common arrays however, utilize 
antibody-antigen interactions. 
Microarray technology has become a frequently used device in genome research and 
compared to long-established tools like two-dimensional gel electrophoresis or mass 
spectrometry, only small sample volumes are required [173], handling simplicity, throughput, 
selectivity and sensitivity – down to single molecule detection [174]. It is also able to screen 
of expression against hundreds of proteins and this is necessary for deep understanding of 
disease processes on a proteomic level [166]. In addition, it can be used to analyze a broad 
range of biological samples such as serum, urine, cell lysate or tissue [175]. 
This technique consists of five steps: array production, protein extraction, samples labeling, 
incubation and data analysis [175, 176]. The procedure for antibody microarray is as follows: 
At first, small amounts of antibodies are attached to a solid support and the remaining surface 
is blocked to prevent unspecific protein binding. Secondly, protein samples are used – either 
directly from serum or isolated from cells, for example. In case of isolation of the cellular 
proteins, it is important that the isolated protein sample gives a good representation of the 
overall proteome as well as provides high quantity and quality. Samples can be incubated with 
the array in various manners depending on the number of samples and/or groups of samples to 
be tested. Hence, different statistical approaches may apply. Protein samples are labeled with 
fluorescent dye before incubation with chip to allow for detection. Following incubation, 
signal intensities are acquired using specialized instrumentation and analyzed with the 
necessary software, whereat the intensities represent the protein levels (Figure 1.5). 
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 Figure ‎1.5 Schematic procedure of an antibody microarray 
The specific antibodies are spotted on epoxysilane coated slides, which need to be blocked to prevent the unspecific 
binding of the sample proteins. The target proteins are labelled with a fluorescent dye and then incubated with the 
blocked slides. After washing and drying of the slides, they are scanned by a laser and the data is analysed by 
appropriate software. Adopted from [178]. 
 
Various factors are relevant for the success of an antibody microarray such as the surface 
material, the antibodies, the incubation or the detection method [173]. The selection of the 
surface is critical for the performance of the microarray. Usually glass, plastic or silicone 
slides are coated with different kinds of substrates for instance nitrocellulose, Streptavidin or 
epoxysilane [173]. For detection, two main types are established. There exists the direct 
labeling method using fluorophores or haptens to label the target proteins themselves. 
Fluorophores are then directly detected by fluorescence measuring while haptens like biotin 
are indirectly detected with labeled Streptavidin. Moreover there is the sandwich method 
using an antibody pair to detect the unlabeled target. In this case the secondary antibody is 
usually biotinylated and is detected by a labeled anti-biotin antibody [179]. Another important 
subject is the choice of the antibodies that are spotted on the slide. Besides poly- and 
monoclonal antibodies, it is also possible to use recombinant antibody fragments, affibodies 
or aptamers as capture molecules [180]. 810 polyclonal antibodies were used enabling the 
detection of 741 cancer-related proteins [181] and every antibody was spotted in 
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quadruplicates [95] on epoxysilane-coated slides. Using mono-specific polyclonal antibodies 
improves the affinity, since they can bind to different epitopes on the target protein [173].  
To block unspecific binding sites on the slide, it was incubated with non-fat dry milk prior to 
the sample incubation. The slides were simultaneously incubated with the target proteins, 
labeled with DY-649 NHS-ester with a protein-dye-ration of 7.5, and a DY-549 NHS-ester 
labeled reference sample made by pooling protein extracts from 24 pancreatic cancer cell lines 
[95]. The advantage of this direct labeling is the ability to label several samples with different 
dye and co-incubate the on the same slide [179]. Some of the analysis conditions like blocking 
buffer composition, blocking duration, labeling parameter and others were previously 
optimized by Alhamdani et al. [175]. 
 
1.11 The importance of studying PSC secreted proteins 
Study of secreted proteins can reflect a broad variety of different conditions of the cancer cell 
types included pancreatic cancer [182-184]. Direct examination of the secretome proteins 
represent a serious technical challenge, because this technical is able to identified proteins in 
large number of clinical body fluid specimens [185]. Secreted proteins, such as cytokines, 
chemokines and hormones into the extracellular microenvironment [186], exhibit central 
functions, like intercellular communication, which is promoting cancer cell intercellular 
communication, cell adhesion, motility and invasion [187]. The cellular secretome does not 
only include actively secreted proteins, but also extracellular matrix proteins and proteins shed 
from the cell surface [186]. 
In fact, a complex interaction between PSCs and pancreatic cells takes place, although the 
molecular basis of this interaction is discovered, the secretome of transplanted PSC is 
considered the driving force behind this process and still a matter of research. To acquire a 
deeper knowledge on this subject, several studies shown that secreted proteins are associated 
with cancer progressive [188-190]. Thus, study analysis of the molecular mechanisms 
underlying the pancreatic stellate cell secretome is essential understanding of the roles of 
PSCs secreted proteins in cancer development and may provide potential targets for the 
treatment or early diagnosis of pancreatic fibrosis. 
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To date, there are a few proteomics studies analyzing PSCs secretome. Only one comparative 
proteomic study compares between quiescent and activated stellate cells secreted proteins by 
using 2D LC-MS/MS analysis have been done [103]. 
However, several novel technology have recently been implemented in proteomics cancer 
research and has been widely applied in the identified and analysis of several cancer cell 
secretomes, like those of breast cancer [191], lung cancer [192] and pancreatic cancer [184]. 
One of those new techniques that has been extensively utilized in the analysis of pancreatic 
cancer, microarray technology [178], which is a powerful tool for analysis of proteins 
expression to identify unique and similar molecular elements in various disease processes. 
 
1.12 Aim 
In this dissertation, I used antibody microarrays as a tool for investigating the molecular 
events at the level of proteome that are associated with PSCs. 
The first part of the study is aimed at defining molecular events that occur as a consequence of 
PSC activation with individual proinflammatory mediators: TNF-α, FGF-2, IL-6, and 
chemokine (C-C motif) ligand 4 (CCL-4). For this purpose, we performed analyses in the 
absence of serum, thus examining the direct effect of individual cytokines in vitro for a 
definition of the biological functions of each of them. 
Following up the functional and network analysis of Part I, in which the potential role of c-
Fos as transcriptional regulator of PSC activation via TNF-α [95] was indicated, the second 
part of this study was aimed at testing the hypothesis that TNF-α meditated dependency of c-
Fos up-regulation is a possible route for PSC fibrogenic activity in pancreatic cancer. 
The third part of the study aimed at testing the hypothesis that PSCs contribute to the growth 
of tumor cells and thus to PDAC development and to provide evidence on the effects of PSCs 
and to gain a deeper insight into the molecular mechanisms of its anti-apoptosis action in 
PDAC. 
The fourth part aimed at an evaluation of the effect of anti-fibrotic drug candidates on 
activated PSCs, then to investigate the effects of the most promising drugs on human PSCs 
and tumor–stromal interactions between PDACs and PSCs.  
And finally, I aimed at controlling PSCs activation and their cell functions by investigating 
the effect of some natural products on PSC activation toward the development of new 
treatments of pancreatic fibrosis. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Cell lines 
Cell line Source of cells Cell type Disease 
PSC human cell line healthy 
PT45P1 human cell line PDAC 
Panc1  human cell line PDAC 
Capan1 human cell line PDAC 
MiaPaca2 human cell line PDAC 
 
2.1.2 Equipment 
Equipment Manufacture 
12-channel-pipette Biohit proline Biohit,Helsinki, Finland 
96-well flat bottom block Qiagen, Hilden, Germany 
96-well reaction plates  Steinbrenner, Wiesenbach, Germany  
6-well culture plates  Steinbrenner, Wiesenbach, Germany  
24-well culture plates  Steinbrenner, Wiesenbach, Germany  
Automatic developing machine  Amersham, Freiburg, Germany  
Beckmann GS-6KR centrifuge  Beckmann, Wiesloch, Germany  
Centrifuge 5810 R Eppendorf  Hamburg, Germany  
Centrifuge 580 R Eppendorf  Hamburg, Germany  
Cell culture incubator  Haenigsen, Germany  
Cell culture microscope  Carl Zeiss, Jena, Germany  
Cell viability analyser  Beckmann, Wiesloch, Germany  
Dismembrator B.  Braun Biotech, Melsungen, Germany  
Dry block heating system  Grant instruments, Cambridge, UK  
Electrophoresis power supply  E-C apparatus corporation, USA  
Epoxysilane-coated slides  Nexterion-E Schott, Jena, Germany  
Infinite m200 multimode reader  Tecan Grp Ltd, Maennedorf, Switzerland  
MicroGrid II Array-Roboter  Biorobotics, Cambridge, UK  
Mini-protein electrophoresis system  Bio-Rad Laboratories, Munich, Germany  
Power supply E835  Hoefer, CA, USA  
QuadriPERM plates  Vivascience, Hannover, Germany  
ScanArray 4000XL  Perkin Elmer, Massachusetts, USA  
Sigma 2k15 centrifuge  M&S laborgeraete gmbh, Wiesloch, Ger 
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Equipment Manufacture 
Slide Booster hybridization station Advalytix, Munich, Germany 
SMP3B stealth pins Telechem, CA, USA 
TE70 PWR semidry transfer unit Amersham, San Fransisco, USA 
Vortex  Scientific industries Genie-2, New York,USA 
Water bath SW22 Julabo Labortechnik, Seelbach, Germany 
Imaging Zeiss Axiocam 3.1 system (Jena, Germany) 
FACSCanto II flow cytometer BD Biosciences, Ustaria 
2.1.3 Chemical reagents, enzymes and general materials 
Reagent Company 
2-Mercaptoethanol Roche Diagnostics, Mannheim, Germany  
n-Dodecyl-ß-maltoside (DDM) > 99% Genaxxon Bioscience, Ulm, Germany 
6-Aminocaproic acid  Sigma-Aldrich, Munich, Germany  
2,7-Dichlorofluorescin diacetate Sigma-Aldrich, Munich, Germany  
Acetic acid  Mallinckrodt Baker, Greisheim, Germany 
Ammonium peroxydisulfate (APS)  Sigma-Aldrich, Munich, Germany  
Acrylamide (30%w/v)/Bisacrylamide  Bio-Rad Laboratories, Munich, Germany  
ASB-14  Sigma-Aldrich, Munich, Germany  
Benzonase EMD Millipore, Billerica, USA 
Bicine Biomol, Hamburg, Germany 
Blotting-Grade Blocker; non-fat dry milk Bio-Rad, Munich, Germany 
Blotting filter paper sheet  Neolab, Heidelberg, Germany 
Bovine serum albumin Sigma-Aldrich, Munich, Germany  
Bromphenol blue  Sigma-Aldrich, Munich, Germany  
cell scraper Neolab, Heidelberg, Germany 
Chloroform  Merck, Darmstadt, Germany  
Cryovial 1,0 ml, Innengewinde, Stern- fuss, Schreibfeld Fisher Scientific, Germany 
Dimethylsulfoxide (DMSO)  Sigma-Aldrich, Munich, Germany  
ECL hyperfilm GE Healthcare Europe, Freiburg, Germany  
Ethylenediaminetetraacetic acid (EDTA)  Merck, Darmstadt, Germany  
Ethanol  Merck, Darmstadt, Germany  
Halt Protease & Phosphatase Single-Use Inhibitor Cocktail Fisher Scientific, Schwerte, Germany 
Glycerine Roth, Karlsruhe, Germany  
Glycine Roth, Karlsruhe, Germany  
Hydrochloric acid (HCl)  Merck, Darmstadt, Germany  
Isopropanol (2-propanol)  Mallinckrodt Baker, Greisheim, Germany  
Magnesium chloride  Merck, Darmstadt, Germany 
Membran Protran NCBA85 Whatman gmbh, Hassel, Germany  
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Reagent Company 
Methanol  Merck, Darmstadt, Germany  
Milk powder (Skimmed)  Sigma-Aldrich, Munich, Germany  
Na2HPO4  Merck, Darmstadt, Germany  
NaH2PO4  Merck, Darmstadt, Germany  
NaOH  Merck, Darmstadt, Germany  
Sodium acetate  Merck, Darmstadt, Germany  
Sodium aside  Merck, Darmstadt, Germany  
Sodium chloride  Merck, Darmstadt, Germany  
Na-cholate  Sigma-Aldrich, Munich, Germany 
NP-40 substitute  Sigma-Aldrich, Munich, Germany  
Nuclease free water Ambion, Austin, USA  
Phenylmethanesulfonylfluoride(PSMF) Sigma-Aldrich, Munich, Germany  
Potassium Chloride  Sigma-Aldrich, Munich, Germany  
Ponceau dye Serva, Heidelberg, Germany 
Roti-Load Carl Roth, Karsruhe, Germany 
Sodium Carbonate  Sigma-Aldrich, Munich, Germany  
UltraCruz™ Reagent Reservoir, 25ml Santa Cruz, Germany 
Sodium dodecyl sulfate (SDS)  Sigma-Aldrich, Munich, Germany 
Spectra multicolor broad range protein ladder  Thermo Scientific, Rockford, USA  
Tetramethylenediamine (TEMED)  Bio-Rad Laboratories, Munich, Germany  
Trichloroacetic acid (TCA) Fisher Chemicals, Reading, UK  
Tris-Base Sigma-Aldrich, Munich, Germany  
Tris-HCl  Sigma-Aldrich, Munich, Germany 
Triton-X100  Sigma-Aldrich, Munich, Germany 
Trizol  Gibco/Invitrogen, Karlsruhe, Germany 
Tween-20  Sigma-Aldrich, Munich, Germany  
VIVASPIN 15R 2,000 MWCO HYDROSART Sartorius, Germany 
2.1.4 Cell culture 
Reagent Company 
IMDM  Gibco/Invitrogen, Karlsruhe, Germany 
Fetal Bovine Serum (FBS) Gibco/Invitrogen, Karlsruhe, Germany 
L-Glutamine  Gibco/Invitrogen, Karlsruhe, Germany 
Phosphate buffered saline (PBS) Gibco/Invitrogen, Karlsruhe, Germany 
Penicillin 1000u/ml-Streptomycin 100μg/ml Gibco/Invitrogen, Karlsruhe, Germany 
Trypsin Gibco/Invitrogen, Karlsruhe, Germany 
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2.1.5 Kits 
Kit Company 
Caspase-Glo® 3/7 Assay Promega, Madison, USA 
CellTiter-Glo Assay  Promega, Madison, USA 
Dy-549-NHS Dyomics, Dresden, Germany 
Dy-649-NHS  Dyomics, Dresden, Germany 
ECL prime western blot detection kit GE Healthcare Europe, Freiburg, Germany 
Mito-ID membrane potential kit Enzo Life Sciences ,Lörrach, Germany 
Novagen BCA protein assay kit  Merck, Darmstadt, Germany 
propidium iodide Sigma-Aldrich, Munich, Germany 
Protoscript first strand cDNA synthesis kit New England biolab, Ipswich, USA 
QuantiTect sybr Green PCR kit Qiagen, Hilden, Germany 
siPORTTM NeoFXTM Reverse transfection kit  Ambion, Austin, USA 
The CyQUANTNFcell proliferation assay kit  Invitrogen, Germany 
Pierce®BCA Protein Assay Kit Thermo Scientific, Bonn, Germany 
Precision Red Protein Assay  Cytoskeleton, Denver; USA 
2.1.6 Software 
Software Company 
Image Reader LAS-4000 Fujifilm, Düsseldorf, Germany 
Software Chipster v.1.4.7 CSC, Espoo, Finland 
Software GenePixPro 6.0  Molecular Devices, Sunnyvale, USA 
Software Ingenuity Systems Pathway Analysis Ingenuity Systems, Redwood City, USA 
STRING 9.1 database for known and predicted protein-protein interaction  
2.1.7 Antibodies 
Item Catalog No. Company 
Anti. p-ERK1/2 sc-16982 Santa Cruz, Biotech. Inc., Texas, USA 
Anti.Bax sc-70406 Santa Cruz, Biotech. Inc., Texas, USA 
Anti.Casp-9 10380-1-AP Acris, San Diego, USA 
Anti.CCNA2 AP7292b Abgent, San Diego, Canada 
Anti.c-Fos AP6585b Abgent, San Diego, Canada 
Anti.COL1A1 sc-8784 Santa Cruz, Biotech. Inc., Texas, USA 
Anti-cortactin AF1269a-AB BioCat, Heidelberg, Germany 
Anti-cytokeratin 19 (CK19)  Sc-6278 Santa Cruz, Biotech. Inc., Texas, USA 
Anti.DCN sc-22753 Santa Cruz, Biotech. Inc., Texas, USA 
Anti.eIF4A 9742 Cell signaling,Danvers,USA 
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Anti.ENO-1 AP6526c Abgent, San Diego, Canada 
Anti.ERK1/2 sc-135900 Santa Cruz, Biotech. Inc., Texas, USA 
Anti.FGF-1 sc-55520 Santa Cruz, Biotech. Inc., Texas, USA 
Anti.FLNA AM2240b Abgent, San Diego, Canada 
Anti.FN1 15613-1-AP Proteintech group,Chicago, USA 
Anti.GAPDH CB1001 Calbiochem,San Diego, USA 
Anti.IL-1β  sc-1251 Santa Cruz, Biotech. Inc., Texas, USA 
Anti.IL-4 ab154591 abcham, Cambridge,  
Anti.IMPDH sc-365171 Santa Cruz, Biotech. Inc., Texas, USA 
Anti.p-SMAD-2 AP3654a Abgent, San Diego, Canada 
Anti.p-SMAD-3 AP3250a Abgent, San Diego, Canada 
Anti.SERPINE ab154591 abcham, Cambridge,  
Anti.SMAD-2 AP7365A Abgent, San Diego, Canada 
Anti.SMAD-3 AP9995a Abgent, San Diego, Canada 
Anti.TNF-α 500-P31A Peprotech, USA 
Anti.α-SMA 14395-1-AP Proteintech group,Chicago, USA 
Anti.α-tubulin T6199 Sigma-Aldrich, Munich, Germany 
Anti- CDKN2A SAB2502016 Sigma-Aldrich, Munich, Germany 
Anti-NFKB-1 HPA027305- Sigma-Aldrich, Munich, Germany 
c-Fos siRNA sc-29221 Santa Cruz, Biotech. Inc., Texas, USA 
Interleukin-6, human recombinant, 99911 Biomol GmbH, Hamburg, Germany 
recombinant Human CCL-4 300-09 Peprotech, Hamburg, Germany 
recombinant human FGF-2 50361 Biomol GmbH, Hamburg, Germany 
Secondary antibody mouse IgG HRP PI-2000 Vector Lab, Burlingame, CA 
Secondary antibody Rabbit IgG HRP PI-2001 Vector Lab, Burlingame, CA 
TNF-alpha, human, recombinant WBP1452 Biomol GmbH, Hamburg, Germany 
Anti. goat cy3  C2571 Sigma-Aldrich, Munich, Germany 
2.1.8 Primers 
All primers used in this study were purchased from Qiagen (Düsseldorf, Germany). 
Gene Name Description  
NFKB-1  nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 
IFI27 Interferon alpha-inducible protein 27, mitochondrial 
CFLAR CASP-8 and FADD-like apoptosis regulator 
BAX BCL-2-associated X protein 
BCL-2 BCL2-like 2 
Caspase-9 Caspase-9, apoptosis-related cysteine peptidase 
APCS Serum amyloid P-component 
LMNA Prelamin-A/C 
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RPS-19 40S ribosomal protein S19 
RB-1 Retinoblastoma 1 
c-JUN Jun proto-oncogene 
CDKN1A Cyclin-dependent kinase inhibitor 1A (p21, Cip1) 
CDKN1C Cyclin-dependent kinase inhibitor 1C (p57, Kip2) 
ATF3 Cyclic AMP-dependent transcription factor ATF-3 
CDKN2B Cyclin-dependent kinase 4 inhibitor B 
MAPK-3 Mitogen-activated protein kinase 3 
HSPA8 Heat shock 70kDa protein 8 
FN1 Fibronectin 
Collagen Collagen type1 
FosB Metallothiol transferase FosB1 
DKK1 Dickkopf-related protein 1 
CCNA2 Cyclin-A2 
EEF1A1 Elongation factor 1-alpha 1 
eIF2B1 Translation initiation factor eIF-2B subunit alpha 
eIF4E Eukaryotic translation initiation factor 4E 
IMPDH Inosine-5'-monophosphate dehydrogenase 2 
2.1.9 Buffers and Solutions 
Solutions and Buffers  Components  
APS  10 % APS w/v in ddH2O 
10X PBS 137 mM NaCl 
27 mM KCl 
100 mM NaH2PO4 
17 mM KH2PO2 
dissolved in ddH2O 
PBST 10X PBS with 0.1% (v/v) Tween 20 
PBSTT PBSTT 10X PBS with 0.1% (v/v) Tween 20 and 0.1% (v/v) Triton-
X 100 
10X TBS 500 mM Tris HCl 
1500 mM NaCl 
dissolve in ddH2O and pH 7.6 
10X TBST TBS with 0.1% (v/v) Tween 20 
10% SDS 10% (w/v) SDS dissolve in ddH2O 
Stacking gel buffer 1.5 M Tris.HCl 
dissolve in ddH2O and pH 6.8 
Resolving gel buffer 1.5 M Tris.HCl 
dissolve in ddH2O and pH 8.8 
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10X SDS gel Tank buffer 50 mM Tris-Base 
400 mM glycine 
10% (w/v) SDS 
dissolve in ddH2O 
Lysis buffer for protein isolation 500 μl of NP-40 
1000 μl of Na-Cholate 
1000 μl of ASB-14 
1000 μl of 12-maltoside 
2000 μl of glycerol (99%) 
1000 μl Bicine (0.5M,pH8.5) 
1000 μl EDTA.2Na (0.02 M) 
1000 μl of NaCl (1.50 M) 
50 μl of PMSF (200 mM in isopropanol) 
100 μl of protease and phosphatase inhibitor cocktail  
0.4 μl of Benzonase (100U/μl) 
1346 μl of ddH2O 
Western blot anode buffer I 30 mM Tris-Base 
20% (v/v) methanol dissolve in ddH2O 
Western blot anode buffer II 5 mM Tris-Base 
20% (v/v) methanol dissolve in ddH2O 
Western blot cathode buffer 20 mM 6-aminocaproic acid  
20% (v/v) methanol  
dissolve in ddH2O  
Milk-blocking buffer 5% milk powder in 1XTBST 
Milk blocking buffer for microarray 10% milk powder in 1XPBSTT 
Paraformaldehyde (PFA) buffer 4% PFA dissolve in DPBS or PBS pH 7.4 
Triton X100 0.1% Triton X100 in DPBS or PBS pH 7.4 
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2.2 Methods 
2.2.1 Workflow 
To uncover the interaction between tumor and pancreatic stellate cells, firstly we designed an 
experiment, in which we individually stimulated PSCs with four proinflammatory factors to 
find the molecular events at the level of proteome and secretome that associated with 
activation of PSC by using a robust high density antibody microarray technology. Secondly, 
depends on the result from first study we designed the next steps. Next study designed to 
investigate the potential mechanisms responsible for PSCs activation and if c-Fos is required 
for TNF expression and for activation of pancreatic stellate cells. Then we tried to stimulated 
PDAC cells with conditioned supernatant from PSCs to investigate the interaction accord 
between them. Finally, we evaluates some of antifibrotic candidate drugs in culture activated 
PSCs, then test the most promising drug in co culture model between PDAC and PSCs 
(Figure  2.1). 
 
Figure ‎2.1 Workflow 
The cells were treated with a desired factor and the proteome and/or the secretome are collected. Antibody 
microarrays identify up- and downregulated proteins and the analysis of those reveals functional alterations. 
Furthermore functional analysis, in form of functional or enzyme assays and western blot, are required to verify the 
data. 
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2.2.2 Experiments for PSCs genome expression profiling 
To find the molecular events at the level of proteome and secretome that associated with 
activation of PSCs. PSCs were incubated with serum-free Iscove's Modified Dulbecco's 
Medium (IMDM) medium for 24h to synchronize cell growth. Serum-free medium was 
removed and cell were incubated for 48h with serum- and phenol red-free IMDM containing: 
0% serum (control), 10% serum, TNF-α (10 ng/ml), FGF-2 (10 ng/ml) and CCL-4 (5 ng/ml). 
To enhance the confidence of analysis each treatment was done in quintuplicate. After 48h 
incubation, about 20 ml of conditioned medium was collected from each flask, centrifuged at 
3000 g for 10 min to remove cell debris. The filtrate was concentrated to 200 μl using a 3000 
kD Amicon Ultra centrifugal filter device followed by added 20 ml 0.1 M Bicine as exchange 
buffer and the filtrate was concentrated to 200 μl. Protein concentration was determined with 
the Bicinchoninic Acid Protein Assay Reagent kit. Protein concentration was adjusted for cell 
secretome to 1.0 mg/mL using the Bicine buffer as diluents. After that anti TNF-α was added 
and incubated for 3 h at room temperature and keep at -80°C until use (Figure  2.2).  
 
 
Figure ‎2.2 Experimental setup to find PSCs genome expression profiling 
42 
 
2.2.3 PDAC cells line 
In total, 23 PDAC cell lines were used in this study (Table  2.2.1). PT45P1, Panc1, MiaPaca2 
and Capan1 were used, in combination, for study the interaction between PDAC and PSCs. 
The other cell lines were used as a pool reference for microarray incubation. 
Table ‎2.2.1 Cell lines used in the study [178]. 
Cell line Source of cells Cell type Age of donor 
Gender 
Differentiation 
BxPC-3 Primary tumor Ductal 61 Moderate 
FAMPAC Primary tumor Ductal 43 Poor 
IMIM-PC1 Primary tumor Ductal - Moderate 
IMIM-PC2 Primary tumor Ductal - Well 
MDA- Panc28 Primary tumor Ductal and 
Acinar 
69 Poor 
MIA PaCa-2 Primary tumor Ductal 65 Poor-moderate 
PANC-1 Primary tumor Ductal 56 Poor 
SK-PC-1 Primary tumor Ductal - Well 
SU.86.86 Primary tumor Ductal 57 Moderate 
Capan-1 Liver metastasis Ductal 40 Well 
Capan-2 Liver metastasis Ductal 56 Well 
CFPAC-1 Liver metastasis Ductal 26 Well 
Suit-2 Liver metastasis Ductal 73 Well 
Suit-007 Liver metastasis Ductal 73 Moderate 
Suit-020 Liver metastasis Ductal 73 Moderate 
Suit-028 Liver metastasis Ductal 73 Moderate 
Colo357 Lymph node metastasis Ductal - Well 
T3M4 Lymph node metastasis Ductal 56 Moderate 
A818-1 Ascites Ductal 75 Moderate 
A818-4 Ascites Ductal 76 Moderate 
A818-7 Ascites Ductal 77 Moderate 
AsPC-1 Ascites Ductal 62 Moderate−well 
HPAF-II Ascites Ductal 44 Moderate−well 
 
2.2.4  Routine maintenance of cells 
Human immortalized pancreatic stellate cells (PSCs) were a kind gift from Dr. Ralf 
Jesenofsky (Mannheim University Hospital) and PDAC were grown in 175 or 75 cm
2
 flasks 
in IMDM supplemented with 10% heat-inactivated fetal bovine serum, and in the presence of 
50 U/ml penicillin and 50 µg/ml streptomycin in 5% CO2 incubator at 37ºC. All cells were 
passaged every 2 to 3 days and sub-cultured in fresh medium. 
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2.2.5 Tumor cells experiments 
To unravel the interaction between tumour and PSCs, at 90% confluence, PT45P1 cells were 
incubated with serum-free IMDM medium for 24 h to synchronize cell growth. Serum-free 
medium was removed and cells were incubated for 48h with serum- and phenol red-free 
IMDM containing: PT45P1 untreated (blank), anti-TNF-α treated PSCs supernatant (activated 
PSC secretome) (1 mg/ml), anti-TNF-α untreated PSCs supernatant (inactivated PSC 
secretome) (1 mg/ml). After 48 h incubation the PT45P1 cells were washed three times with 
ice-cold DPBS and subjected to protein extraction as below. To enhance the confidence of 
analysis each treatment was done in quintuplicate. Additionally, to insure that incubation for 
48 h in serum-free medium is not affecting cell viability, cell growth was monitored at 24, 48 
and 72 h for PSCs and PT45P1 grown in serum-free media (negative control) and viability of 
cells was equal or higher than 95% at all tested time points (Figure  2.3). 
 
 
Figure ‎2.3 Experimental setup to find cell-cell communication in PDAC microenvironment 
 
2.2.6 Drugs treatment 
PSCs were cultivated in 6 or 96 well plates, after 75% confluence, cells were incubated with 
serum free medium overnight, then incubated with 1 µM of emtricitabine, ribavirin, 
thalidomide, date extracts and 10 ng TNF-α for 24h.  
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2.2.7 Preparation of date fruit extract 
Fresh ripened date fruits were collected from the authenticated date palms. A portion of 10 g 
of date fruit material from Tamer stage was extracted with 30 ml of distilled water, ethanol, 
ethelacitate and acetone, after being mixed by a magnetic stirrer for 1 h, and then filtered with 
Whatman no.2 filter paper. The homogenate was centrifuged at 8000 g for 30 min at 4°C. The 
supernatant was recovered and the pellet re-extracted three times under the same conditions. 
All resulting supernatants were collected, lyophilized, and stored at -80 °C till use. 
2.2.8 In vitro indirect co-culture system 
PSCs were co-cultured with PDAC using cell culture inserts with 0.4 μm pore size according 
to the manufacturer's instructions. PSCs were plated on the membrane insert in 2 ml at a 
density of 25,000/cm
2
 in 2 ml of IMDM in the presence of 10% FBS 24 h prior to the onset of 
co-culture. Human PDAC were seeded on the bottom of 6-well cell culture plates in 2 ml of 
the same culture medium.  
After 6 h, cells were incubated with serum-free IMDM medium for 12 h. PSCs treated with 
TNF-α and or with drugs and gemcitabine as above. After overnight incubation (24 h), the 
upper chambers (cell culture inserts) were put inside 6 well plates containing PDAC and 
incubated for more 48 h. 
2.2.9 Protein extraction 
Protein extraction was performed as described previously [171]. In brief, after washing with 
ice-cooled DPBS, the PSCs and PDAC cells were layered with minimal volume of extraction 
solution (2.1.9). Flasks were kept on ice for 30 min with occasional mixing. Cell lysates were 
collected with cell scrapper followed by centrifugation at 20,000 g at 4°C for 20 min. 
Supernatant was collected and protein concentration was determined with the Bicinchoninic 
Acid Protein Assay Reagent kit. 
2.2.10 Antibody microarray 
Protein labeling 
Protein labeling was performed as described previously [175, 176]. In brief, protein 
concentration was adjusted for cell secretome to 1.0 mg/mL using the Bicine buffer and for 
cell lysates 2.0 mg/mL using the cell lysate buffer as a diluent respectively, with the DY-649 
NHS-ester and DY-549 NHS-ester dyes at a molar ratio of dye/protein of 7.5. 
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Incubation, scanning, and image processing of arrays 
Antibody microarray procedure was performed in accordance to our optimized protocol 
described previously [173]. All the following steps were performed in the dark. Before 
incubation with labelled samples, slides were washed twice (for 10 and 5 min, respectively) 
with phosphate buffered saline containing 0.05% tween-20 (PBST). Following washing, the 
slides were blocked with 10% non-fat dry milk in PBST for 3h at room temperature. Each 
blocked slide was incubated with 35 μg of DY-649 labelled sample and pooled reference of 
all samples labeled with DY-549 [181]. Incubation was done using Quadriperm chambers in 5 
mL of PBST supplemented with 10% milk at 4°C overnight. The slides were washed 4 times 
(5 min each) with PBST, rinsed with deionized water and dried in a ventilated oven at 37°C. 
Scanning of the slides was performed using a Tecan power scanner at constant laser power 
and PMT. Image acquisition was performed with GenePix Pro 6.0 software. The TIFF files 
from both red (DY-649) and green (DY-549) channels of the same array were loaded in the 
software and inspection of the alignment of feature over the spots and the necessary 
adjustments were made to generate the GPR files. 
2.2.11 siRNA transfection  
All the RNA transfections in this study were carried out in 6-well or 96-well plates using 
siPORTTM NeoFXTM reagent. Reverse transfection by means of siPORTTM NeoFXTM 
involves simultaneous transfecting and plating of cells. siPORTTM NeoFXTM transfection 
agent and the RNA molecules are mixed and distributed on the culture plates over which the 
cells are overlaid. The final transfection volume in a 6-well plate is 2.5 ml of medium 
containing 2 x 10
5 
cells per well and in a 96-well plate is 100 μl of medium containing 5 x 103 
cells per well. As the transfection complexes are stable in presence of serum, no change of 
medium or other precautionary measures taken in case of traditional transfections methods are 
needed. The final concentration of the RNA molecules transfected ranges from 5 nM to 50 
nM. After this procedure, the plates were maintained at 37ºC and 5% CO2. PSCs were 
transfected with siRNA transfection reagent according to the manufacturer's instructions. 
After that incubated PSCs in serum-free medium overnight before stimulating with either 
TNF-α (10 ng/ ml) or PSC secretome for more 24 h. 
2.2.12 Western blotting 
10% SDS gels were used for resolving protein. 10% and 5% acrylamide/bisarcylamide were 
used respectively for resolving and stacking part of the gel. 0.06% (w/v) 
ammoniumpersulphate and 0.1% (v/v) N, N, N’, N’ – tetramethylethylenediamine (TEMED) 
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were used to induce the polymerization of the gel. 10 μg of protein with rotiload loading dye 
were boiled together for 5 minutes and loaded into the respective slots in the gel. A 
prestained- protein ladder was also loaded referring to the molecular weight. Electrophoresis 
of the gel was carried out for 90 minutes at 135 V and 500 mA in 1X SDS-gel tank buffer. 
The transfer of polypeptides from the gel to a nitrocellulose membrane was carried out by 
TE70 PWR semidry transfer apparatus. A sandwich model was prepared by soaking Whatman 
filter papers in anode buffers I, II and cathode buffer. The membrane was activated in anode 
buffer II.  
The stacking part of the gel was cut and the sandwich was assembled with the filter papers, 
membrane and the gel after which the semidry electrophoretic transfer was carried out for 60 
minutes at 35 V and 500 mA. To detect the transferred protein, after the transfer the 
membrane was blocked for 1h at room temperature with the milk blocking buffer. After 
blocking, the membrane was incubated with the diluted primary antibody over night at 4ºC. 
After incubation, the membrane was washed 3 times with 1XTBST and was incubated with 
secondary antibody conjugated with horse radish peroxidase for 1h at room temperature. 
Then, the membrane was washed for 3 times with 1XTBST and protein was detected by 
enhanced chemiluminescence (ECL) using the ECL prime western blot detection kit. The 
ECL substrate was prepared according to the manufacturer’s instructions and incubated on the 
membrane for 1 minute and the solution was drained off. Now, the membrane was kept on a 
clean plate inside the LAS Fujifilm 5000 machine and images were captured using a CCD 
camera on exposing the membrane gradually to the X- rays. Similarly, the procedure was 
repeated for the detection of the house keeping protein in the same membrane. 
2.2.13 Functional assays 
To confirm the proteomic data from antibody microarray, several assays were performed. 
Proliferation assay  
Two kits used to detect proliferation in this study, CyQUANT NF Cell Proliferation Assay kit 
and cellTiter-Glo Luminescent cell viability assay kit. CyQUANT NF Cell Proliferation assay 
kit is based on the measurement of cellular DNA content via fluorescent dye binding. Briefly, 
100 µl of the CyQUANT NF reagent was added to each well, and the plate was incubated for 
1h at 37°C. Absorbance measurements were made with excitation at 485 nm and emission at 
530 nm. PSC or PT45P1 were seeded in 96-well flat bottom tissue culture plates at a density 
of approximately 5000 cells/well and allowed to attach for 5 h. Then cells washed twice with 
DPBS and incubated with serum-free medium for 24 h. Serum-free medium was removed and 
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cells were incubated for 48h with serum-free IMDM and treated as in above. After 48h 
incubation medium was removed and proliferation was determined according to the 
manufacturer’s recommendations. Briefly, 100 µl of the CyQUANT NF reagent was added to 
each well, and the plate was incubated for 1h at 37°C. Absorbance measurements were made 
with excitation at 485 nm and emission at 530 nm. 
While cellTiter-Glo Luminescent cell viability assay kit is based on the measurement of ATP 
content in an ATP- dependent luciferase reaction. ATP content is a measure of cells. 
Conversion of luciferin by a recombinant luciferase produces oxyluferin and light which can 
be measured in a luminometer. Briefly, 6000 cells were plated in 96-well plates and allowed 
to adhere. Cell proliferation was determined according to the instructions of the manufacturer. 
Apoptosis assay  
Two kits used to measure apoptosis, a form of programmed cell death. First one used to 
determine the effect of various factors on PSCs and PT45P1 cells. Apoptosis was conducted 
via measurement of mitochondrial membrane potential assay using Mito-ID Membrane 
Potential kit from Enzo Life Sciences according to the manufacturer instructions. Briefly, 
PSCs and PT45P1 cells were seeded at 2 x 10
4
 cells per well and allowed to attach overnight. 
After that, cells were as in above. 48 h later, Mito-ID Membrane Potential was used according 
to the manufacturer instructions. A decrease in mitochondrial membrane potential is a 
function of accelerated apoptotic activity. 
The second was Caspase Glu3/7 assay kit and used according to the manufacture’s 
instruction. Cells apoptosis was determined by differences in luminescence. Briefly, cells 
treated as above and the dye solution was added to cells and incubation continued at 37ºC for 
30 min. Cells apoptosis was determined by differences in luminescence. 
Cell migration assay 
Cell migration was assayed using in vitro wound healing assay. For this assay, cells were 
plated in 6-well-plates. When the cells grew into full confluence, the medium was changed to 
0% IMEM for 24 h. A wound was created on the monolayer cells by scraping a gap using a 
sterile yellow micropipette tip and washed with PBS three times; the cells were then treated as 
in above for 48 h. At the end of the incubation time, images of the cells were taken.  
Cellular reactive oxygen species assay (ROS) 
Cellular ROS was measured using 2´,7´-dichlorofluorescein diacetate (DCFH-DA) as 
described previously [193]. DCFH-DA is a fluorescent dye that readily diffuses into cells and 
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hydrolyzed by esterases to a polar and non-fluorescent derivative 2´,7´-dichlorofluorescein 
(DCFH) that is trapped within cells. When present, ROS oxidize this compound to the 
fluorescent DCF. Briefly, cells were cultured in 96 well plates at 75% density and treated with 
as in above. After the 48 h of treatment, cells were loaded with 50 µM of DCFH-DA for 30 
min and fluorescence intensities were measured at excitation/emission wavelengths of 
485/530.  
Flow cytometry 
PSCs were cultured in 6-well plates at 75% density. After 48 h of incubation with treatment, 
cells were harvested and resuspended in Nicoletti buffer composed of 0.1% tri-sodium citrate, 
0.1% Triton X-100, 50 _g/ml propidium iodide, and 50 µg/ml RNase A. Cells were mixed for 
a short time and incubated at 4°C in the dark for 1.5 h. The cell cycle status was detected with 
a BD FACSCanto II flow cytometer as recommended. 
Immunohistochemistry analysis 
Immunohistochemistry analysis was performed as described previously (35). PDAC tissues 
were obtained from the Department of General, Visceral, and Transplantation Surgery at the 
University of Heidelberg. Informed written consent was obtained from patients, and the study 
was approved by the ethics committee of the University of Heidelberg. Samples were directly 
fixed with 5% paraformaldehyde solution and embedded in paraffin for 
immunohistochemistry analysis. Anti- FLNA, anti- MMP-3, anti-cytokeratin 19 (CK19), and 
anti-cortactin, and anti-α-SMA antibodies were used at 1:100 dilution. Isotype-negative 
controls were used to correct for nonspecific binding. The imaging of section was performed 
using a Zeiss Axiocam 3.1 system. 
ELISA 
To measure TNF-α, FN1 and collagen, 100 μl PSCs culture supernatant (20 µg/ml) were 
coated in five biological replicates on to 96-well microtiter plates and incubated overnight at 
4°C. Plates were blocked with 5% milk powder in PBST for 3h prior to incubation overnight 
at 4°C with anti-TNF-α, anti-FN1 and anti-collagen type I. Wells were washed with PBST 
and incubated with HRP-conjugated secondary antibody. Antibody complexes were detected 
with the peroxidase substrate SureBlue TMB. Plates were read on a standard plate reader at 
540 nm. 
Real-time RT–PCR 
Analysis of mRNA expressions was accomplished with RT-PCR. mRNA levels were 
determined using primers from Qiagen, Germany. Total RNA was extracted from PT45P1 
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and Miapaca2 cells using the Trizol reagent following the manufacturer’s instructions. 
Briefly, after a 48 h incubation with PSC secretome or/and drugs, PDAC cells were washed 
with PBS once after removal of medium. One milliliter Trizol reagent was added to each well. 
The cell layer was dissolved by gently beating and sucking into an Eppendorf tube to stand at 
room temperature for 5 min, and was then mixed with 200 ml chloroform and 2 µl of 
glycogen for 5 min, followed by centrifugation at 12,000 g at 4°C for 15 min. The centrifuge 
tube was carefully taken out, and the homogenate showed three layers; the upper suspension 
was transferred to a new Eppendorf tube and mixed with 500 ml isopropanol for 10 min. 
Centrifugation was performed at 12,000 g at 4°C for 10 min, and the suspension was removed 
carefully. One milliliter 70% ethanol was used to wash the tube, followed by another 
centrifugation at 12,000 g at 4°C for 5 min. The pellet was dried at room temperature for 5-10 
min, dissolved in 30 μl inactivated RNase water and the RNA had been incubated at 60°C for 
10 min, and stored at -80°C. The cDNA was synthesized using protoscript first strand cDNA 
synthesis kit. A total of 2 mg of total RNA was reverse transcribed using a SYBR Green PCR 
Kit. All steps were performed on ice. Following the guidelines of the manufacturer, PCR was 
performed under the following conditions: 95°C for 10 min, 50 cycles of 15 s at 95°C, 1 min 
at 60°C. The reactions were performed in triplicate. 
Immunofluorescence (ICC) 
Exponentially growing cells were fixed with 4% PFA, after two washes in PBS cells were 
permeabilized with 0.1% Triton-X 100 (in PBS), followed by three washes with PBS, and 
then blocked with 10% normal goat serum (in PBS). Incubated at 4°C overnight with α-SMA 
antibody, FN1, DCN and Collagen. After incubation with anti-goat anti rabbit secondary 
antibody labeled by cy3 diluted to 1:800, and the VECTASHIELD® Mounting Medium with 
DAPI was used to visualize the nuclei. Micrographs were collected on a laser scanning 
confocal microscope (LSM510 Carl Zeiss, Inc) using a 20X with further two times digital 
zoom at room temperature. 
2.2.14  Data analysis 
The GPR files for microarray data were analyzed with the Chipster software package (v1.4.6, 
CSC, Finland). The median of signal intensity with local background for each spot at both red 
(DY-649) and green (DY-549) channels was used to generate ratios. Ratios were normalized 
using Loess method with background correction offset [0, 50] of the normexp method [194]. 
Test for significance between control and treatment groups was performed using the 
Empirical Bayes test with Bonferroni–Hochberg adjustment of p values [195]. The empirical 
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Bayes make use of a moderated t-statistic in which posterior residual standard deviations are 
applied rather than of ordinary standard deviations, which give a far more stable inference 
when the number of arrays is small [195]. A p-value of 0.05 or less was considered 
significant. Multiple-set Venn diagrams were generated using the open-source software 
VENNTURE [196]. The bio-functional annotation of the differentially expressed proteins was 
performed with the Ingenuity Pathways Analysis (IPA) software (version 6.3, Ingenuity 
Systems, Redwood City, USA). Prediction of variations in biological functions was 
performed using a z-score of +2 or -2, respectively, as threshold for significance. Protein 
functional interaction networks were evaluated using the open-source software STRING 9.0 
[197]. Unpaired student t-test (two-tailed) was used to compare for significance between the 
control (serum-free incubations) and each of the other treatments in for the proliferation and 
ROS production assays. The coefficient of variance (CV) for the inter- and intra-assay was 
less than 20%.  
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3 Results 
3.1 Proteome variations in pancreatic stellate cells upon stimulation 
with proinflammatory factors 
In this work, we demonstrated a multivariate proteomics data from human PSCs, with the aim 
to identify the molecular changes at the level of the proteome that are associated with the 
activation of pancreatic stellate cells by proinflammatory factors, namely TNF-α, FGF-2, IL-
6, and chemokine (C-C motif) ligand 4 (CCL-4). 
3.1.1 Optimization of culture conditions 
To optimize the growth conditions of cell lines, the following was performed: 
1. Human immortalized PSCs [198] were grown in serum-free medium to avoid the 
effects of the various growth factors contained in serum. 
2. TNF-α, CCL-4, IL-6, or FGF-2 were added to the medium separately. 
3. Control experiments were conducted in the absence of any supplement or in the 
presence of serum. 
4. For good coverage of the proteome of supernatants, at least 1 mg of total protein was 
required. Therefore cell lines were grown such that at least 1 mg of total protein was 
obtained after growth in serum-free medium (SFM). Each cell type was seeded in 175 
cm2 cell culture flasks and cultured to 80- 85% confluence in normal growth medium. 
5. Each condition was performed on five biological replicates.  
3.1.2 Identification of Proteins by antibody microarray 
After cell growth in the selected media, both activated and non-proliferating cells were 
lysed and the cellular proteins were isolated and analyzed on a complex microarray of 810 
antibodies that permit the detection of 741 proteins that are closely associated with cancer, 
and particularly pancreatic tumors [181].The scanned image for a representative 
treated/untreated pair extract is shown in Figure  3.1a, which shows the same slide at the 
two fluorescence emission wavelengths for DY-649 NHS-ester and DY-549 NHS-ester. 
The morphology of the spots, the dynamic range of the intensity response and the signal-
to-noise ratio as well as positive and negative controls were routinely checked. These 
parameters showed consistent correctness (Figure  3.1b). 
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Figure ‎3.1 Representative image of an antibody microarray.  
Antibody microarray incubated with equals amounts of a PSCs cellular extract labelled with DY-649 NHS-ester and 
its corresponding pool reference extract labelled with DY-549 NHS-ester. a, the combined images corresponding to 
the two fluorescence emission wavelengths, channels red (treated signal) and green (untreated). b, a close-up image of 
one of the subarrays reflects the morphology of the printed spots, the dynamic range of fluorescence intensities, the 
reproducibility of replicates, the low background, and the diversity of responses for different antibodies. 
 
 Comparison to cells grown in serum-free medium, preliminary statistical testing showed a 
number of regulated proteins of 175 (103 up and 72 down), 283 (129 up and 154 down), 
248 (119 up and 129 down) and 174 (75 up and 99 down) in TNF-α, FGF2, IL6 and CCL4 
respectively.  
 
 
Figure ‎3.2 Venn diagram showing the number of proteins that were found Regulated up on growth of PSCs. Figure 
continues on following page 
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Venn diagram showing the number of proteins that were found Regulated up on growth of PSCs in the presence of 
TNF-α,‎CCL-4, IL-6, and FGF-2. A yellow background indicates the number of proteins uniquely regulated at one 
condition only. Light grey and medium grey stand for molecules that were regulated at two or three growth 
conditions, respectively. The number of proteins that were differentially expressed under all four conditions is shown 
in the area with the darkest background. 
 
Figure  3.2 illustrates the number unique and common protein molecules regulated in each of 
these treatments.  
3.1.3 IPA functional analysis 
Using the IPA tool, common bio-functions observed among all treatments were cancer related 
functions including tumourigenesis, neoplasia, solid tumour and carcinoma as well as cell 
death related functions including apoptosis, and cell growth and proliferation (Table  3.1.1-
Table  3.1.4). 
 
Table ‎3.1.1 List of some of the tope diseases or functions upon TNF-α‎treatment.‎ 
Listed are the diseases or functions annotations, their p-values, predicted activation state, activation z-score, number 
of correlated molecules which are related to these functions and the symbols of some of these molecules. 
Functions Annotation p-Value 
Predicted 
Activation 
State 
Z-
score 
# 
Molecules 
Examples of Molecules 
proliferation of fibroblasts 6.23E-10 Increased 2.822 15 
CDKN1A, CDKN2B, CTGF, IGF1, IL4, 
IL6, TIMP1, TNF,  
synthesis of reactive oxygen 
species 
3.20E-05 Increased 2.702 17 
BAK1, CDKN1A, CTTN, FN1 , IGF1, 
IL4 , IL6, TGFA, TNF,  
T cell homeostasis 1.87E-06 Increased 2.404 13 
ACHE, IGF1, IL12A, IL15, IL2RB, IL4, 
IL6, TNF 
Lymphocyte homeostasis 5.08E-07 Increased 2.404 14 
IGF1, IL12A, IL15, IL1A, IL2RB, IL4, 
IL6, TNF 
development of lymphocytes 5.40E-06 Increased 2.4 13 
IGF1, IL12A, IL15, IL1A, IL2RB, IL4 , 
IL6, TGFBR2, TNF 
T cell development 8.11E-06 Increased 2.378 12 IGF1, IL12A, IL15, IL4, IL6 
metabolism of reactive oxygen 
species 
1.66E-05 Increased 2.363 18 
IGF1, IL12A, , IL2RB, IL4, IL6, 
TGFBR2, TNF 
interphase 8.37E-15 Increased 2.345 34 
BAK1, CDKN1A, CTTN, FN1 FPR1, 
IGF1, IL4, IL6, INS, TGF, TNF 
fibrosis 4.59E-07 Increased 2.338 24 
APCS, CYP3A5, CYP4B1, DCN, IGF1, 
IL1R2, IL4, IL6, IMPDH2, , S100A4, 
SERPINE1, TGFBR2, TNF 
activation of cells 1.90E-11 Increased 2.226 34 
FN1 FOS, IGF1, IL12A, IL15, IL1A, 
IL2RB, IL4, IL6, INS, KDR, PKM, 
S100A7, S100A8, TNF,  
proliferation of peripheral 
blood leukocytes 
1.09E-05 Increased 2.201 6 HMGA1, IL15, IL2RB, IL4, IL6, TNF 
S phase 4.96E-10 Increased 2.185 17 
CCNA2, CDKN1A, CDKN1C, 
CDKN2B, FN1, FOS, IGF1, IL4, IL6, 
TGFA, TNF 
entry into S phase 3.62E-07 Increased 2.078 10 
CDKN1A, CDKN1C, CDKN2B, FN1 
FOS, IGF1, IL6, TNF 
chemotaxis of mononuclear 
leukocytes 
2.76E-05 Increased 2.074 10 
FN1 IL15, IL4, KDR, S100A7, S1PR1, 
SERPINE1, TNF 
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Table ‎3.1.2 List of some of the tope diseases or functions upon FGF-2 treatment.  
Listed are the diseases or functions annotations, their p-values, predicted activation state, activation z-score, number 
of correlated molecules which are related to these functions and the symbols of some of these molecules. 
Function annotation p-Value 
Predicted 
Activation 
State 
z-
score 
# 
Molecules 
Examples of Molecules 
gene Expression 5.00E-15 Increased 2.907 30 
ALB,ATP,BCL2,EP300, ,IL1A, IL2, IL4, 
IL6,IL8, SMAD3, ,TGFB1,TP53  
gene Expression (binding of E 
box motif) 
2.02E-06 Increased 2.408 6 ETS2,ID1,ID3,MYCN,SMAD3,TGFB1 
development of tumour 1.80E-06 Increased 2.239 13 
BCL2,CDKN1A, MMP14, MMP3, 
S100A4,SELE TGFB1,TIMP1,TP53 
genital tumor 8.79E-20 Increased 2.216 66 
BCL2,CCL5,CDH1,CDKN1A, CYP1B1, 
CYP3A7,EP300FLNA,FN1 IGF1, IGF2, 
IL2,IL4 IL6,IL8,IMPDH2, MMP14, 
MMP3,MSR1 OCLN, PLAUR, 
TGFBR2,TIMP1,TP53,VCAM1 
genital tumor 8.79E-20 Increased 2.216 66 BCL2,CCL5,CDH1,CDKN1A, 
Gene Expression (binding of 
DNA) 
5.44E-17 Increased 2.084 45 
ALB,ATP,BCL2,CDKN1A,CYP1B1,CY
P2D6,EP300,ERBB2,ETS2,FN1 
Cellular Movement (egression 
of cells) 
8.16E-07 Increased 2  IL4,PLAUR,S1PR1,TGFB1,TP53 
 
 
Table ‎3.1.3 List of some of the tope diseases or functions upon IL-6 treatment. 
Listed are the diseases or functions annotations, their p-values, predicted activation state, activation z-score, number 
of correlated molecules which are related to these functions and the symbols of some of these molecules. 
Function annotation p-Value 
Predicted 
Activation 
State 
z-
score 
# 
Molecule 
Examples of Molecules 
adhesion of monocytes 3.86E-09 Decreased -2.517 10 CCL5,FN1,IFNG,IL1B,IL8, SELE,TNF 
binding of DNA fragment 7.13E-08 Decreased -2.298 10 
CDKN1A,EP300,IFNG IL1B, IL2, 
MAPK1,TNF,TP53  
quantity of Ca2+ 1.64E-07 Decreased -2.274 23 
BCL2,CCL5,CXCL10,,DCN,IFNG 
,IL1B,IL4 ,IL6, IL8,TNF,VCAM1 
apoptosis of epithelial cells 1.01E-12 Decreased -2.254 18 
BCL2,BCL2A1,CASP3,CDH1IFNG, 
IL1B, IL2, IL8, MAPK1, MMP3, TNF, 
TP53 
binding of vascular endothelial 
cells 
2.09E-10 Decreased -2.093 12 
DCN,FN1 IFNG,IL1B,IL4, IL8, 
TNF,VCAM1 
cell death 1.84E-35 Decreased -2.07 131 
BCL2,BCL2A1,BCL2L2,CASP3,CASP
9,CCL5, TNF 
activation of neutrophils 1.03E-12 Decreased -2.008 15 
CCL5,CEACAM6,EDN1,GRN,IFNG 
IL1B,IL1RN,IL2,IL6,IL8,S100A7,SELE 
TNF 
 
 
Table ‎3.1.4 List of some of the tope diseases or functions upon CCL-4 treatment. 
 Listed are the diseases or functions annotations, their p-values, predicted activation state, activation z-score, number 
of correlated molecules which are related to these functions and the symbols of some of these molecules. 
Function annotation p-Value 
Predicted 
Activation 
State 
z-
score 
# 
Molecule 
Examples of Molecules 
development of tumour 6.65E-11 Increased 2.416 15 
BCL2,CDKN1A,IL12A,IL5, MMP9, 
MUC1,S100A4, TGFB1, TNF, TP53  
neovascularization 2.45E-09 Increased 2.138 9 
ICAM1,IL1B,IL2,MMP14,MMP9,S100
A4,TGFB1,TNFAIP3,TP53 
Gene Expression 1.24E-14 Increased 2.616 24 
,BCL2,EP300FOS,IL1B,IL2,IL4 
IL5,IL8,ITGB3,SMAD3,SMAD4,TGFA
,TGFB1,TNF 
Cell Death and Survival 7.29E-11 Decreased -2.108 12 
BCL2,FAS,IL1B,IL2,IL4,IL8,MMP9, 
TGFB1,TNF,TP53 
Cellular Growth and Proliferation 1.92E-13 Decreased -2.112 20 
CCL5,CDKN1A,IGFBP2,IL2,IL4 
IL8,MMP14 ,TGFB1,TNF,TP53 
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We determined the expression of 42 proteins was similarly changed under all four conditions, 
although differences in the degree of variation were observed (Figure  3.3). About 28 proteins 
of those showed a significantly increased function of cell proliferation in TNF-α, IL-6 and 
CCL-4, but not in FGF-2 which caused mostly a border line increase. To each of these 
functions a contribution of more than 30% of regulated molecules in each treatment was 
observed. This distinction has its significance in the contribution of these factors rather than 
TNF-α to the implication of PSCs in the invasiveness and metastasis of pancreatic cancer. 
 
 
Figure ‎3.3 Expression level variations of the 45 commonly regulated proteins. These proteins are presented as the 
logarithm of fold change (Log-FC). 
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With a significant z-score prediction analysis, each of TNF-α, FGF-2 and CCL-4 showed an 
increased gene expression function specifically through binding of protein binding site as 
presented by the expression pattern of 17, 30 and 24 protein molecules, respectively 
(Table  3.1.1-Table  3.1.4). Of interest, TNF-α was the only factor, which always demonstrated 
increased, although not significant, functions of development and movement of endothelial 
cells. CCL-4 accordingly showed a prediction of significantly increased neovascularization 
function, presumably due to the synergic effect paused by induction of TNF-α in CCL-4 
treated cells. Both FGF-2 and IL-6 showed a decreased cellular movement like migration, 
invasion, recruitment, chemotaxis and homing as well as decreased development of 
endothelial system as compared with TNF-α and CCL-4. Moreover, an increased function of 
development of tumor with a significant prediction was observed in both FGF-2 and CCL-4 
treatments (Table  3.1.1-Table  3.1.4). Both of FLNA and MMP-3 proteins determined to be 
similarly regulated under all treatment conditions. The expression of both proteins was also 
found up-regulated in stromal cells of PDAC tissue sections (Figure  3.4). In addition, 
development of blood vessels and vasculogenesis was also common to all four factors.  
3.1.4  The effect of TNF- 
TNF-α treatment resulted in a significant regulation of 174 (102 up and 72 down) proteins in 
PSCs. Of these 175 proteins, 56 were significantly expressed only in TNF-α but not the other 
treatments (Figure  3.2). The expression pattern for some of these unique proteins, like 
cortactin (up-regulated), was found to have a similar regulation in PDAC tissue sections 
(Figure  3.4). Findings of IPA showed many of the discovered proteins were assigned to the 
hepatic fibrosis/hepatic stellate cell activation signaling pathway underlined by an over-
expression of IGF-1and IL-4. Of all the other factors, TNF-α was endowed with several 
increments of cellular functions that not observed under the other treatments. Among the 
effects of TNF-α were increased activation of cells in cell-to-cell signaling and interaction, 
fibrosis, proliferation of fibroblasts and differentiation of progenitor cells. Figure  3.5 displays 
the most important functions investigated in this experiment.  
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Figure ‎3.4 Immunohistochemical analysis of normal and PDAC tissues. 
Tissue sections were analysed with antibodies binding FLNA, MMP-3, and cortactin (CTTN) in normal versus PDAC 
tissue sections. Cytokeratin 19 (CK19) and‎α-SMA were used to stain ductal and stellate cells, respectively. Original 
magnification was 100- and 663-fold for the insets. 
 
In addition, there was significantly increased cellular development and cellular movement 
functions with direct connection to immune cells like the lymphocytes and monocytes. 
Among these functions were chemotaxis and homing of monocytes and development of T 
cells and lymphocytes. Prediction analysis also showed increased synthesis of reactive oxygen 
species upon TNF-α treatment and changes at the level of the cell cycle with a significantly 
increased S phase activity. These functions indicate the direct implication of TNF-α in the 
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activation of PSCs, their differentiation to myofibroblast-like cells, and their regulatory 
interaction with immune cells. Additionally, the role of TNF-α in activation of PSCs was 
further confirmed by the finding of increased α-SMA expression in these cells (Figure  3.4).  
 
 
Figure ‎3.5 Overview of the regulated proteins leading most important functions investigated in this study. 
(Activation of cells, fibrosis, proliferation of fibroblast, reactive oxygen species synthesis and S phase). The 
corresponding regulated proteins, on which the prediction of activation of the diseases and functions was based, are 
depicted with their locations, expression (upregulated or downregulated), predicted activation or inhibition, and the 
predicted relationship between the proteins and the corresponding functions (leads to activation, inhibition, findings 
inconsistent with state of downstream molecule or effect not predicted) are color-coded and indicated in the figure 
legend. The functional analyses were generated through the use of Ingenuity Pathways Analysis (Ingenuity® Systems, 
www.ingenuity.com). 
 
 
Figure ‎3.6 Immunoblotting analysis showing‎the‎expression‎of‎α-SMA in PSCs under various treatment conditions.  
Ctrl, control. 
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3.1.5 The effect of FGF-2 
Treatment of PSCs with FGF-2 resulted in a significant regulation of 283 (129 up and 154 
down) proteins. There were 66 (23 up and 43 down) unique proteins regulated solely by FGF-
2 but not the other treatment. Similar to TNF-α, IPA showed that most of these proteins were 
related to hepatic fibrosis / hepatic stellate cell activation and pancreatic adenocarcinoma 
signaling pathway (Table  3.1.1-Table  3.1.2). IPA functional analysis of the regulated proteins 
under FGF-2 treatment reported a significant prediction of increased functions related to gene 
expression like binding of DNA, binding of E box motif, and binding of protein binding site 
(Table  3.1.2). The increased gene expression functions are presumably due to the elevated 
expression of endogenous TGF-ß1 and IL-4 observed with FGF-2 treatment. These functions 
suggest a potential mechanism of the action of FGF-2 in acceleration of gene expression in 
PSCs.  
3.1.6 The effect of IL-6 
PSCs showed 247 (118 up and 129 down) regulated proteins in the IL-6 treatment. Further 
analysis of these proteins showed 33 (16 up and 17 down) significantly expressed proteins 
only in IL-6 (Figure  3.2). Generally, a decrease in several functions was observed with 
significant prediction from the expression pattern of the regulated proteins upon IL-6 
treatment of PSCs (Table 3.1.3). There was a decrease in activation of neutrophils, adhesion 
of monocytes, apoptosis of epithelial cells, cell death, quantity on Ca ions and binding of 
vascular endothelial cells.  
3.1.7 The effect of CCL-4 
In the CCL-4 treated cells, statistical analysis showed that the expression of 174 (75 up and 99 
down) proteins was significantly changed in the CCL-4 treated group (Figure  3.2). A unique 
list of 14 (4 up and 10 down) proteins were expressed only with CCL-4. IPA revealed a 
significant prediction of increased neovascularization function with CCL-4 treatment 
(Table  3.1.4). However, network analysis using String 9.0 software for the combined number 
of molecules showed that CCL-4 actually is triggering this effect through TNF-α, while FGF-
2 follows an alternative path possibly via endogenous increment in IGF-1 and INS expression 
levels observed with FGF-2 treatment. 
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Figure ‎3.7 Protein interaction network analysis using STRING 9.0. 
STRING 9.0. showing the proteins controlling gene expression via binding to protein binding site. Analysis was 
performed using highest confidence score (0.900).  
 
3.1.8 Functional assay  
We performed several functional analyses to confirm the predictions that were made on the 
basis of the proteome data. 
Cell proliferation in response to cytokines 
To further confirm the functional findings from proteome data, we detected cell proliferation 
of PSCs treated with or without proinflammatory cytokines. Figure  3.8 shows that TNF-α, 
FGF-2 and CCL-4 treatment resulted in a significant increase in the proliferation rate of PSCs 
(p = 0.00006, p = 0.001 and p = 0.017). PSCs proliferation was unaffected by exposure to IL6 
(p = 0.06). Thus, proteome data and results of cell proliferation consistently suggest that TNF-
α, FGF-2 and CCL-4 may have an inducer effect by promoting PSCs proliferation. 
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Figure ‎3.8 Proliferation of PSCs under various incubation conditions.  
The assay measured the incorporation of a fluorescent dye to the DNA that was proportional to the number of cells in 
the system. The fluorescence intensities are shown in arbitrary units (AU). The p values were calculated in comparison 
with the control cells grown in serum-free medium. 
 
 
Figure ‎3.9 Apoptosis assay.  
The fluorescence signal is representative for the mitochondrial membrane potential, which, in turn, is a function of 
reduced apoptotic activity. The higher the signal, the smaller the apoptosis activity. The measurements were done 
relative to analyses in serum-free medium. AU, arbitrary units. 
Cell apoptosis in response to cytokines 
Figure  3.9 shows the effect of TNF-α, FGF-2, IL-6 and CCL-4 on apoptosis in PSC. As 
compared to serum-free medium, PSCs treated with all factors as well as 10% showed a 
decreased apoptotic activity as judged by the enhanced mitochondrial membrane potential that 
was measured with the Mito-ID commercial kit. These findings are comparable with those 
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from the functional annotation results obtained from Ingenuity analysis of the regulated 
proteins under treatment with each factor. Of all treatments, TNF-α showed the most anti-
apoptosis effect in PSC followed by CCL-4. Interestingly, our network analysis showed that 
some functions, such as gene expression, for CCL-4 are triggered via the regulation of cellular 
level of TNF-α.  
Cell migration in response to cytokines 
To further confirm the functional finding from proteomic data, we detect cell migration assay. 
Wound healing scratch assay was used to investigate if all proinflammatory factors influenced 
migration ability of PSCs. The addition of proinflammatory cytokines to PSCs induced an 
increase in PSCs migration compared with serum free medium control after 24 h. Exposure to 
TNF-α, FGF-2 and CCL-4 caused increased the rate of PSCs migrated into the scratched 
space in greater number. Migration was also observed in experiment using IL-6, but this was 
delayed compared with the other proinflammatory (Figure  3.10). All this is in agreement with 
the proteome analysis. Even the smaller effect observed for incubations with IL-6 concurs 
directly with the degree of proteome variations detected under this growth condition. 
 
 
Figure ‎3.10 Migration assay. PSCs were grown to confluence. A gap was generated by physically scraping off cells. 
The number of cells was determined before and after 48 h of growth under the indicated incubation conditions. 
 
FACS analysis 
Figure  3.11 shows the effect of TNF-α, FGF-2, IL-6 and CCL-4 on S phase in PSCs. As 
compared to serum-free medium, PSCs treated with both TNF-α and FGF-2 as well as 10% 
showed an increased activity in S phase. These findings are comparable with those from the 
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functional annotation results obtained from Ingenuity analysis of the regulated proteins under 
treatment with each factor.  
 
 
Figure ‎3.11 FACS sorting analysis revealed the percentage of PSCs (% of events) in S phase. For each condition, three 
independent measurements were performed. 
 
Assay of cellular reactive oxygen species (ROS) 
The proteome data also indicated a strongly increased reactive oxygen species synthesis 
(ROS) upon incubation with TNF-α. Therefore, the level of cellular ROS was determined 
under the four conditions. As expected, the level of reactive oxygen species increased more 
than 5-fold when the cells were incubated with TNF- α, whereas no change could be observed 
in presence of the other cytokines (Figure  3.12). Only cells grown in 10% serum exhibited an 
increased level as well, but the effect was much less pronounced. 
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Figure ‎3.12 Analysis of the level of reactive oxygen species. 
 The cellular level of reactive oxygen species was determined as a function of the conversion of 2,7-dichlorofluorescein 
to its oxidized and then fluorescent version. AU, arbitrary units; Ctrl, growth in serum-free medium. 
 
 
3.2 Proteomics profiling of pancreatic stellate cells reveal a primary 
role of c-Fos in TNF-α mediated pancreatic fibrogenesis 
Our previous study showed evidence that TNF-α results in significant regulation of many of 
the unique proteins associated with cell activation, in a process that involves up-regulation of 
the transcription factor c-Fos in pancreatic cancer. Therefore, this part of the study aimed to 
test the hypothesis that TNF-α-meditated dependency of c-Fos up-regulation is a possible 
route for PSC fibrogenic activity in pancreatic cancer. 
3.2.1 Regulation of PSC activation 
Based on previous results, TNF-α represents a prime factor responsible for PSC activation. 
Findings of IPA showed the effects of TNF-α were increased activation of functions like 
activation of cells (34 proteins), proliferation of fibroblasts (15 proteins), fibrosis (24 
proteins) metabolism of reactive oxygen species (17 proteins), and entry into S phase (17 
proteins), with z-score predictions of 2.226, 2.822, 2.338, 2.702 and 2.185, respectively 
(Table  3.1.1).  
To identify key proteins involved in this gene expression alteration, we generated a network 
for the main biological functions in the activated PSCs. Among the many differentially 
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expressed proteins identified in the activated PSCs, transcription factor c-Fos was unique in 
that it is detected in many different functions such as cell activation, fibrosis as well as 
synthesis of reactive oxygen species, proliferation and entire S phase pathway networks 
(Figure  3.5). 
To investigate the molecular mechanisms leading to PSC activation (Figure ‎3.13), common 
networks were generated based on the connectivity of these proteins using IPA. Based on the 
input information, the up regulated proteins are shown in red and the down regulated proteins 
shown in green. The differentially expressed proteins in cells activation of conditioned 
groups, such as c-Fos, TNF-α, SP-1, CD46, FN1, BAK-1, INS, IGF-1, CD-84, IL-1ß, S100A-
7, KDR, IL-4, IL-6, S100A-8, and some other proteins were used to generate networks and 
pathways using IPA. 
 
Figure ‎3.13 Overview of cell activation functions upon TNF treatment. 
The results highly predicted to be increased in activation PSCs. The corresponding regulated proteins, on which the 
prediction of activation of the diseases and functions was based, are depicted with their locations. The correlation 
(upregulated, i.e positive or downregulated, i.e negative), predicted activation or inhibition, and the predicted 
relationship between the proteins and the corresponding functions (leads to activation, inhibition, findings 
inconsistent with state of downstream molecule or effect not predicted) are color-coded and indicated in the figure 
legend. The functional analyses were generated through the use of Ingenuity Pathways Analysis (Ingenuity® Systems, 
www.ingenuity.com). 
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Many of the genes are involved in regulation of cellular pathways, such as ERKs signaling 
and TGF-ß/Smad-3 signaling. c-FOS is positively correlated with PSC activation (r= 0.71225) 
and is highlighted by IPA to be activated based on the expression of the correlated proteins, 
the relationship between FOS as an upstream regulator with the targeted proteins in the 
experimental dataset is illustrated in Figure  3.14. 
 
Figure ‎3.14 Network of genes involved in PSC activation function. 
Differentially expressed molecules from the selected cut-off P values and fold values were used to generate interacting 
networks from IPA software. The genes shown in green are down regulated in microarray data and those shown in 
red were up regulated. The intensity of color is in proportion to the fold values. Genes or molecules without any color 
are intermediate in the network but not found in our microarray data. The indirect relations between the genes were 
shown in dotted or solid arrows which represent direct interaction.  
 
Different protein types, such as cytokines, enzymes or growth factors are displayed with their 
relationship to FOS. For instance, FOS leads to the inhibition of the connective tissue growth 
factor CTGF and activation of the TGF-ß1. As shown in Figure  3.13, TGF-ß1 positively 
correlated with cell activation, while CTGF correlated negatively. 
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3.2.2 Enhanced TNF-α expression  
To determine the differential expression of the proteins identified in the proteomics analysis, 
we hypothesized that c-Fos activation during TNF-α stimulation. To validate that, PSC was 
treated with siRNA specific to c-Fos. As show in Figure  3.15a, the c-Fos level in the PSCs 
increased after TNF-α treatment. In contrast, siRNA to c-Fos reduced c-Fos protein levels 
significantly when compared with non-targeted siRNA (Figure  3.15a). Furthermore, it was of 
interest to determine whether blockade of c-Fos expression led to inhibition of the level of 
TNF-α in PSCs. The results showed that TNF-α production was suppressed in PSCs 
transfected with c-Fos-siRNA (Figure  3.15b). To further confirm the role of c-Fos on TNF-α 
expression, the TNF-α level in the culture media was determined. The inhibitory effect of 
siRNA-c-Fos decreased TNF-α release by PSCs (P=0.0001). The results demonstrate that c-
Fos is required for TNF-α expression in PSCs. 
 
 
Figure ‎3.15 siRNA-c-Fos blocks TNF-α‎activity,‎and‎TNF-α‎secretion‎in‎PSC. 
(a) c-Fos-siRNA blocks c-Fos expression under TNF-α‎treatment.‎Total‎cell‎lysate‎were‎isolated from PSC for western 
blotting using the indicated antibodies. (b and C) siRNA-c-Fos inhibits TNF-α‎secretion‎in‎PSC‎(b)‎in‎cellular‎and‎(c)‎
in condition medium. Data represent the mean ± SD of triplicate wells. *p < 0.0001 compared with the siRNA-Ctrl 
samples. 
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3.2.3 Role of c-Fos in PSCs Proliferation, apoptosis, migration assay and 
expression of α-SMA production 
It has been shown that TNF-α is one the most pro/inflammatory factors for PSCs. activation 
and proliferation [95]. In agreement with our previous report, TNF-α significantly increase of 
cell proliferation in serum-free medium after 24 h (Figure  3.16a).  
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Figure ‎3.16 Knocking down of c-Fos by small interfering RNA inhibits TNF-α‎-induced PSCs activation.  
PSCs were transfected with 50 nM either c-Fos or negative control (N.C) for 24 h, cells were serum starved overnight 
and either left untreated (Serum free) or treated with TNF-α‎ (10‎ ng/ml)‎ in‎ serum-free medium for 24 h. (a) 
Proliferation assay (b) apoptosis assay (c) Migration assay. PSCs were treated as above and a gap was generated by 
physically scraping off cells. The number of cells was determined before and after 24 h of growth under the indicated 
incubation condition. Data represent the mean ± SD of triplicate wells. *p < 0.05 compared with the siRNA-Ctrl 
samples. 
 
To investigate if siRNA-c-Fos also inhibited proliferation of PSCs, PSCs were treated as 
above, and the results demonstrated that proliferation rates of knock down c-Fos was reduced 
and the densities was only 60% compared with PSCs treated with TNF-α only.  
 Same trend was seen in PSCs apoptosis which significantly increased apoptotic activity 
(Figure  3.16b). In addition, it was found that c-Fos knock down significantly decreased the 
migration of PSCs (Figure  3.16c). Moreover, to further study the effect of c-Fos and TNF-α 
suppression on PSCs activation, siRNA-c-Fos and PSCs were treated with TNF-α and I 
performed Western blot, immunofluorescence staining and measured α-SMA mRNA by real- 
time quantitative RT-PCR (Figure  3.17). The results obtained by the different methods were 
concordant. α-SMA mRNA expression were induced by TNF-α. However, these effects were 
diminished by siRNA-c-Fos treatment (Figure  3.17b). Western blots were performed on 
proteins derived from triplicate wells. α-SMA protein expression was induced by TNF-α, and 
pre-treatment with siRNA-c-Fos diminished this effect (Figure  3.17a). Furthermore, 
immunofluorescent staining demonstrated that siRNA-c-Fos decreased TNF-α induced α-
SMA expression as well (Figure  3.17c).  
3.2.4 Effect of c-Fos knockdown on fibrogenesis in PSCs 
To investigate whether siRNA-c-Fos was capable of inhibiting ECM proteins production in 
PSCs, we expressed a control or an siRNA-c-Fos in PSCs and then treated the cells with 
TNF-α for 24 h to study the effect of c-Fos knock down on PSC markers. We determined the 
expression of the major factors involved by Western blotting, qRT-PCR and 
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immunofluorescence assay. Control siRNA did not affect the expression of Col1A1 and FN1 
mRNA expression in TNF-α treated cell. siRNA-c-Fos, however, significantly inhibited TNF- 
α induced expression of Col1A1 and FN1 mRNA expression in PSCs (Figure  3.18b). 
Western blots showed that TNF-α induced a significant increase in Col1A1 and FN1 as well 
as DCN expression in PSCs. c-Fos knock down, however, significantly blocked Col1A1, FN1 
and DCN expression (a). Immunofluorescent staining demonstrated increased expression of 
Col1A1, FN1 and decorin occurred in culture receiving TNF-α. siRNA-c-Fos, however, 
decreased TNF-α induced Col1A1, FN1 as well as decorin expression (Figure  3.18c). 
 
 
 
Figure ‎3.17 Effect of c-Fos‎Knockdown‎on‎α-SMA expression in PSCs.  
Figure continues on following page 
PSCs transfected with 50 nM control (N.C) or siRNA-c-Fos for 24h. After that cells were treated with TNF-α‎ for‎
another‎24h.‎(a)‎western‎blot‎analysis‎shows‎decreased‎expression‎of‎α-SMA after c-Fos knockdown compared with 
N.C or cells treated with TNF-α‎only.(b)‎Quantitative‎Reverse‎ transcriptase polymerase chain reaction (qRT-PCR) 
revealed marked siRNA-c-Fos‎decreased‎the‎expression‎of‎α-SMA in PSCs.(c) Immunofluorescence of PSCs showed 
decreased‎number‎ of‎ α-SMA expression compared with N.C or cells were treated with TNF-α‎ only.‎Western blot, 
qRT-PCR and immunofluorescence staining data represent consistent trend in three independent repeats with the 
best image quality. 
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3.2.5 c-Fos Knock down inhibits Smad2/Smad3 and ERK1/2  phosphorylation 
It was found that TNF-α augmented in Smad-2/3 [199] and for ERKs pathway activation 
[200]. In fibroblast, it was shown that Smad-3 is important for the activation of α-SMA 
promoter activity [201]. Although Smad-2 is also involved in activation, but Smad-3 has the 
major effect in activating [201, 202]. We hypothesized that c-Fos interacts with Smad3 to 
induce PSC activation. To investigate our hypothesis, we transfected PSC with or without 
siRNA-c-Fos for 24h and then treated the cells with TNF-α for 1h. TNF-α induced Smad2/3 
phosphorylation, however, the level of phosphorylation was decreased in the siRNA-c-Fos 
group (Figure  3.19a-b). 
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Figure ‎3.18 Effect of c-Fos knockdown on fibrogenesis in PSCs.  
Figure continues on following page. 
PSCs were treated as above and (A) after 24 h from cells treated with TNF-α,‎total‎cell‎lysates‎were‎prepared,‎and‎the‎
levels of FN1, DCN and GAPDH were examined by Western blotting.( B) total RNA was prepared from human PSCs, 
and the levels of Col1A1, FN1were determined by real-time PCR. *P < 0.0008 vs. N.C. (C) Immunofluorescent 
staining showed TNF-α‎induced‎Col1A1,‎FN1‎and DCN formation were reduced by c-Fos knockdown. RT-PCR Data 
represent results from three independent experiments with duplicate repeats. Western blot and immunofluorescence 
staining data represent consistent trend in three independent repeats with the best image quality. 
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Next we investigated effect of c-Fos silencing on TNF-α induced ERKs phosphorylation. 
PSCs were cultivated, transfected with siRNA-c-Fos for 24 h and then   exposed to TNF-α for 
another 12 h. ERKs were determined by Western blot analysis. c-Fos knock down decreased 
TNF-α mediated ERK phosphorylation compared with PSCs treated with TNF-α only 
(Figure  3.19c).  
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Figure ‎3.19 c-Fos knockdown inhibits Smad-2/Smad-3 and ERK1/2 phosphorylation. 
 (a - c) PSCs were transfected with siRNA-c-Fos for 24 h and then cells were serum starved overnight. After that cells 
were treated with TNF-α‎ (10‎ng/ml)‎ for 24 h. TNF-α‎ did‎ not‎ affect‎ total‎ Smad-2 and Smad-3 expression, but did 
increase their phosphorylation. TNF-α‎induced‎Smad-2 and Smad-3 phosphorylation were blocked by siRNA-c-Fos. 
 
3.3 Interaction between PSCs and tumor cells 
We previously examined the effect of some pro inflammatory factors (TNF-α, CCL-4, IL-6 
and FGF-2) on the PSCs’ biological function using a robust, high-density antibody microarray 
technology and identified that TNF-α is the prime factor responsible for the activation of 
pancreatic stellate cells [95]. Therefore, the potential involvement of activated PSC paracrine 
in the crosstalk of various cell types has emerged as an important issue that needs further 
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investigation. To search for a potential role of PSCs under effect of TNF-α, we systematically 
analyzed proteins secreted from these cell lines. Before proceeding with antibody microarray 
analysis, three criteria had been set to be met with our analysis. First, stellate cells (PSCs) 
[198] were grown in serum-free medium, in which we were confident that the proteins 
detected were not from growth factors contained in serum. Second, serum-free medium was 
exchanged during filtration with bicine buffer in order to avoid its incompatible effects with 
BCA kit. Third, the condition media were analyzed on a complex microarray of 810 
antibodies that permit the detection of 741 proteins, which are closely associated with cancer, 
and particularly pancreatic tumors [181].  
3.3.1 The effect of TNF-α on the secretion of PSCs 
To search for potential role of PSCs under effect of TNF-α, we systematically analyzed 
proteins secreted from these cell line. PSCs were grown in serum-free medium for 24 h, and 
then treated with TNF-α; subsequently the culture supernatants were harvested. After medium 
concentration, proteins were resolved on a robust high-density antibody microarray. The 
proteomic analyses identified 309 regulated secreted proteins in the culture media. We further 
analyzed the subcellular localization of the identified proteins. In the activated PSC 
secretome, 18% of the identified proteins were known to be secreted, and 17% were 
categorized as plasma membrane proteins. The remaining proteins were either intracellular or 
unknown proteins (Figure  3.20).  
 
Figure  3.20 Type of cellular components 
of PSCs in the presence of TNF-α. 
3.3.2 IPA Functional Analysis 
The functional analysis of TNF-α treated PSCs versus untreated controls highlighted more 
than 1000 related diseases. The results were filtered to relevant functions, mainly focusing on 
those related to tumor and fibroblast (Table  3.3.1). A significant number of proteins were 
involved in cancer pathologies, cell apoptosis, cellular growth and proliferation. In addition, 
the enriched biological functions also included proteins related to cancer metastasis, cellular 
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movement and adhesion of eukaryotic cells. TNF-α also showed enhanced extracellular 
matrix synthesis and modulation extracellular matrix degradation through matrix-
metalloprotease (MMPs) and tissue inhibitor of metalloproteinase (TIMPs) secretion and was 
found to increase the expression of FN1, MMP-10, MMP-11 and MMP-14. To investigate the 
potential involvement of the identified secreted proteins in activated PSCs, a network map 
was constructed using the IPA software. Figure  3.21 displays the most important functions 
investigated in the activated PSC secretome: invasion, proliferation, apoptosis, migration and 
cell activation of cells. The corresponding target proteins are also illustrated with their 
locations, expression (upregulated or downregulated), predicted activation or inhibition, and 
the predicted relationship between the proteins and the corresponding functions (leads to 
activation, inhibition, findings inconsistent with a state of downstream molecule or effect not 
predicted).  
Table ‎3.3.1 Functional analysis of the antibody microarray data received from PSC secretome upon TNF treatment. 
Functions annotation p-Value 
Predicted 
Activation 
State 
z-
score 
# 
Molecules 
Examples of Molecules 
 
invasion of cells 1.21E-23 Increased 2.952 33 
CCL11,CSF2,CTGF,FGF2,FN1, IFNG, 
IGF1,IGF2, IL1B, IL6, TIMP1, TIMP2, 
TNF,VEGFA,VEGFB,VEGFC,VTN 
stimulation of connective 
tissue cells 
3.14E-19 Increased 2.951 12 
CSF2,FGF2 ,IFNG,IGF1, IL10,IL1B, 
IL4,IL6,TNF,VEGFA 
generation of reactive oxygen 
species 
1.22E-13 Increased 2.884 15 
ALB,CSF2,IFNG,IGF1,IL10,IL1B,IL6, 
,MMP14,SERPINB5, ,TNF 
migration of cells 1.54E-39 Increased 2.876 58 
CCL11,CCL4,CSF2,CTGF, 
FGF1,FGF2,FN1, IGF1, IL4, IL6, 
MMP10,MMP11,MMP12,MMP14, 
TGFBI, THBS2, TIMP1,TIMP2,TNF, , 
VEGFA,VEGFB, VEGFC,VTN 
proliferation of fibroblasts 8.27E-14 Increased 2.747 17 
CTGF,DCN,FGF1,FGF2,FN1, 
IGF1,IGF2,IGFBP3,IL1B,IL4,IL6, TNF,  
growth of tumour 3.50E-31 Increased 2.745 38 CCL11,CSF2,CTGF, FGF1,FGF2,FN1 
proliferation of lymphoma cell 
lines 
1.08E-13 Increased 2.739 13 
CCL11,IFNG,IGF1,IGF2,IGFBP1,IGFB
P3,IL10,IL15,IL2,IL4,IL6,TF,TNF 
activation of fibroblasts 6.06E-14 Increased 2.563 8 ENO1,IFNG,IGF1,IGFBP3,IL6,VEGFB 
invasion of tumour cell lines 3.90E-18 Increased 2.515 25 
CCL11, FGF2,FN1,MMP14,SERPINB5, 
TIMP1,TIMP2,TNF,VEGFA,VEGFB 
growth of malignant tumour 6.38E-24 Increased 2.412 27 
FGF1,FGF2,GRN, ,IL10, IL12A, IL15, 
IL1AIL6,KLK3,TNF, 
cell movement of tumour cell 
lines 
1.63E-26 Increased 2.37 35 
AREG,CCL11,CCL4,CSF2,CTGF,CXC
L10,CXCL8,CXCL9,DCN,FGF1,FGF2, 
migration of tumour cell lines 4.10E-27 Increased 2.364 33 
AREG,CCL11,CSF2,CTGF,CXCL10,C
XCL8,MMP14,SERPINE1,TGFBI,THB
S2,TIMP1,TIMP2,TNF,VEGFA, 
proliferation of tumour cell 
lines 
1.58E-24 Increased 2.339 42 IL10,IL12A,IL1B,IL1RN,IL2,IL32, INS, 
mitogenesis 1.18E-22 Increased 2.315 19 FGF1,FGF2,GRP,IGF1,IGF2,IGFBP2 
proliferation of antigen 
presenting cells 
1.11E-17 Increased 2.225 13 
ENO1,EWSR1,FGF1,FGF2,FLNA,FN1,
CSF2,DCN,IFNA1/IFNA13,IFNG,IGF1,
IL10 
formation of cells 8.35E-15 Increased 2.219 27 
ADCYAP1,ALB,AREG,BGN,CCL11, 
CCL4,CSF2,CTGF,CXCL10 
proliferation of cells 3.78E-24 Increased 2.15 59 
FGF2,FN1,FRZB,GRN,GRP,GSN,IFNA
1/IFNA13,IFNG,IGF1,IGF2,IGFBP1,IG
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Functions annotation p-Value 
Predicted 
Activation 
State 
z-
score 
# 
Molecules 
Examples of Molecules 
 
FBP2,IGFBP3,IL10,IL12A,IL15,IL1A,I
L1B,IL1RN,IL2,IL32,IL4 
activation of cells 8.99E-30 Increased 2.142 41 
TF,TG,TIMP1,TNF,TNFSF14,VEGFA,
VTN 
proliferation of tumour cells 2.73E-34 Increased 2.13 35 
IGFBP3,IL10,IL12A,IL15,IL1A,IL1B, 
IL1RN,IL2,IL32,IL4,IL6,KLK3, 
proliferation of immune cells 2.18E-20 Increased 2.042 30 
ALB,CCL11,CCL4,CSF2,CTGF, 
CXCL10 
proliferation of leukocyte cell 
lines 
8.60E-20 Increased 2.032 18 CSF2,FGF1,FGF2,FN1,IFNG,IGF1 
proliferation of cancer cells 5.56E-22 Increased 2.02 24 
AREG,CSF2,CXCL8,DCN,FGF1,FGF2,
GRN 
apoptosis of cancer cells 1.27E-14 Decreased 
-
2.578 
15 
ALB,CSF2,FGF2,IFNG,IGF1,IGFBP3,I
L10,IL15,IL4,IL6,MMP11,TF,TNF,VE
GFA,VEGFC 
apoptosis of tumour cells 8.67E-21 Decreased 
-
2.882 
21 
FGF2,IFNG,IGF1,IGFBP3,IL10,IL15,IL
2,IL4,IL6,KLK3,MMP11,TF,TNF,VEG
FA,VEGFC 
cell death of tumour cells 1.92E-23 Decreased 
-
3.598 
25 
,CSF2,CXCL8,FGF2,IFNG,IGF1,IGFBP
3,IL10,IL15,IL1A,IL1B,IL2,IL4,IL6,KL
K3,MMP11,SERPINB5,SERPINE1,TF,
THBS2,TIMP1,TIMP2,TNF,VEGFA,V
EGFC 
 
3.3.3 Verification of secreted proteins by Western blotting  
Protein expression was also assessed in activated PSC secreted proteins. Relative protein 
levels varied greatly in both activated and inactivated secreted proteins. As shown in 
Figure  3.22, the expression levels of SERPINI-2, IL-4, IL-1ß, and FGF-1 proteins were 
increased in activated PSC secretome. In addition, ECM expression (FN1 and Coll), was 
preferentially observed in PSCs and reported to be involved in cell proliferation and 
angiogenesis [203], was also analyzed by Western blot and ELISA (Figure  3.22b). As 
expected on the basis of the proteomic results, SERPINI-2, IL-4, IL-1ß, FGF-1 and ECM 
were confirmed to be secreted by activated PSCs (Figure  3.22a, c). The expression of FN1 
and Coll has also been evaluated by ELISA in the secretome of both activated and inactivated 
PSC (Figure  3.22 b, c). 
 
78 
 
 
Figure ‎3.21 Overview of the regulated proteins leading to Invasion, proliferation, apoptosis, migration and cell 
activation of cells.  
The corresponding regulated proteins, on which the prediction of activation of the diseases and functions was based, 
are depicted with their locations, expression (upregulated or downregulated), predicted activation or inhibition, and 
the predicted relationship between the proteins and the corresponding functions (leads to activation, inhibition, 
findings inconsistent with state of downstream molecule or effect not predicted) are color-coded and indicated in the 
figure legend.  
 
 
Figure ‎3.22 Verification of PSCs secretome. 
(a) Western blotting of conditioned media supernatant from activated or quiescent PSCs demonstrating the presence 
of proteins of interest. (b) Diagram representing the expression of fibronectin in ELIAS. (c) Western blot analysis of 
fibronectin and collagen. PSCs were treated with TNF-α‎ (10‎ ng),‎ .After‎ 48h‎ condition‎ media‎ were‎ collected,‎
concentrated and analyzed either by ELISA or electrophoresis and western blot analysis using a specific antibodies. 
ENO1 served as loading control.  
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3.3.4 The effect of PSCs secretome on PDAC 
Pancreatic adenocarcinoma PT45P1 cells were used as a model of the crosstalk between 
PDAC and activated PSCs in the context of pancreatic cancer. Pancreatic cancer-PSCs 
crosstalk was next addressed by adding activated and inactivated PSC secretome to the 
PT45P1 cell line. Analysis of PT45P1 treated with condition medium of PSCs showed a 
number of regulated proteins of 246, 265 and 247, respectively, in PT45P1 treated (activated 
PSCs secretome) vs. control (Ctrl; inactivated PSCs secretome), PT45P1 Ctrl vs. blank 
(PT45P1 in serum free medium) and PT45P1 treated vs. blank. A Venn diagram shows the 
distribution of unique and shared proteins for the PT45P1 treated with activated and 
inactivated PSCs (Figure  3.23). We observed that 46, 71 and 41 proteins were uniquely 
secreted by PT45P1 treated, PT45P1 Ctrl and PT45P1 blank, respectively, while 43 proteins 
were common in all condition medium (CM) samples.  
 
Figure ‎3.23 Venn-Diagram showing the number of proteins that were found regulated upon growth of PT45P1 in the 
presence of activated PSCs, inactivated PSCs and Blank. 
 
3.3.5 IPA Functional Analysis 
PT45P1 cells, treated with activated PSCs secretome resulted in a significant regulation of 
246 proteins. Using IPA analysis, proteins were clustered in 12 functional categories 
according to their biological functions, morphological criteria and cellular components. The 
molecular and cellular functions of proteins were mainly related to cell death, apoptosis of 
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pancreatic cancer cell lines, tumorigenesis of benign tumor, quantity of antigen presenting 
cells, metabolism of prostaglandin and differentiation of cells (Table  3.3.2).  
Table ‎3.3.2 Functional analysis of the antibody microarray data received from PT45P1 cell proteome treated with 
activated PSC secretome. 
 
Functions annotation p-Value 
Predicted 
Activation State 
z-score 
 
tumorigeneses of epithelial neoplasm 3.28E-17 Increased 2.019 
benign neoplasia 2.31E-24 Increased 2.342 
tumorigeneses of benign tumour 1.11E-15 Increased 2.667 
degeneration of cells 3.07E-14 Increased 2.73 
quantity of phagocytes 6.70E-30 Decreased -3.032 
metabolism of prostaglandin 6.09E-19 Decreased -2.958 
differentiation of antigen presenting cells 1.48E-17 Decreased -2.958 
synthesis of eicosanoid 2.02E-20 Decreased -2.814 
stimulation of connective tissue cells 3.41E-14 Decreased -2.462 
quantity of antigen presenting cells 4.54E-19 Decreased -2.461 
apoptosis of pancreatic cancer cell lines 2.20E-15 Decreased -2.269 
binding of DNA 1.09E-31 Decreased -2.256 
cell death of pancreatic cancer cell lines 3.08E-15 Decreased -2.254 
differentiation of cells 1.47E-30 Decreased -2.193 
differentiation of phagocytes 4.01E-20 Decreased -2.18 
quantity of leukocytes 9.40E-36 Decreased -2.145 
stimulation of cells 1.55E-17 Decreased -2.079 
 
The two major biological functions associated with this set of proteins were regulation of 
apoptosis of pancreatic cancer cell lines and differentiation of cells. Results reveal that only 
PT45P1 cells treated with activated PSC secretome showed a decreased differentiation and 
apoptosis of pancreatic cancer cell lines. Furthermore, proteins were selected with relevance 
to the major pathways that were expected to be responsible for the effects of PSC on PDAC 
apoptosis, differentiation, translation initiation and guanylate metabolism. This selected group 
also included oncogenes, tumor suppressors and other factors belonging to main cancer-
related signaling pathways (Table  3.3.3). 
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Table ‎3.3.3 Expression of genes grouped according to biological role 
Functions annotation 
& proteins name 
Sequence description Fold-change 
APOPTOSIS   
Extrinsic pathway   
NFKB-1  nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 -0.858 
NFKB-2 
nuclear factor of kappa light polypeptide gene enhancer in B- cells 2 
(p49/p100) 0.465 
FAS Fas cell surface death receptor 0.363 
FASTK Fas-activated serine/threonine kinase -0.871 
Intrinsic pathway   
BAX BCL2-associated X protein -0.578 
BCL-2 BCL2-like 2 0.295 
Caspase- 9 caspase 9, apoptosis-related cysteine peptidase -0.321 
DIFFERENTIATION   
APCS  -0.481 
CD81  -0.797 
IGHM  -1.012 
LMNA  -0.497 
POU5F1  -0.661 
RPS19  -0.756 
RUNX3  -0.486 
ONCOGENES/TUMO
UR SUPPRESSORS   
CDKN2A cyclin-dependent kinase inhibitor 2A -0.512 
RB-1 retinoblastoma 1 -0.497 
BRCA1 breast cancer 1, early onset -0.492 
c-JUN jun proto-oncogene 0.397 
EP300 E1A binding protein p300 -0.772 
IRF7 interferon regulatory factor 7 -0.772 
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) 0.411 
CDKN1C cyclin-dependent kinase inhibitor 1C (p57, Kip2) 0.393 
SIGNALING   
GNAS GNAS complex locus 0.308 
VEGFC vascular endothelial growth factor C 0.458 
MAPK-10 mitogen-activated protein kinase 10 0.401 
MAPK-3 mitogen-activated protein kinase 3 -0.516 
HSPA8 heat shock 70kDa protein 8 0.441 
IFNGR1 interferon gamma receptor 1 0.523 
SOCS1 suppressor of cytokine signaling 1 -0.932 
S100A-4 S100 calcium binding protein A4 0.31 
S100A-6 S100 calcium binding protein A6 -1.444 
S100A-8 S100 calcium binding protein A8 0.382 
S100A-9 S100 calcium binding protein A9 -0.733 
CELL CYCLE   
CD72 CD72 molecule 0.442 
CCNB1 cyclin B1 0.448 
BUB1 BUB1 mitotic checkpoint serine/threonine kinase 0.489 
GAS1 growth arrest-specific 1 0.403 
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Functions annotation 
& proteins name 
Sequence description Fold-change 
CDKN1C cyclin-dependent kinase inhibitor 1C (p57, Kip2) 0.393 
CCNA2 cyclin A2 0.745 
TRANSLATION 
INITIATION   
EEF1A1 eukaryotic translation elongation factor 1 alpha 1 -0.422 
EIF2B1 eukaryotic translation initiation factor 2B, subunit 1 alpha, 26kDa 0.49 
EIF3B eukaryotic translation initiation factor 3, subunit B -0.974 
EIF3I eukaryotic translation initiation factor 3, subunit I -0.657 
eIF4E eukaryotic translation initiation factor 4, subunit I 0.867 
 
3.3.6 Activated PSCs inhibited PDAC cell apoptosis  
To further confirm the activation of PSCs to prompt pancreatic cancer cell apoptosis, 
proliferation and migration; we collected the supernatant from activated PSCs. After 
incubation with the supernatant from PSCs, PT45P1 cells were harvested and the total RNA 
was extracted for real-time PCR analyses. At the mRNA and protein levels, PSC co-culture 
resulted in down-regulated mRNA and protein expression of pro-apoptotic factors (BAX, 
CASP-9, NFKB-1, NFKB-2, FSATK) or up-regulated (BCL-2, NR4A1) in PT45P1 cells 
treated with the supernatants from activated PSCs than those in the other group (Figure  3.24, 
Table  3.3.3). The inhibited apoptosis pathways were also observed in PT45P1 cells after 
treatment with the supernatants from the activated PSCs using mitochondrial potential 
membrane (represents extrinsic pathway) and Caspase Glu3,7 assays (represents intrinsic 
pathways). Conditioned medium from activated PSCs also stimulated decreased cells 
apoptosis in pancreatic cancer cells. PT45P1 cells, which had been treated with activated 
PSCs secretome, significantly decreased apoptosis activity as determined by the enhanced 
mitochondrial membrane potential and Caspase Glu3, 7 assays after 48 h compared with 
inactivated secretome (Figure  3.24 b, c). These findings are comparable with those from the 
functional annotation results obtained from Ingenuity analysis of the regulated proteins under 
treatment with each condition. 
To determine whether the differentiation was also inhibited in PT45P1 cells, we examined the 
expression of differentiation proteins such as APCS, LMNA and RPS19. As shown in 
Table  3.3.3, the mRNA levels of LMNA and RPS19 were reduced after treatment with the 
supernatants from the activated PSCs. Furthermore, most proteins of the purine metabolism 
and translation initiation were up-regulated (IMPDH, eIF2B1 and eIF4E) (Figure  3.24d, 
Table  3.3.3). Expression profiling further indicated up-regulation in expression of such proto-
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oncogene or oncogenes as c-JUN and down-regulation of RB-1 tumor suppressor gene 
expression in response to treatment. Cell-cycle regulator genes that activate cell cycle 
progression, such as CCNA2, CCNB1, CD72, and GAS1, were also up-regulated, whereas 
expression of selects cell-cycle inhibitors, including CDKN2A, decreased in the PDAC as 
compared to controls (Figure  3.24d, Table  3.3.3). Taken together, these results indicate that 
the activated PSCs prompt pancreatic cancer cell apoptosis through multiple pathways 
including extrinsic and intrinsic pathways. 
 
 
 
 
 Figure ‎3.24 Interaction between PSCs and PDAC. 
 Serum-starved PDAC were treated with inactivated PSC secretome or treated with activated PSC secretome (PSC-
SN). (a and d) Western blot analysis of PDAC treated with activated or inactivated PSC secretome. After 48h cells 
were lysate and the protein concentration was adjusted to 1 mg/ml. The dilutions that were used for the antibodies 
were‎ the‎ following:‎ BAX‎ 1:1000;‎ α‎ -tubulin 1:5000, GAPDH 1:5000, CASP-9 1:500, NFKB-1 1:1000, CDKN2A 
1:1000, CCNA2 1:1000, IMPDH 1:500 and eIF4E 1: 1000. (b and c) Apoptosis assay.(b) The fluorescence signal is 
representative for the mitochondrial membrane potential, which in turn is a function of reduced apoptotic activity. 
The higher the signal, the smaller is the apoptosis activity. (c) Caspase Glu3, 7 assay showed decreased apoptosis in 
PT45P1 cells treated with activated PSC secretome as compared to cells treated with inactivated PSC secretome. The 
fluorescence intensities are shown in arbitrary units (AU) or (RLU). The p-values were calculated for each individual 
treatment in comparison to the cells treated with inactivated PSCs secretome. 
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3.3.7 Validation of the Proteomic Results by comparative functional analyses 
in response to PSC secretome 
We further demonstrated that incubation with supernatants from the activated PSCs increased 
the proliferation and migration of PT45P1 cells. The CyQUANT NF cell proliferation assay 
demonstrated that exposure to activated PSCs secretome significantly increased the rate of 
proliferation of pancreatic cancer cells, as compared with inactivated PSCs secretome. 
Pancreatic cancer cells proliferation was unaffected by exposure to the inactivated PSCs 
secretome (Figure  3.25a). Moreover, same trend was seen for wound healing scratch assay in 
order to investigate the influence of activated PSCs secretome on the migration ability of 
PT45P1 compared with cells treated with inactivated PSC secretome. Compared with 
inactivated PSC secretome, activated PSC conditioned medium significantly upregulated 
PT45P1 cell migration after 24 h. The cells migrated into the scratched space in greater 
numbers than PT45P1 cells which treated with inactivated secretome (Figure  3.25b). These 
results were confirmed by proteomic data, which showed activation of several proliferative 
and apoptosis-related proteins may contribute to PSC secretome-induced proliferation in 
pancreatic cancer cells. Taken together, these data suggest that activated PSCs prompt 
pancreatic cancer cell apoptosis, proliferation and migration through multiple pathways. 
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Figure ‎3.25 Interaction between 
PSCs and PDAC.  
Serum-starved PDAC were treated 
with either inactivated or activated 
PSC secretome (PSC-SN). (a) 
Proliferation of PT45P1 under 
various incubation conditions. The 
assay measures the incorporation 
of a fluorescent dye to the DNA, 
which is proportional to the 
number of cells in the system. (b) 
Migration assay. PT45P1 were 
grown to confluence. A gap was 
generated by physically scraping 
off cells. The number of cells was 
determined before and after 48 h of 
growth at the indicated incubation 
conditions. The fluorescence 
intensities are shown in arbitrary 
units (AU). The p-values were 
calculated for each individual 
treatment in comparison to the cells 
treated with inactivated PSC 
secretome. 
 
3.3.8 Activated PSCs promoted pancreatic cancer cell growth through eIF4E 
pathway 
Microarray data were submitted to IPA for a validation of the obtained results and to visualize 
complete signaling pathways. The major canonical pathways related to the input data were 
displayed. The pathway with high z-score included for example Eukaryotic translation 
initiation factor 2 subunit 3(EIF2). Components of the EIF2 pathway for example are well 
represented in the microarray (Figure  3.26). Many of these components were activated at 
different ratios; GRB2 activated the SOS signaling cascade through c-RAF, MEK1, and 
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ERK1/2 with an increasing up-regulation. The emerging complex regulates other downstream 
molecules such as eIF4E and triggers a signaling cascade leading finally to tumor cell growth, 
differentiation and initiate translation. In summary, functional analysis through the use of 
Ingenuity Pathways Analysis revealed significant changes in translation initiation proteins 
like eIF4E, which was reported to enhance the translation expression of many oncogenes and 
growth factors to promote PDAC [204, 205]. Therefore, we postulated that the eIF4E 
signaling pathway might be involved in networks controlling PDAC maintenance.  
 
 
Figure ‎3.26 Ingenuity pathways analysis. 
 Alteration of protein expression of some molecules in this pathway such as eIF4E or eIF2ß triggers a signalling 
cascade leading to initiate translation, proliferation and inhibition of apoptosis. Eukaryotic translation initiation 
factor 2 subunit 3 (EIF2) pathway with indication of proteins whose expression levels appeared up- or down-regulated 
in our analysis (coloured symbols). Gene products in red boxes indicate that the corresponding protein levels are 
raised in the PT45P1 cells line. Gene products in green boxes indicate that the corresponding protein level has been 
found to be decreased in cells. 
 
To determine the effects of eIF4E on the tumor–stromal interactions between PSCs and 
PDAC cells, we prepared PSC supernatant (PSC-SN), and used eIF4E siRNA to 
downregulate eIF4E expression and then determined its impact on the growth of PDAC cells. 
eIF4E-siRNA was transiently transfected into PT45P1, Panc1 and Capan1 cells and the cells 
were cultured for 24 or 48 h Afterwards, these cells were treated with PSC secretome for 
more 24 h. As seen in Figure  3.27A and B, PSC-SN increased the proliferation of PDAC cells 
(Panc1 and PT45P1 cells, P < 0.05, A (a) and B (d)). In contrast the proliferation of cells 
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transfected with eIF4E-siRNA and treated with PSCs secretome was obviously inhibited at 
any time point, indicating that silencing of eIF4E inhibits the growth of PDAC cells.  
Moreover, we tested the effects of eIF4E-siRNA transfection on the apoptosis of PDAC cells. 
In contrast the proliferation of cells transfected with eIF4E-siRNA and treated with PSCs 
secretome was obviously inhibited at any time point, indicating that silencing of eIF4E 
inhibits the growth of PDAC cells. Moreover, we tested the effects of eIF4E-siRNA 
transfection on the apoptosis of PDAC cells. Again, we detected much less cells transfected 
with eIF4E-siRNA than in control siRNA-transfected cells (Figure  3.27 (A) and B(e)), further 
indicating that inhibition of eIF4E expression may suppress the production of factors involved 
in tumor–stromal interactions in PSC-SN. To future determine whether eIF4E plays a major 
role in the functions of activated PSC, PDAC cells were pre-transfected with eIF4E siRNA 
and then incubated with the supernatants from the activated PSCs. We found that the 
induction of eIF4E protein by activated PSCs in PDAC cells was markedly inhibited by 
siRNA (Figure  3.27A (c) and B (f)). 
 
  
88 
 
 
 
Figure ‎3.27 Knocking down of eIF4E by small interfering RNA inhibits proliferation and-induced apoptosis in PDAC 
cells. 
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Figure ‎3.27 B Knocking down of eIF4E by small interfering RNA inhibits proliferation and-induced apoptosis in 
PDAC cells. 
 PT45P1 and Panc1 were transfected with 100 nM either eIF4E or negative control (N.C) for 48h, after that, cells were 
serum starved overnight and either left untreated (Serum free) or treated with activated PSC secretome (PSC-SN) for 
24h. (a and d) PSC-SN increased the proliferation for PT45P1 and Panc1 cells. In contrast, the proliferation of cells 
transfected with eIF4E-siRNA and treated with PSCs secretome was obviously inhibited (b and e) apoptosis assay. 
Again, we detected much less cells transfected with eIF4E siRNA than in control siRNA-transfected cells (c and f) 
Western blot analysis. The transient transfection of eIF4E-siRN knocked down eIF4E protein expression in PT45P1 
and Panc1 cells. The p-values were calculated for each individual treatment in comparison to the transfected with 
eIF4E-siRNA and treated with activated PSC secretome. 
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We next determined whether inhibition of eIF4E expression impacted migration of PDAC 
cells. Capan1 cells line were used as a model for pancreatic cancer metastasis. 
 
Figure ‎3.28 Transient silencing or knockdown of eIF4E in Capan1 pancreatic cancer cells inhibit the migration of 
cells.  
Capan1 cells were transfected with 100 nM either eIF4E or negative control (N.C) for 48h, after that, cells were serum 
starved overnight and either left untreated (Serum free) or treated with activated PSC secretome (PSC-SN) for more 
48h. A gap was generated by physically scraping off cells. The number of cells was determined before and after 48h of 
growth at the indicated incubation conditions.  
 
Knockdown of eIF4E expression significantly reduced the number of migrated cells in 
Capan1 cell lines compared with control siRNA-transfected cells Figure  3.28a-d). Thus, 
inhibition of eIF4E expression suppresses the invasion of PDAC cells, suggesting that 
elevated eIF4E expression is associated with positive regulation of cell migration. 
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3.4 Analysis of the interaction between pancreatic ductal adeno-
carcinoma (PDAC) and stroma (PSCs) and the effect of drug 
combinations affecting tumor and stroma simultaneously. 
The objective of this part is an evaluation of some anti-fibrosis candidate drugs in cultures of 
activated PSCs, then to test the most promising drug in a co-culture model of tumor cells and 
PSCs, and after that to test the drug with the strongest effect in animals model for pancreatic 
fibrosis. 
3.4.1 Effect of Drugs on PSCs Proliferation, apoptosis, migration and ROS 
production  
Culture-activated human PSCs were incubated with emtricitabine, ribavirin, and thalidomide. 
We found that all anti-fibrotic drugs inhibited proliferation, apoptosis, migration, and ROS 
production in PSCs (P ≥ 0.05, Figure  3.29). Although both emtricitabine and thalidomide 
 
Figure ‎3.29 Effect of anti-fibrogenesis drugs on PSCs. 
PSC cells were serum starved overnight and either left untreated (Serum free) or treated with TNF-α‎(10‎ng/ml)‎ in‎
serum-free medium for 24h. After that, cells were treated with 10uM from, ribavirine, thalidomide and emetricitabin 
for more 48h. (a) Proliferation assay (b) apoptosis assay (c) Migration assay. PSCs were treated as above and a gap 
was generated by physically scraping off cells.  
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also inhibited PSCs activity, ribavirin showed greater inhibitory activity on PSCs than 
emtricitabine and thalidomide drugs. In addition, ribavirin significantly decreased the 
migration of PSCs, where there was no effect of emtricitabine and thalidomide (Figure  3.29c). 
These data indicate that PSCs are more strongly affected by ribavirin than emtricitabine and 
thalidomide. 
3.4.2 Effects of antifibrogenisis drugs on activation and ECM induced by TNF-
α in PSCs 
The activation of PSCs is identified by their expression of α-smooth muscle actine (α-SMA), 
we therefore determined whether antifibrogenisis drugs inhibited the expression of α-SMA in 
PSC. PSCs were pre-treated with TNF-α (10 ng/ml) for 24 h and then treated with previous 
drugs for another 48 h. Treatment with TNF-α resulted in an increase in the expression of the 
α-SMA (fold change=1.12), whereas treatment of each ribavirin and thalidomide blocked this 
effect (fold change= -2.14 and -1.31 respectively) (Figure  3.30).  
 
 
Figure ‎3.30 qRT-PCR showing the effect of anti-fibrogenesis drugs on PSCs. 
PSC cells were serum starved overnight and either left untreated (Serum free) or treated with TNF-α‎(10‎ng/ml)‎ in‎
serum-free medium for 24 h. After that, cells were treated with 10uM from, ribavirine, thalidomide and emetricitabin 
for more 48 h. qRT-PCR showed that TNF-α‎ induced‎α-SMA, FN1, Col1A1 and DCN formation were reduced by 
ribavirin. qRT-PCR Data represent results from three independent experiments with duplicate repeats. The p-values 
were calculated for each individual treatment in comparison to the cells treated with TNF-α. 
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ICC and Western blot demonstrated that TNF-α increases α-SMA protein expression and that 
treatment of each ribavirin and thalidomide inhibits this effect (Figure  3.32 and Figure  3.33), 
where there was no effect for emtricitabine. We also examined the expression of FN1, 
collagen and DCN in PSC. As shown in Figure  3.32, the expression of FN1 and collagen were 
decreased in group treated with ribavirin, but up-regulation of FN1 and collagen were 
observed in group treated with TNF-α. Furthermore, qRT-PCR revealed that FN1 and 
collagen level in group treated were administrated with ribavirin (Figure  3.30). However, 
emetricitabin did not lead to a significant down-regulation of in the treated group. 
 
Figure ‎3.31 Immunofluorescent staining (ICC) showing the effect of anti-fibrogenesis drugs on PSCs. 
Figure continues on next page. 
PSC cells were serum starved overnight and either left untreated (Serum free) or treated with TNF-α‎(10‎ng/ml)‎ in‎
serum-free medium for 24 h. After that, cells were treated with 10uM from, ribavirine, thalidomide and emetricitabin 
for more 48h. ICC showed TNF-α‎induced‎α-SMA, FN1, Col1A1 and DCN formation were reduced by ribavirin. ICC 
data represent consistent trend in three independent repeats with the best image quality. 
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Figure ‎3.32 Immunofluorescent staining (ICC) showing the effect of anti-fibrogenesis drugs on PSCs. 
 
 
Figure ‎3.33 Western blot showing the effect of anti-fibrogenesis drugs on PSCs. 
PSC cells were serum starved overnight and either left untreated (Serum free) or treated with TNF-α‎ (10ng/ml)‎ in‎
serum-free medium for 24h. After that, cells were treated with 10uM from, ribavirine, thalidomide and emetricitabin 
for more 48h. Results showed TNF-α‎induced‎α-SMA and FN1, formation were reduced by ribavirin. 
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Ribavirin stimulatory effects of PSC on PDAC 
The findings of this study indicate that ribavirin is a promising anti-tumor agent for pancreatic 
cancer, owing to its suppression of desmoplasia through regulating PSCs. Then we try to 
determine the effects of ribavirin on the tumor–stromal interactions between PSCs and PDAC. 
To determine the effects of ribavirin on the tumor – stromal interactions between PSCs and 
PDAC, we prepared co-culture system using cell culture inserts with 0.4 μm pore size. PSC 
were plated on the membrane insert and MiaPaca2 cells, which were chosen for their higher 
resistance to the drug, were seeded on the bottom of 6-well cell culture plates in 2 ml of the 
same culture medium. To understand whether ribavirin affected cell proliferation and/or 
death, we analyzed cell cycle progression and apoptosis. Ribavirin significantly increased cell 
death in MiaPaCa2 cells (Figure  3.34 b).  
Notably, ribavirin also inhibited the proliferation in MiaPaca2 cells (Figure  3.34 a). 
Furthermore, ribavirin also decreased migration of Capan1 cells (Figure  3.34 c). These results 
suggest that the synergic inhibitory effect on cell growth and migration by triggered PSC is 
mainly because of enhanced apoptosis in ribavirin-treated cells and the production of factors 
involved in tumor–stromal interactions. 
 
 
Figure legend on next page. 
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Figure ‎3.34 Effect of ribavirin on PDAC-stroma interaction. 
To determine the effects of ribavirin on the tumour – stromal interactions between PSCs and PDAC, we prepared co-
culture system using cell culture inserts‎ with‎ 0.4‎ μm‎ pore‎ size.‎ PSC‎ were‎ plated‎ on‎ the‎ membrane‎ insert‎ and‎
MiaPaca2 cells were seeded on the bottom of 6-well cell culture plates in 2 ml of the same culture medium. PDAC and 
PSC cells were serum starved overnight and left untreated (SFM) serum-free medium for 24h. After that, PDAC cells 
either left with SFM or were treated with inactivated PSC (UnPSC) or activated PSC (AcPSC) or ribavirin for more 
48h. (a) Effects of ribavirin on PDAC on co-culture system. Co-culture MiaPaca2 with (AcPSC) enhanced the 
proliferation of MiaPaca2 cells compared with (UnPSC) cells. Ribavirin also suppressed the effects of (AcPSC) on 
MiaPaca2 cells proliferation. (b) Apoptosis assay, showed stronger inhibitory effects on co-culture system for PDAC 
cells. (c) Ribavirin decreased the migration of Capan1 cells in co-culture system. * P < 0.05 for PDAC treated with 
(UnPSC) versus (AcPSC) or (AcPSC + ribavirin) versus (AcPSC). 
 
 
3.4.3 Ribavirin decreases the mRNA and protein expression of genes involved 
in tumour–stromal interactions in PDACs 
On the basis of its prominent role in the response of PDAC cells to ribavirin, we focused on 
the major factors, which increased in the previous study by qRT-PCR and Western blotting. 
Treatment with ribavirin significantly reduced / increased the protein and mRNA expression 
of pro-apoptotic factors BAX, CASP-9 and BCL-2 (Figure  3.35).  
 
Figure ‎3.35 Expression profile of 13 genes affected by ribavirin treatment on PDAC-stroma interaction. 
PSC were plated on the membrane insert and MiaPaca2 cells were seeded on the bottom of 6-well cell culture plates in 
2 ml of the same culture medium. PDAC and PSC cells were serum starved overnight and left untreated (SFM) 
serum-free medium for 24h. After that, PDAC cells either left with SFM or were treated with inactivated PSC 
(UnPSC) or activated PSC (AcPSC) or ribavirin for more 48h. Treatment with ribavirin significantly reduced mRNA 
expression of pro-apoptotic factors BAX, CASP-9 and BCL-2 and increased or decreased oncogenes as c-FOS, c-JUN 
and NFKB-1 and down-regulation of RB-1 tumor suppressor gene. 
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Results further indicated down-regulation in expression of such proto-oncogenes or 
oncogenes as FOS, JUN and NFKB-1 and down-regulation of RB-1 tumor suppressor gene 
expression in response to treatment. Cell-cycle regulator genes that activate cell cycle 
progression, such as CCNA2, CCNB1 and CD72, were also down-regulated, whereas 
expression of select cell-cycle inhibitors, including CDKN1A and CDKN2A, increased in the 
PDAC as compared to controls. In addition, proteins involved in purine metabolism and 
translation initiation were down-regulated (Figure  3.35). 
3.5  Evaluation of the effect of some natural products on PSCs 
PSCs were treated with four different extractions from dates to explore the effect of the 
different extractions on activation. The results showed a significant reduction of cell viability 
against PSCs when compared to untreated cells (p<0.05) after 48 h of treatment 
(Figure  3.36a). We also examined the expression of α-SMA in PSC. As shown in Figure  3.36 
b, the expression of α-SMA was decreased in the group treated with all extractions, but the 
ethelacitate and action had a greater effect than the other treatments. 
 
Figure ‎3.36 Effect of different date extraction treatment on PSCs activation. 
 PSC cells were serum starved overnight and either left untreated (Serum free) or treated with TNF-α‎(10ng/ml)‎ in‎
serum-free medium for 24h. After that, cells were treated with 100uM from date-H2O, date-Ethanol, date-
Ethelacitate and date-Aceton for 48h. (a) Cells viability assay clearly showing the decrease in No. of viable PSC cells 
when treated with date extraction compared to untreated PSC cells(SFM).(b) Western blot showed TNF-α‎induced‎α-
SMA were reduced by date extraction. 
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4 Discussion 
4.1 Proteome variations in pancreatic stellate cells upon stimulation 
with proinflammatory factors  
PSCs are now established to play a critical role in pancreatic fibrosis associated with chronic 
pancreatitis and pancreatic cancer. Several potential activators between inflammatory and 
tumor cells and PSCs may participate in this process. Many studies investigated the role of 
growth factors, cytokines and chemokines in the process of activation of PSCs and their 
transformation into proliferative and fibrogenic myofibroblast, but the exact molecular 
process responsible of the activation and the contribution of each factor had not been 
addressed sufficiently. To date, there were only few proteomics studies analyzing PSCs. 
These studies focused only on the proteome of the quiescent and activated state of PSCs in the 
presence of serum [206-208]. To our knowledge, in the present study, we performed the first 
comparative secretome analysis of human PSCs by examined the direct effects of individual 
cytokines in vitro and highlighting the potential biological functions of these proteins using a 
robust high-density antibody microarray. The pro-inflammatory cytokines used in this study 
(TNF-α, FGF-2 and IL-6) are known to be elevated in serum of patients with acute 
pancreatitis [53]. CCL-4 has been shown as one of the highly secreted mediator in human 
chronic pancreatitis [209] and it has been found to be overexpression from pancreatic cancer 
tissues which are rich in stroma (Alhamdani et al., unpublished data).  
4.1.1 The effect of TNF-α 
IPA was performed to investigate the expression pattern of the PSCs proteome under each 
treatment gave a distinct functional attributes. TNF-α was the factor with most and numerous 
significantly observed predictions of functions among all tested factors. The main noticeable 
predictions in this analysis was the significant increase in stromal cell activation (n= 34 
proteins), which was observed only with TNF-α but not the other treatments. In addition, 
there was also a significant prediction of increased reactive oxygen species (ROS) synthesis 
(n= 18 molecules) with TNF-α treatment. ROS have been reported to induce activation of 
PCSs [67]. TNF-α is a well know stimulant of ROS and oxidative stress [210]. This 
observation suggests that TNF-α could be the prime modulator of PSCs’ increased activation, 
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potentially via increasing ROS synthesis. Of note is that there was also a significant prediction 
of increased fibrosis (n= 24 molecules) and proliferation of fibroblasts (n= 15 molecules) 
following TNF-α treatment of PSCs. IGFBP-2, TGF-ß1 and IL-15 are examples of proteins 
leading to proliferation. Similarly, SERPIN-1, TNFSF-10, CFLAR and MMP-11 appear to 
regulate fibrosis and were shown to be correlated with and upstream regulated by TNF-α. In 
the same manner, c-Fos, IGF-1, IL-6, INS, KDR, TNF-α and S100A-4 were detected to 
correlate with the cell activation upon TNF-α treatment. It was shown, for example, that 
IGFBP-2 participates in regulating cell proliferation, differentiation, and apoptosis [211]. An 
increased level of TNF-α is well documented in pancreatic cancer patients [212-214], and 
suggested to play an important role in tumor microenvironments remodeling [215]. The high 
level of TNF-α in pancreatic cancer could be the source of the constant priming of PSCs and 
their sustained proliferation and fibrogenesis. The possible mechanism by which TNF-α 
increased the proliferation of PSCs could also be further confirmed by the observation of 
increased cell cycle functions like entry into S phase, and interphase, all observed under TNF-
α treatment. 
4.1.2 The effect of CCL-4 
CCL-4 has been reported to stimulate fibrosis in vitro and in vivo [216] and has been shown 
to exert angiogenic effects in animal models [217]. On the other hand, high levels of CCL-4 
have been reported in chronic pancreatitis [209]. The most prominent effect of CCL-4 
observed in the present study, although without significant prediction, stimulated a similar 
effect as that observed with TNF-α. Our results suggested that the possible pathway for the 
effect of CCL-4 on PSCs could belong to the increase in endogenous levels of TNF-α in these 
cells as observed in the study. There is also a potential synergistic effect between TNF-α and 
CCL-4 in affecting the cellular proteome of PSCs towards monitoring the endothelial system. 
A recent study reported that TNF-α regulates PSCs to increase cellular development and 
movement of endothelial cells, while CCL-4 showed a significant prediction of increased 
neovascularization. Neovascularization regulating proteins like IL-2 [218], IL-1ß [219], TGF-
ß1 [220] and matrix metalloproteinase [221] were all found significantly altered by treatment 
of PSCs with CCL-4. In addition to endothelial promoting effects, CCL-4, along with FGF-2, 
also exhibited increased tumor development function in PSCs.  
4.1.3 The effect of FGF-2 
Pancreatic tumor cells have the ability to express and secrete FGF-2, which contribute to 
enhance the malignant phenotype of pancreatic cancer [222]. Prediction of changes of the 
100 
 
cellular proteome pool towards a decreased cell death and increased cellular survival was the 
most prominent effect of FGF-2 observed in the present study. A recent study reported that 
FGF-2 increased expression cell survival proteins under the influence of FGF-2 and that it 
was associated with increased gene expression functions like binding of DNA, binding of Ex 
box motif and binding of protein binding site. This study showed that FGF-2 regulated 45 
proteins that are involved with gene expression via binding of DNA. For instance, TP53, 
CDKN1A, MYCN, IL-1A, IGF-1, IL-4 and TGF-ß1, which are known for their regulatory 
effect on gene expression and cell survival, were all found regulated in PSCs upon treatment 
with FGF-2. 
4.1.4 The effect of IL6 
IL-6 has been reported in pancreatic cancer cell lines [178] as well as in medium of these cells 
[223] and also in sera of pancreatic cancer patients [224]. The anti-apoptotic effect of IL-6 has 
been well documented previously [225, 226]. A recent study showed a proteome feature of 
decreasing apoptosis of epithelial cells upon IL-6 treatment as well as a decrease in ionized 
cellular calcium level prediction as noted by the expression of 23 proteins in PSCs treated 
with IL-6. For example, proteins, IL-1ß, INFG and IL-8 are known to increase cellular 
calcium level [227-229] which were all found decreased by the effect of IL-6. Indeed, IL-6 is 
known to cause reduction of cytosolic calcium [230]. Under certain pathological stimuli, 
calcium can play a detrimental role in cell death and apoptosis [231]. The anti-apoptotic effect 
triggered by IL-6 is presumably attributable to its effect on calcium modulatory proteins. Of 
interest, treatment of PSCs with FGF-2 caused an increase in endogenous levels of IL-6, 
which may explain the similar cell survival effect observed with the two. There was a lowered 
expression of several proteins that control cell death such as BCL2, TP53, AIFM1 and 
MYCN, under both treatments of FGF-2 and IL-6. However, the anti-apoptotic effect was 
more prominent under the effect of IL-6, probably as a result of down regulation of CASP-3 
[232], which was not observed with FGF-2.  
The present study provides a comparative proteomic overview of the influence of pro-
inflammatory factors on PSCs and the individual effect of each on the molecular and 
functional characteristics of these cells in vitro (Figure  4.1). 
 
Figure, see next page. 
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Figure ‎4.1 Schematic summary of the different effects of TNF-α,‎FGF-2, IL-6, and CCL-4 on PSCs. 
 
4.1 Proteomics profiling of pancreatic stellate cells reveals the primary 
role of c-Fos in TNF-α mediated pancreatic fibrogenesis 
Activation of PSCs is crucial to the pathogenesis of pancreatic fibrosis [233]. Activated PSCs 
are the cell type responsible for ECM protein production in experimental pancreatic fibrosis 
[101]. The results of various studies show that cytokines factors are involved in PSC 
activation. It is known that increased TNF-α protein levels occur in acute and chronic 
pancreatitis and that TNF-α plays an important role in various pathological processes in the 
pancreas. It was reported that TNF-α modulates pancreatic fibrogenesis by PSC proliferation 
and ECM synthesis [65]. Accumulated evidence suggests that TNF-α is a key mediator of 
change in PSC cell phenotype [55], which increases the expression of α-SMA and ECM 
proteins such as collagen and fibronectin in PSCs [65, 95]. Therefore, elucidation of 
mechanisms involved in the progression of PSC activation is important for designing a 
strategy to prevent progression fibrosis in pancreatic cancer. 
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4.1.1 c-Fos leads to PSCs activation  
As mentioned above, the biological function categories which most significantly predicted 
PSC activation were cell activation, cell proliferation, reactive oxygen species metabolism, 
and entry into S phase and interphase. The most important function in activated PSCs was 
related to cell activation, which corresponded to increased proliferation, migration, ECM 
synthesis, and directors exhibiting the myofibroblast trans-differentiation of activated PSCs. 
To determine the differential expression of the proteins identified in the proteomics analysis, 
we hypothesized that c-Fos is activated during TNF-α stimulation. c-Fos is unique in that it 
can be detected in many different functions and is known to directly control the expression of 
different inflammatory cytokines, such as TNF-α [234]. It also plays an important role in 
contributing to the pathologic activation of fibroblasts [235]. More interestingly, it has been 
reported that an increase in c-Fos levels results in an increase in the expression of SP-1, which 
is up regulated in our microarray data [236]. It is well-known that SP-1 and Smad-3 are 
involved in inducing collagen expression in human glomerular mesangial cells [237], which is 
made possible through TNF-α [238]. Another interesting finding was the involvement of c-
Fos in the increased expression and the autocrine loops of TNF-α in activated PSCs 
(Figure  3.15). It was documented that c-Fos/AP-1 directly binds to AP-1 motifs in the site of 
the TNF-α promoter, which controls the expression of TNF-α [239, 240], and, in turn, is 
involved in PSC activation [65, 95]. From these observations, it was evident that the 
transcription factor c-Fos is critical for inducing TNF-α expression and production in PSCs. 
Knockdown of c-Fos protein expression through siRNA-c-Fos was capable of blocking TNF-
α induced marker gene expression. 
Our data also showed that blockade of c-Fos and the subsequent suppression of TNF-α 
production could repress cell proliferation and PSC migration (Figure  3.16), which is then 
correlated with the expression of α-SMA, suggesting that c-Fos mediated TNF-α production 
contributes to PSC activation. c-Fos protein has been implicated as a key molecule in cell 
proliferation, differentiation [241], and transformation [242]. In addition, PSC is a form of 
pancreatic cancer stroma, which is identified as the source of fibrosis in chronic pancreatitis 
[41]. When activated PSCs secrete α-SMA, a stress fiber not only affects the compliance of 
the pancreas but also works as a signal transduction molecule to regulate ECM protein 
production [102]. Here, our results reveal that c-Fos-siRNA significantly suppressed 
proliferation, migration, as well as TNF-α, c-Fos, and α-SMA production in PSC. The down 
regulation of α-SMA expression observed by immunoblotting was confirmed by real-time 
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PCR. Furthermore, immunofluorescent staining results confirmed that mRNA changes were 
translated into a decrease in α-SMA protein level in PSCs, thus demonstrating that c-Fos is 
essential for PSC activation. 
4.1.2 c-Fos leads to fibrogenesis 
The transcription factor AP-1 consists of heterodimers of c-Jun and c-Fos proteins [243]. 
Since the promoter region of the human collagen I gene contains many transcription factor 
binding sites, including c/EBPβ, Smads, and AP-1 [244], once AP-1 is activated, these sites 
have the ability to modulate transcription of a number of fibrotic genes, such as collagen 
[245]. In this study, we found that knockdown of c-Fos also inhibited ECM protein 
production in cultured PSCs. The decreased expression observed by immunoblotting was 
confirmed by real-time PCR. As shown in 3.18, transfection of the c-Fos precursor markedly 
suppressed mRNA expression of Col1a1 and FN1. In addition, immunofluorescent staining 
showed a reduction in Col1a1, FN1, and DCN expression (3.18c). Hence, our data suggest 
that knockdown of c-Fos plays a crucial role in the suppression of Col1a1 expression in 
human PSCs. Furthermore, we found that transfecting cells with siRNA c-Fos inhibited TNF-
α induced FN1 and DCN. This change in these proteins suggests that c-Fos may be an ideal 
target for reversing the progression of pancreatic cancer fibrogenesis.  
4.1.3 Cell signaling during activation 
There are three major MAPK families (extracellular, signal-regulated kinases [ERKs], c-Jun 
N-terminal kinase [JNK], and p38) in mammalian cells [200], all of which participate in the 
regulation of PSC activation. Several studies reported the involvement of an ERK1/2 
signaling pathway in an early event that precedes the exhibition of a myofibroblastic 
phenotype [74, 75]. Smad and ERKs activation are two key pathways involved in the 
development of TNF-α induced activation and fibrogenic phenotypes. In addition, the smad-3 
signaling pathway has been reported as critical for PSC activation in rats [246], which directly 
affects the activation and expression of collagen [247]. In this study, we found that TNF-α 
causes activation of ERK pathways in PSCs, leading to the activation of ERK1/2 
phosphorylation. Moreover, knockdown of c-Fos blocked ERK1/2 phosphorylation but did 
not influence ERK1/2 expression in the cells. Furthermore, c-Fos appears to partner with 
Smad-3 to regulate PSC activation. In this study, we show that siRNA c-Fos inhibits TNF-α 
induced Smad-3 but not Smad-2 phosphorylation, and that it does not decrease Smad-3 and 
Smad-2 expression (Figure  3.19 a-b). Taken together, it appears that activation of ERK 
pathways induces c-Fos expression, which increases the cellular activity of transcriptional 
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factor AP-1 [239]. The AP-1 transcriptional factors, c-Jun and c-Fos, physically interact with 
smad3 [248] before Smad-3, in turn, increases the expression of α-SMA[249]. 
4.2 Interaction between PSC and PDAC tumor cells 
It has been shown that the secreted proteins in the extracellular space are major factors in 
cancer progression during tumorigenesis and metastasis. These secreted proteins which 
interact between stroma and tumor cells represent the main class of molecule alteration and 
are involved in intercellular communication, cell adhesion, motility, and invasion [250].  
4.2.1 The effect of TNF-α on the secretion of PSCs 
We previously examined the effect of some pro inflammatory factors (TNF-α, CCL-4, IL-6 
and FGF-2) on the PSCs biological function and identified that, TNF-α is the prime factor 
responsible for the activation of pancreatic stellate cells [95]. Therefore, this study aimed to 
investigate the potential involvement of activated PSC paracrine in the crosstalk between PSC 
and PDAC cells by examined the direct effects of TNF-α in vitro and highlighting the 
potential biological functions of these proteins using our antibody microarray technology. 
Then, we tested the hypothesis that PSCs contribute to the growth of tumor cells, thus 
contributing to PDAC development. 
It has been shown that the secreted proteins in the extracellular space are major factors in 
cancer progression during tumourigenesis and metastasis. These secreted proteins which 
interact between stroma and tumor cells represent the main class of molecules alteration and 
involved in intercellular communication, cell adhesion, motility and invasion [250]. In this 
study, we provide further insight into the regulatory mechanisms that govern the PSC niche, 
and its effects in PDAC.  
A comparison of the secretome of activated PSC versus inactivated allows us to identify 
proteins that are uniquely secreted by cancer activated stromal cells but not by their quiescent 
cells. 309 proteins were found to be differentially secreted by activated PSCs versus quiescent 
PSCs (Table  3.3.3). This set of proteins was significantly associated with cancer pathologies. 
Among them, proteins were identified that are involved in biological processes closely related 
to cell apoptosis, cellular growth and proliferation, cancer metastasis, cellular movement, and 
ECM-interaction. Several proteins known to participate in tissue altering and tumor apoptosis 
were commonly detected in the activated PSC like IL-1ß, which stimulates the cellular growth 
and metastases [251] and vascular cell adhesion protein 1(VCAM-1), which is aberrantly 
expressed in breast cancer cells and mediates pro-metastatic tumor-stromal interactions [252]. 
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It has been reported that IL-1ß along with TNF-α up-regulate the expression of VCAM-1 on 
hepatic sinusoidal endothelium (HSE) in vivo which promotes cancer cell adhesion and liver 
metastases [251].  
Another protein commonly identified in activated PSC secretome was plasminogen activator 
inhibitor 1 RNA-binding protein (SERPINE), whose deregulation has been associated with 
cancer progression in various human diseases, including pancreatic cancer [253]. In addition, 
accumulating evidences indicate that the expressions of SREBP-1 were co-localized with 
hypoxic regions in the tumors, which induced chemoresistance for many drugs [254]. Our 
results also identified thrombospondin 3 (THBS-3) proteins in activated PSC secretome. 
THBS-3 is a member of adhesive glycoprotein that mediates cell-to-cell and cell-to-matrix 
interactions, whose can bind to ECM proteins including fibronectin, laminin and type V 
collagen [255]. Several ECM proteins previously reported as involved in pancreatic cancer 
aggressiveness and implicated in cancer progression were identified, like FN1 and collagen. 
However, in this study, Western blot validation revealed an increased expression of ECM 
proteins such as FN1 and collagen in activated PSC compared to quiescent PSC, suggesting 
that aberrant secretions and not only de novo induction of these markers can be associated 
with PSC activation as well. An active role for activated PSC in enhancing tumourigenicity, 
producing ECM proteins, which have important roles in acquired resistance to anticancer 
drugs and cell proliferation regulation of pancreatic cancer cells in vitro and in vivo [256]. 
Therefore, the expression of ECM proteins in pancreatic cancer specimens could provide 
valuable information to aid anticancer drug cytotoxicity, and gemcitabine would be useful for 
treatment of patients with pancreatic cancer. Activated PSCs synthesize multiple cytokines 
and growth factors. IL-1ß [257], S100-A4 [258], TNF-α [259], connective tissue growth 
factor (CTGF) [260] and activing [261] are addressed in PSC-induced proliferation, migration 
or invasion of pancreatic cancer cells. Besides, PSCs produce PDGF [103], VEGF [104], 
TGF-β1 [262] and COX-2 [263], which maybe promote cancer cell growth. The secretions of 
FGF-1, interleukin-6 (IL-6), IL-4 and insulin-like growth factor I (IGF-1) for example, were 
also clearly enhanced in media of activated stellate cells as compared with media of normal 
stellate cells. These results were also directly confirmed in activated stellate cells secretome. 
In addition, proliferation of pancreatic cancer cells is mediated by PDGF and FGF signaling 
pathways [103]. Other studies shown that tumor cells have the capability to manipulate 
different signaling pathways, such as the IGFs signaling pathway and FGFs signaling pathway 
and the effect of this growth factors which results from their interplay within the 
microenvironment [264]. Furthermore, IL-1ß, IL-6 and TNF-α, are present in the 
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microenvironment of cancer and believed to contribute metastasis and drug resistance [65]. 
Consequently, the up-regulation of IL-6 in activated stellate cells strongly suggests some 
role(s) in regulating the growth of stellate cells as well as other cells in the cancer 
microenvironment [95]. Therefore, it is possible that these proteins are actively secreted also 
in vivo and they may thus regulate the growth and proliferation of cells in the damaged 
pancreas via paracrine and autocrine mechanisms. Consequently, study PSC proteins 
secretions represent strong candidates for further investigations. 
4.2.2 The effect of PSCs secretome on PDAC 
The present study also addresses the possible regulatory role of activated PSCs to mimic 
pancreatic cancer microenvironment, and to test the hypothesis that PSCs contribute to the 
growth of tumor cells, thus contributing to PDAC progression. To achieve that, PT45P1 cells 
were treated with the secretome (ultrafiltrated conditioned media) from TNF-activated PSCs, 
and PT45P1 cellular proteome was analyzed with antibody microarray and qRT-PCR. We 
found that activated PSCs, could remarkably inhibition the apoptosis and enhance the 
migration of PDAC. Furthermore, we demonstrated that supernatants from the activated PSCs 
induced proliferation in pancreatic cancer cells, suggesting a cross-talk between stellate cells 
and tumour cells, promotes pancreatic cancer growth, and may regulate to the desmoplastic 
tumour microenvironment that promotes PDAC tumorigenesis. To further explain these 
results, we detected the mRNA level for some candidates’ genes in PT45P1 pancreatic cancer 
cells. In response to PSC secretome, PT45P1 cell pro-apoptotic factors (extrinsic and intrinsic 
pathway) were either down-regulated such as for BAX, Caspase-9 (CASP-9), Nuclear factor 
NF-kappa-B p105 subunit (NFKB-1), Fas-activated serine/threonine kinase (FASTK) as well 
as Caspase-3 (CASP3) and Caspase-7 (CASP-7) (caspase Glu3,7 assay) or up-regulated as 
with (BCL-2). These results showing that activated PSCs can inhibit both the extrinsic and 
intrinsic apoptotic pathways in PT45P1 cells. Among proteins detected in PT45P1 cells 
treated by activated PSCs secretome, NFKB-1 was identified. This protein is not expressed by 
normal cells, but it was reported to be over expressed in a number of human cancer including 
non-small cell lung carcinoma, pancreatic cancer, colon cancer, prostate cancer, breast cancer, 
bone cancer and brain cancer. NFKB-1 is often active in pancreatic cancer cells and decrease 
expression of NFKB-1 activating molecules can obstruct tumor progression in in vitro and in 
vivo studies [265]. In addition, NFKB-1 prompts the expression of inflammatory cytokines, 
adhesion molecules, key enzymes in the prostaglandin synthase pathway (COX-2), nitric 
oxide (NO) synthase and angiogenic factors. Furthermore, by inducing anti-apoptotic genes 
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(e.g. BCL-2), it promotes survival in tumor cells and in epithelial cells targeted by 
carcinogens [266, 267]. 
The majority of differentiated proteins like RPS-19, LMNA and IGHM in tumor cells showed 
decreased expression upon treatment with PSC secretome. The results seem to support the 
previous observations that PSCs can reduce differentiation of PDAC cells [268-270]. These 
molecular changes could be responsible for inducing both the differentiation and the apoptotic 
processes [271, 272]. 
In response to treatment, expression profiling further indicated down-regulation of proto-
oncogene or oncogenes such as RB-1 tumor suppressor gene. Cell-cycle regulator genes that 
activate cell cycle progression, such as CCNA2 was also up-regulated, whereas expression of 
selects cell-cycle inhibitors, including CDKN2A, decreased in PDAC as compared to 
controls. RB1 is a crucial regulator of appropriate cell cycle progression, including G1 to S 
and G2 to M phase transitions [273]. The activity of RB1 is mainly regulated by the upstream 
CDKN2A/CCND1 pathway [274]. In accordance with the important role of RB-1 as a cell 
cycle regulator, RB-1 deregulation is frequently observed in multiple types of cancers [275]. 
Functional loss of RB-1 causes accelerated E2F1 mediated transactivation, followed by 
uncontrolled cell cycle progression [276]. 
Activated PSCs, also caused a significant increase in the expression of most proteins of the 
purine metabolism and translation initiation such as IMPDH, EIF2B1 and eIF4E. According 
to resent studies eIF4E selectively enhances the synthesis of a variety of proteins involved in 
cell growth, proliferation and invasion, including the cell cycle regulatory protein cyclin D1 
[277], the transcription factor c-Myc, growth factors such as VEGF and FGF-2 [278], as well 
as the anti-apoptotic protein MCL-1 [279]. 
Even though the existence role of PSCs in the microenvironment is well-established [102, 
103], the cellular mechanisms mediating crosstalk between PSCs and PDAC cells and the 
signaling molecules involved remain a complex web waiting to be untangled. Recent studies 
have demonstrated that progression and resistance to standard therapies in tumor is closely 
related to the eIF4E pathway [204, 205, 280]. Moreover, eIF4E selectively enhances the 
synthesis of a variety of proteins involved in cell growth, proliferation and invasion, including 
the cell cycle regulatory protein cyclin D1 [277], the transcription factor c-Myc, growth 
factors such as VEGF and FGF-2 [278], as well as the anti-apoptotic protein MCL-1 [279]. To 
this end, we identified eIF4E as a key signaling molecule that mediates crosstalk between 
PSCs and tumor cells. We also showed that eIF4E enriches the percentage of PDAC cells in 
cell cultures and increases their expression of eIF4E. Additionally, eIF4E also increased 
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tumor cell motility and inhibited pancreatic cancer cells apoptosis. Critically, all these effects 
were effectively blocked by eIF4E-siRNA, confirming the essential role of eIF4E in PSC-
tumor cell crosstalk. These results are intriguing given that constitutive activation of eIF4E is 
commonly observed in tumors and is a validated target for therapy of solid cancers, including 
pancreatic cancer [204, 205]. 
In conclusion, the identified candidate proteins from PSCs activated by TNF-α hold great 
promise to further investigate the mechanisms of pancreatic cancer aggressiveness, as well as 
to serve as a source of potential disease biomarkers. In addition, we demonstrated in this study 
that activated PSCs promoted pancreatic cancer cell proliferation, migration and inhibited 
apoptosis through eIF4E activation. Our findings provide novel evidence for the modulation 
of pancreatic cancer cells by PSCs under inflammatory environment and further insight to the 
roles of stromal cells in the progression from chronic inflammation to cancer. Although 
further efforts are required to fully elucidate their biological functions in PDAC progression 
and inhibition of apoptosis, information derived from the analysis of the identified proteins 
may provide useful suggestions for clarifying the role of PSCs in pancreatic cancer 
development processes (Figure  4.2). 
 
 
Figure ‎4.2 Schematic representation of anti-apoptosis effects of PSC. 
 The main effects of the PSC involve inhibition of both apoptosis and differentiation. PSC can act through inhibition 
or induction of the following processes: cell proliferation, oncogenic signalling, and expression of proteins involved in 
purine biosynthesis and translation initiation. In addition it down or up-regulates several tumour suppressors. The 
direction of the expression changes that are supposed to be responsible for the effects of PSC is indicated by arrows 
(down-regulation or up-regulation). 
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4.3 Analysis of the interaction between pancreatic ductal adeno-
carcinoma (PDAC) and stroma (PSCs) and the effect of drug 
combinations affecting tumor and stroma simultaneously. 
It is well established that the growth of dense, collagen rich, extracellular matrix and stroma 
with high interstitial pressure around pancreatic tumors, known as the desmoplastic reaction, 
creates a unique microenvironment that paradoxically promotes both tumor growth and 
metastatic spread and, at the same time, generates a hypovascular microenvironment that 
limits drug delivery [281]. Therefore, targeting components of the tumor stroma that 
contribute to the desmoplastic reaction is a promising new platform of investigation. 
The present study demonstrated that ribavirin inhibited several key parameters of PSC 
activation including proliferation, α-SMA gene expression, and FN1 and collagen expression. 
These inhibitory effects were not due to the non-specific cytotoxicity, because the 
concentrations of ribavirin used in this study inhibited proliferation more than they caused cell 
death directly. These ECM factors (FN1 and collagen) play critical roles in the tumor–stromal 
interactions in pancreatic cancer and thus form a barrier to chemotherapy penetration [256, 
282]. In agreement with our study, activated PSC significantly increased the growth of PDAC 
cells where ribavirin treated activated PSC decreased the ability of PSC to enhance the 
proliferation and migration of PDAC in our study. This finding may be due to the role of 
ribavirin in the suppression of the biologic activation of PSCs and the attenuation of the 
tumor–stromal interactions by suppressing the production of growth factors and ECM 
proteins. 
The results of this study demonstrate that a complex series of molecular events prepares 
Ribavirin-PSC cells for the inhibition of proliferation, the induction of programmed cell 
death, and/or the initiation of PDAC differentiation. Ribavirin-PSC induced programmed cell 
death in MiaPaca2 cells, significantly (almost 40%) increased the percentage of cells 
undergoing apoptosis, as observed at 48 h after the treatment of PSCs with ribavirin. In 
addition, inhibition of PSC activation by Ribavirin correlated with the up-regulation of several 
genes of the intrinsic pro-apoptotic pathway, like CASP-9, as well as of the extrinsic pro-
apoptotic pathway, like BAX/BCL-2. 
It is well known that pancreatic tumors are not responsive to apoptosis, a trait which probably 
contributes to their resistance to chemotherapy. High BCL-2 and c-Fos expression in 
pancreatic tumors prevents the effectiveness of BAK and BAX. Under the Ribavirin-PSC 
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effect, the expression of BCL-2 antagonists BAX is modestly stimulated and this result may 
tilt the balance toward apoptosis [281]. These results show that Ribavirin can activate both the 
extrinsic and intrinsic apoptotic pathways in MiaPaca2 cell lines. 
The reduction in PSC activation was also associated with a profound modulation of cell cycle 
arrest and classical tumor suppressors as represented by increased CCNA2, RB-1, and NFkB-
1 gene expression in MiaPaca2 cells. These molecular changes could be responsible for 
inducing apoptotic processes [283, 284]. 
Evidence has been provided that the inhibition of PSC activation with Ribavirin has strong 
inhibitory effects on MiaPaca2 mRNA expression levels in IMPDH, a key enzyme of purine 
metabolism which is associated with decreased expression levels of the translation initiation 
gene eIF4E. eIF4E is widely overexpressed in various cancers and has been considered an 
important target for ribavirin anti-tumor activity [285-287]. Thus, the direct effect of 
Ribavirin-PSC on MiaPaca2 cells might be associated with eIF4E. 
Our previous studies have indicated that PSC had strong inhibitory effects on the expression 
of oncogenes and tumor suppressor proteins (CDKN2B and CDKN2A) in PDAC cells. This 
effect was reduced by inhibition PSC activation by Ribavirin and reduced CDKN2B and 
CDKN2A production on MiaPaca2 cells, thus exerting a stroma modulatory effect in the 
PDAC microenvironment. 
The results of our study are consistent with previously reported data, which showed that 
ribavirin exhibits anti-tumor properties for different types of tumors, such as head and neck 
squamous cell carcinoma (HNSCC), breast cancer, and AML [288-290].  
Our study provides the evidence that ribavirin inhibits the biologic activity of PSCs. 
Inhibition of PSC activation in combination with ribavirin can significantly prevent cell 
proliferation and migration, induce apoptosis, arrest the cell cycle, and decrease expression of 
translation initiation genes as well as modifying several other cancer-related processes in 
PDAC cells (Figure  4.3). Therefore, targeting PSC with ribavirin may offer a promising 
treatment strategy for pancreatic cancer. 
 
111 
 
 
Figure ‎4.3 Schematic representation of antifibrotic effects of Ribavirin.  
The main effects of the drug involve induction of both apoptosis and differentiation. By targeting PSCs ribavirin can 
act against PDAC cells through inhibition of the following processes: cell proliferation, oncogenic signaling, and 
expression of genes involved in purine biosynthesis and translation initiation. In addition it up-regulates several 
tumour suppressors. The direction of the expression changes that are supposed to be responsible for the effects of 
Ribavirin is indicated by arrows (down-regulation or up-regulation). 
 
4.4 Evaluation of the effect of natural products on PSCs  
Little or no progress has been accomplished in PDAC treatment over the last 40 years. Novel 
therapeutics against this lethal malignancy must inhibit several pathways that promote 
survival, progression, and metastasis of PDAC cells as well as stromal tumor 
microenvironment. Many hypotheses suggest a role of the microenvironment on contributing 
to the efficacy of drug delivery to tumor cells [139]. Therefore, control of the activation of 
PSCs and their cellular functions are potential targets for the development of new treatments 
for pancreatic fibrosis. 
It is well known that an increased consumption of fruits and vegetables is associated with a 
reduced risk of most cancers, including PDAC [291]. For this reason, the potential of natural 
products in PDAC therapies has been widely investigated [292]. 
Traditionally, the fruits from the date palm Phoenix dactylifera have been used for a wide 
range of human diseases including inflammatory conditions, diarrheal dieses, parasitic 
infections, and cancer [293]. Although it has not been extensively studied in terms of its anti-
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pancreatic cancer activity, studies from our laboratory demonstrated that date extracts 
inhibited several key parameters of PSC activation including proliferation and expression of 
α-SMA and FN1.  
In order to explore the effect of the different date extracts on cell activation, PSCs were 
treated with four different ones. The date extracts significantly reduced PSC cell viability, 
when compared to respective untreated cells (p<0.05) after 48 h of treatment. We also 
examined the expression of α-SMA in PSCs and found that the expression level of α-SMA 
was decreased in PSCs treated with the extracts. The ethyl acetate and acetoin groups were 
exhibiting greater effects than the others. As shown in our previous studies, TNF-α potently 
induces proliferation of PSCs, mainly through the activation of the c-FOS-ERK pathway [95]; 
it seems that inhibition of proliferation by date extracts correlates with the inhibition of TNF-
α activation, which is clearly noted by decreased expression of α-SMA. 
Although these observations suggest that extracts of date palm may be a useful therapeutic 
agent for the attenuation of pancreatic cancer, we still need to conduct further investigations 
to know the precise mechanism by which this extracts suppress PSC cells. Anti-tumor effects 
of date palm should also be carefully examined in a model of PSC-PDAC co-culture. 
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5 Conclusions & Outlook 
 
The current study presented here focused on the application of complex antibody microarrays 
for the identification of molecular processes that are relevant to human cancer. In the first part 
of the study, we found that TNF-α is a prime activator of PSCs. Along with CCL-4, TNF-α 
also contributes to changing the PSC proteome toward an endothelial system. FGF-2 and IL-6 
increase cellular survival, presumably via an accelerated cellular gene expression mechanism 
in the former case, and by decreasing apoptotic activity through modulation of ionized 
calcium in the latter. The identified direct effects of individual cytokines on human pancreatic 
stellate cells provide new insights about their contribution to pancreatic cancer promotion. 
In the second part of the study, we determined that c-Fos is a novel factor for PSC activation 
and fibrogenesis and also demonstrated that c-Fos mediates TNF-α induced PSC activation by 
interacting with Smad3, which activates the transcription programs of PSC marker genes. 
This process involves not only the activation of ERK1/2 but also the transduction of 
activation signals through the regulation of c-Fos. 
In the third part, we investigated how PSCs act via multiple pathways in the promotion of 
PDAC cell apoptosis and how these effects are mediated through the modulation of key 
molecular and metabolic pathways. In addition, we demonstrated in this study that activated 
PSCs promote pancreatic cancer cell proliferation, migration and inhibited apoptosis through 
eIF4E activation. 
Our study revealed that ribavirin inhibits PSC activation. Ribavirin also inhibited the 
production of ECM proteins like collagen type I, fibronectin, and DCN, factors that play 
important roles in the interaction between tumors and stromal cells in pancreatic cancer. 
Therefore combining ribavirin with traditional anticancer drugs, such as gemcitabine, may 
offer a promising treatment strategy for pancreatic cancer. In addition, we showed that palm 
date extracts inhibit key cell functions and PSC activation. It has been increasingly recognized 
that PSCs are potential targets of anti-fibrogenic and anti-inflammatory strategies. The 
characteristics of date extract, including its antioxidant potential and ability to inhibit cell 
function and PSC activation make it a potential candidate for the treatment of pancreatic 
fibrosis. 
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